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Abstract 
As other many transcription factors, FoxO family members are involved in several 
cellular processes, including proliferation, apoptosis, stress resistance and 
metabolism. Their activity is finely regulated by phosphorylation, acetylation and 
ubiquitination events, which are modulated by multiple signalling pathways. 
Through the combination of specific post-translational modifications, composing a 
unique “molecular FoxO code”, FoxO proteins modulate different physiological 
processes and pathological events, such as cancer. 
Previously, a mitochondrial arm of the AMPK-FoxO3A axis, representing a 
mechanism sustaining the energy metabolism upon nutrient shortage, has been 
revealed in normal cells and tissues. Data collected during this project show that in 
metabolically stressed cancer cells, FoxO3A is recruited to the mitochondria 
through activation of MEK/ERK and AMPK pathways. These kinases 
phosphorylate Serine 12 and 30, respectively, on the FoxO3A N-terminal domain, 
which is required for FoxO3A recruitment to the mitochondrial surface. Upon 
translocation into the organelle, the N-terminal domain is cleaved by processing 
peptidases, and the released product reaches the mitochondrial matrix. Here, the 
cleaved form of FoxO3A binds to the mitochondrial DNA (mtDNA) and activates 
the transcription of the mitochondrial genes, to support mitochondrial metabolism 
and cell survival. Interestingly, it seems to be a cancer-specific mechanism. 
Moreover, in cancer cells treated with chemotherapeutic agents, accumulation of 
FoxO3A into the mitochondria promotes their survival in a MEK/ERK-dependent 
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manner. Importantly, mitochondrial FoxO3A is required for apoptosis induction by 
Metformin. Elucidation of FoxO3A mitochondrial versus nuclear functions in 
cancer cell homeostasis might help devise novel therapeutic strategies to disable 
FoxO3A pro-survival activity selectively.
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1.1 Introduction 
1.2 Cancer 
Cancer is the second largest cause of mortality in the western world, after 
cardiovascular disease. In Europe, in 2017, 3.5 million people were diagnosed. 
Every year the number of diagnosed cancer cases is increasing, regardless of sex, 
type or country. Colorectal cancer (13,0%) and breast cancer (13,5%) are the most 
prevalent ones in the world today.  
Cancer is a heterogeneous disease resulting from a multistep process, by which 
several genetic and epigenetic alterations lead normal cells to evolve progressively 
to a neoplastic state. The abnormal cell growth, resulting in the neoplasia, is the 
biological endpoint of the process. The fundamental alternations that cancers have 
to undergo to transform from normal to cancer cells are outlined as “hallmarks of 
cancer” (Hanahan and Weinberg, 2000; Hanahan and Weinberg, 2011). All the 
procedures of transformation of normal cells to cancer cells include the ability to 
sustain proliferative signalling, evading growth suppressors, resist cell death, 
enabling replicative immortality, inducing angiogenesis, activating invasion and 
metastasis, re-programme energy metabolism and avoid immune destruction. 
Behind these events, there is the characteristic neoplastic genome instability, which 
induces the genetic variability that allows the hallmarks acquisition. The loss of the 
“caretakers” genes, involved in detecting and repairing DNA damage (Roth et al., 
2000), supports the genomic instability, allowing the pre-malignant cells to reach 
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the essential hallmarks of cancer (Hanahan and Weinberg, 2000). Finally, yet 
importantly, tumour-promoted inflammation is essential to sustain multiple 
hallmark abilities and tumour microenvironment, by producing growth factors to 
promote proliferative signalling, survival factors to escape from cell death, pro-
angiogenic factors and extracellular matrix-modifying enzymes to facilitate 
angiogenesis, invasion and metastasis. Cells that acquire all the hallmarks generate 
a malignant neoplasia’ or ‘malign cancer’. However, cells that do not acquire 
invasive and metastatic abilities nor immortality feature generate ‘benign cancers’, 
which are mostly well differentiated and unable to proliferate as much as malignant 
tumours (Figure 1.1). 
 
Figure 1.1 - Hallmarks of cancer. 
The illustration encompasses the six hallmark capabilities originally proposed in 
2000 Hanahan and Weinberg perspective (sustaining proliferative signalling, 
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evading growth suppressors, resisting cell death, enabling replicative immortality, 
inducing angiogenesis, and activating invasion and metastasis) and the new 
emerging characteristics and hallmarks described in 2011 (avoiding immune 
destruction, tumour-promoting inflammation, genome instability and mutation, 
deregulating cellular energetics). Image modified and adapted from Hanahan and 
Weinberg, 2011. 
1.2.1 Beyond Warburg effect 
The energy metabolism reprogramming has been considered for decades as 
synonymon with the “Warburg effect” (Warburg O, 1956). This phenomenon, also 
known as “aerobic glycolysis”, was described by the German biochemist Otto 
Heinrich Warburg as the impaired cell metabolism in the origin of cancer, due to 
mitochondrial respiration defects. Moreover, the theory proposed that the increased 
glycolytic flux as a compensatory mechanism of energy production required to 
maintain the viability of cancer cells. In the following decades, both biochemists 
and oncologists criticized Warburg theory to be too simplistic, not consistent with 
evidence of apparent normal respiratory function in some tumour cells. 
Furthermore, Warburg did not consider the role of tumour-associated 
mutation. Therefore, the view of cancer as a metabolic disease was gradually 
replaced with the one of cancer as a genetic disease involving nuclear mutations in 
oncogenes and tumour suppressor genes (Hanahan and Weinberg, 2011). 
Nowadays, numerous experimental evidence is still keeping alive the resolve “the 
chicken and the egg” dilemma, about mitochondrial dysfunction and tumour 
formation. Specifically, two distinct hypotheses about mitochondrial role in 
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tumorigenesis keep the question still on the table: on the one hand the mitochondrial 
dysfunction considered as a primary cause of tumorigenesis, on the other as a 
“second hit” in the process of cancer metabolic transformation, consequence of 
accelerated glycolysis. Specifically this event may be caused by loss of tumour 
suppressors or activation of oncogenes. 
The preference of aerobic glycolysis is currently recognised as one of the 
numerous ways by which malignant cells undergo metabolic reprogramming to 
survive and proliferate during tumour initiation, progression and metastasis 
(Koppenol et al., 2011). These pathways, such as mitochondrial metabolism, 
oxidative phosphorylation or redox balance, are usually pre-existing in normal cells 
and they are still functional in malignant ones. Among reprogrammed activities, 
there are mechanisms that allow tumour cells to take up abundant nutrients to 
produce ATP (Adenosine triphosphate), generate biosynthetic precursors and 
macromolecules, tolerate malignancy-associated stress (redox stress and hypoxia), 
allow cancer cells to tolerate nutrient depletion by catabolizing cellular or extra-
cellular macromolecules through autophagy, macropinocytosis, or lipid scavenging 
(Commisso et al., 2013). The induction of these activities is regulated by signalling 
pathways commonly perturbed in cancer cells. Notably, even though the broad 
genetic heterogeneity of tumours, malignant cells share the induction of pathways 
related to anabolism, catabolism, and redox balance (Cantor and Sabatini, 2012). 
The resulting alterations in metabolite levels, in turn, induce post-translational 
modifications (PMTs) – such as acetylation, methylation, and thiol oxidation – that 
influence cellular signalling, epigenetics and gene expression. However, the 
acceptance of Warburg effect as the main consequence of genomic instability 
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selected during tumour progression (Kim et al., 2006), renewed the interest in the 
energy metabolism of cancer cells. Consequently, a new view of cancer cell 
homeostasis is emerging, related to the balance between newly acquired oncogenic 
and typical normal cell features (DeBerardinis and Chandel, 2016; Cairns et al., 
2011). Importantly, the biological functions of normal cells are strongly required 
for the acquisition of malignant phenotype, and they are ensured by the proper 
preservation of key mitochondrial functions (Wallace, 2012; Weinberg and 
Chandel, 2015; Zong et al., 2016). Consistent with this view, proteins that have 
been classically considered as tumour suppressors are sometimes required to be 
functional for full malignant transformation. This is the case for the transcription 
factor FoxO3A which can be both friend and foe to cancer cells depending on the 
cellular context (Gomes et al., 2008; Zhang et al., 2011; Chiacchiera and Simone, 
2010).  
1.2.2 Altered energy-supplying pathways in cancer 
The uncontrolled oncogene-driven proliferation of cancer cells causes 
hypoxia in tumours in the absence of an efficient local vascular bed (Eales et al., 
2016). Moreover, mitochondria are not able to provide enough ATP for malignant 
cell survival. Thus tumour cells must up-regulate the glycolytic pathway. As in 
cancer cells p53 is often mutated, or its expression is impaired, the hypoxic 
condition is not lethal for them (Moll et al., 1998). 
Furthermore, to restore an adequate supply of oxygen and nutrients, tumours 
need to induce the growth of the vascular network, in the process known as 
angiogenesis (Nishida et al., 2006). However, even after re-establishment of oxygen 
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supply, tumour cells prefer to perform glycolysis and to keep mitochondrial activity 
suppressed. This is a way, for example, for tumours to take advantage to support 
the invasion, since the improved production of lactate, because of the high rate of 
glycolysis, generates an acidic environment toxic for non-malignant cell 
populations (Gillies et al., 2007). Malignant cells can trigger the glycolytic 
pathway, mainly by inducing the Hypoxia-Inducible Factor-1 (HIF-1), an important 
regulator of genes involved in the control of angiogenesis, cell survival and 
invasion. HIF-1 can upregulate the enzymes stimulating glucose utilization. 
Remarkably, HIF-1 plays a very complex role in hypoxia, as it can induce apoptosis 
and, at the same time, prevent cell death, or even stimulate cell proliferation (Greijer 
et al., 2004).  Moreover, hypoxia can increase the production of ROS in tumour 
cells, leading to cell damages, such as to mitochondrial DNA. Consequently, 
mitochondrial function is impaired and glycolytic pathway sustained (Wallace et 
al., 2012). 
Dysfunction of mitochondria also leads to the activation of the glycolysis. 
For example, the nicotinamide adenine dinucleotide (NADH)-induced inactivation 
of the PI3K-phosphatase PTEN, causes the activation of AKT (Pelicano et al., 
2006). This kinase can trigger post-transcriptional mechanisms related to the 
glycolytic pathway, such as the localisation of the glucose transporter to the cell 
surface or maintenance of hexokinase function in the absence of extrinsic factors 
(Elstrom et al. 2004). Furthermore, the impairment of mitochondrial respiration in 
tumour cells can lead to the accumulation of Krebs cycle substrates, such as 
succinate, lactate or pyruvate. This event allows the stabilization and activation of 
HIF-1 that, in turn, stimulates the glycolysis (Gottlieb et al., 2005; Lu et al., 2006) 
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and induces apoptosis through the stabilization of p53 (Greijer et al., 2004). 
Importantly, in tumour cells, HIF-1 also is a key modulator of the balance between 
glycolysis and oxidative phosphorylation. The energy utilization switch is directly 
controlled by the pyruvate dehydrogenase (PDH) and lactate dehydrogenase 
(LDH), both required for pyruvate utilization. HIF-1 modulates the pyruvate 
dehydrogenase kinase 1 (PDK1), which controls the activity of PDH and, 
consequently, the pyruvate oxidation. As a result, the Krebs cycle and 
mitochondrial respiration are severely impaired. Similarly, the HIF-mediated 
induction of the LDH expression diminishes the amount of pyruvate available for 
mitochondrial respiration (Kim et al., 2006; Semenza et al., 2007).  
1.2.3 Mitochondrial basics 
The ATP production for metabolic demands is the main but not the only 
mitochondrial activity affecting the cellular physiology. Other mitochondrial vital 
and lethal functions are essential for tumour cell homeostasis, growth and survival, 
in physiological and pathological conditions. As an example, mitochondria 
integrate many of the signals for initiating apoptosis. This awareness suggests that 
understanding the mitochondrial function in cancer might be helpful to design novel 
targeted approaches for cancer therapy.  
Mitochondria can act as a buffer of intracellular calcium and iron homeostasis. 
Furthermore, they produce respiration reactive oxygen species (ROS) as a by-
product of aerobic respiration. ROS are important regulators of various cellular 
signalling pathways (Yun & Finkel, 2014), but their excess might also damage the 
cell. Additionally, they are important for thermogenesis and the 
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synthesis/modulation of various metabolic intermediary pathways, including 
metabolism of amino acids, lipids, cholesterol and steroids.  
Mitochondria are maternally inherited small cytoplasmic organelles, originated 
from symbiotic bacteria, characterized from a high dynamicity due to constant 
cycles of division and fusion (Wallace, 2012). The latter is very important to 
maintain the normal mitochondrial function, and it consists in the process of joining 
together neighbouring mitochondrial membranes. The mitochondrial fusion is 
required to recover the activities of depolarized membranes and ensure the proper 
distribution of metabolites and mitochondrial DNA (mtDNA). Moreover, to 
preserve the proper mitochondrial function, regular “fission” activity is also 
required, with the aim to redistribute correctly the mitochondrial DNA during cell 
division, as well as for mitochondrial transport during mitosis and meiosis process.  
Each cell has a different number of mitochondria. To maintain the highest 
number of mitochondria, cells require a lot of energy, such as in the heart, brain, 
liver, muscles or kidneys (Alberts et al., 1994).The cells ability to increase in the 
mitochondrial population (proliferation), and to improve the functional capabilities 
of pre-existing mitochondria (differentiation), is defined as “mitochondrial 
biogenesis”. 
Furthermore, upon stress stimuli, mitochondrial turnover can be accelerated 
through an autophagy process called “mitophagy”. Moreover, mitochondria can 
adopt different shapes depending on the metabolic demands of the cell. The 
“mitochondrial dynamics” describes the mitochondrial morphology and 
distribution in the cell (Alberts et al., 1994). 
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Mitochondria are composed of two highly specialized membranes, the outer 
(Mitochondrial Outer Membrane, MOM) and inner (Mitochondrial Inner 
Membrane, MIM): the MOM is a more porous membrane for the high content of 
Porin, whereas the MIM is folded into numerous cristae. The space between the 
outer and the inner membrane is defined as Intermembrane Space (IMS). The space 
enclosed by the inner membrane is the core of the mitochondria, the matrix, in 
which harbours the mitochondrial DNA. The mtDNA is a 16.6 kB circle of double-
stranded DNA, packaged into small clusters called nucleoids. The two mtDNA 
strands are named heavy (H) and light (L), for their buoyant density. Notably, 
mtDNA is not protected by histones, so it is more exposed to oxidative damage 
(Alexeyev et al., 2009). Moreover, mtDNA lacks repair mechanisms (Alexeyev et 
al., 2009). mtDNA is present in thousands of copies in each human cell, which are 
usually all identical at birth (homoplasmy). However, it is possible that an 
individual may harbour a mixture of mutated and wild-type mtDNA within each 
cell (heteroplasmy), which can lead to mitochondrial disorders resulting from 
mutation of mtDNA, mainly related to dysfunctions of the mitochondrial 
respiratory chain (Zeviar et al., 2014). 
The mitochondrial DNA produces mitochondrial proteins, in concert with the 
nuclear DNA. Specifically, it encodes 37 genes, of which 24 are dedicated to tRNAs 
and rRNAs, and 13 encode respiratory chain polypeptides of respiratory Complexes 
I, III, IV, and V, and 24 nucleic acids necessary for intra-mitochondrial protein 
synthesis (Birch-Machin et al., 2006; Wallace et al., 2012). Interestingly, Complex 
II proteins are encoded by nuclear genes. Briefly, oxidative phosphorylation is 
driven by pyruvate produced from the metabolism of carbohydrates and fatty acids, 
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which are imported into the mitochondrial matrix to produce acetyl-CoA that is 
used to produce substrates for the oxidative phosphorylation (OXPHOS). Among 
them, there is NADH, which generates electrons that are pumped from the 
mitochondrial matrix across the inner membrane through respiratory complexes III, 
IV, and I and then returned to the matrix down their electrochemical gradient, 
allowing the complex V to synthesize ATP (Figure 1.2). 
 
Figure 1.2 – Scheme of mitochondrial biogenesis.  
The mtDNA is packaged in the nucleoid and is replicated by DNA polymerase-γ 
(pol-γ). It is transcribed by mitochondrial RNA polymerase from both strands. The 
mtDNA encodes 22 tRNAs, and 12S and 16S rRNAs and 13 proteins: seven of 
complex I; (ND1, ND2, ND3, ND4, ND4L, ND5 and ND6), cytochrome b of 
17 kB 
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complex III; three of complex IV (cytochrome oxidase I (COI), COII and COIII); 
and two of complex V (ATP6 and ATP8). All of the remaining mitochondrial 
proteins, including OXPHOS subunits and all four subunits of complex II, are 
encoded by nuclear DNA (nDNA). Then, nDNA-encoded subunits proteins are 
imported into the mitochondrion by transport through the outer (TOM) and inner 
(TIM) membrane complexes. Modified and adapted from Wallace, 2012. 
Notably, the major part of the mitochondrial respiratory chain polypeptides, 
as well as the components of the import machinery, are encoded by nuclear genes 
and translated in the cytoplasm with a mitochondrial targeting sequence that directs 
them through the mitochondrial translocation machinery. Also, the proteins for the 
maintaining of the mitochondrial genome are nuclear-encoded. Among them, there 
are the mitochondrial DNA polymerase γ (POLG1) (Van Goethem et al., 2001), the 
mitochondrial transcription factor A (TFAM) and the mitochondrial transcription 
factors B1 and B2 (TFBM1 and TFBM2) (Larsson et al., 1998; Falkenberg et al., 
2002), crucial factors for mitochondrial biogenesis during development and 
differentiation (Larsson et al., 1998). 
If on one hand mitochondria are indispensable for cell survival, on the other 
hand, mitochondria are key regulators of cell death, mainly apoptosis.  In 
mammalian cells, apoptosis is controlled by a wide range of extra- and intra-cellular 
signals, such as chemotherapy, growth factors or cytokines. Apoptosis can be 
initiated by two different ways: an “intrinsic” and an “extrinsic” pathways, 
converging in the apoptosis execution phase. The first one is activated by internal 
signals, such as DNA damage caused by chemotherapeutic agents, while the 
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extrinsic pathway is “switched on” by external signals. Mitochondria are essential 
regulators of the intrinsic pathway of apoptosis, by effector mechanisms by 
regulating the translocation of pro-apoptotic proteins from the mitochondrial 
intermembrane space to the cytosol (Zanzami et al., 1996). 
Interestingly, mitochondria are involved in non-apoptotic cell death, such as 
the regulated necrosis mechanism named “necroptosis”. It has been described that 
necroptosis involves mitochondrial permeability transition (MPT), to lead the 
release of the apoptosis-inducing factor AIF. Furthermore, in the final step of 
programmed necrosis, the rapid mitochondrial dysfunction leads to ROS production 
failure in intracellular ATP production (Galluzzi and Kroemer, 2008). 
1.2.4 Mitochondrial functions in cancer 
Recent advances in cancer understanding suggest that not all the major 
hallmarks of cancer are linked to impaired mitochondrial function, as hypothesized 
by Otto Warburg. In some malignant tumours, there is the accumulation of 
morphologically normal respiration-proficient mitochondria (Lang et al., 2015). 
Indeed, although aberrant tumour cell growth is frequently associated with 
alterations of biochemical metabolism, mitochondrial function is not always 
impaired (Wallace, 2012; Weinberg and Chandel, 2015; Zong et al., 2016). 
Since the lacking of histones and the absence of self-repair mechanisms, 
mtDNA molecules are frequently exposed to damage from ROS produced by these 
organelles. Notably, ROS is one of the most important causes of mitochondrial 
DNA mutations. The accumulation of constant oxidative damage to mtDNA, and 
subsequent nuclear DNA (nDNA) influences cellular and organ functions, leading 
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to disease states and ageing (Zeviar et al., 2014). Somatic and germline mtDNA 
mutations have been described for various tumours, such as renal adenocarcinoma, 
colon cancer, head and neck tumours, astrocytic tumours, thyroid tumours, breast 
tumours, ovarian tumours, prostate and bladder cancer and neuroblastomas 
(Wallace et al., 2012; Brandon et al., 2006). This evidence suggest the possibility 
that mtDNA mutations might contribute to cancer aetiology. However, large studies 
conducted to examine the mutational status of the mitochondrial genome in tumours 
revealed that selective pressure in human cancers allows the cells to retain 
mitochondrial genome functions. A wide analysis of the mitochondrial genome 
mutational landscape has been performed in over 2000 human cancers, including 
more than 30 tumour types, in comparison with normal tissue from the same 
patients (Zong et al., 2016). This analysis identified many somatic substitutions 
(with C to T and A to G) with strong replicative strand bias, on the mtDNA heavy 
strand. Surprisingly, these results revealed the mitochondrial polymerase G errors 
as the major cause of mutations, overshadowing the role of mitochondrial ROS. 
Moreover, while missense mutations are selectively neutral toward homoplasmy, 
harmful and pathogenic mtDNA mutations that remain heteroplasmic are 
negatively selected (Ju et al., 2014; Stewart et al., 2015).  
On the other hand, while there is a negative selection for pathogenic 
mitochondrial genome mutations, some cancers have mutations in nuclear-encoded 
Krebs cycle enzymes – such as the isocitrate dehydrogenase (IDH) 2, succinate 
dehydrogenase (SDH) and fumarate hydratase (FH) - that lead to the oncogenic 
metabolites production (Gaude and Frezza, 2014). Interestingly, this kind of 
mutations induces tumour cells to perform reductive carboxylation to generate the 
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necessary Krebs cycle intermediates. As a result, the metabolism of these tumours 
is distinct from normal cells (Cardaci et al., 2015). 
1.2.5 Targeting mitochondria for cancer therapy 
The increasing understanding of the role of mitochondria in cancer cells 
represents a great opportunity to design novel approaches to targeted therapy for 
the treatment of various cancer (Fulda et al., 2010; Zong et al., 2016). One of the 
most challenging strategies explored for cancer therapy is to correct cancer-
associated mitochondrial dysfunctions to re-establish cell death programmes by 
pharmacological agents that can facilitate mitochondrial membrane 
permeabilisation. Cancer cells bypass the mitochondrial apoptosis pathway by 
suppressing signals related to the process of rupture of MOM defined mitochondrial 
outer membrane permeabilisation (MOMP). Importantly, the loss of the MOM 
impermeability is the result of the process of dissipation of the mitochondrial 
membrane potential and osmotic swelling of the mitochondrial matrix that occur 
during the mitochondrial permeability transition (MPT).  The MPT can be triggered 
by using various agents that can stimulate ROS generation, which represents a pro-
apoptotic stimulus able to induce MPT, through the permeability transition pore 
complex (Fulda et al., 2010). Some of them are able to induce directly excess 
generation of ROS and antioxidant systems inhibition, such as the Menadione and 
Motexafin gadolinium, that have been successfully investigated in clinical study 
involving paediatric glioblastoma and hepatocellular carcinoma patients, 
respectively (Costantini et al., 2000; Magda and Miller, 2006). Other drugs elevate 
ROS levels by inhibiting the antioxidant systems (Maeda et al., 2004; Dragovich et 
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al., 2007), for example, by inhibiting the synthesis of reduced glutathione (e.g. 
buthionine sulphoximine) or by depleting its pool (e.g. Imexon). This approach 
demonstrated some efficacy in breast, prostate and lung cancer patients, alone or in 
combination with chemotherapy. Furthermore, agents able to increase superoxide 
levels by inhibiting the Superoxide dismutase (e.g. 2-methoxy oestradiol) showed 
selectively killing activity on human leukaemia cells (Huang et al., 2000).  
The dependence of tumour cells on glycolysis for ATP generation can be 
exploited by anti-tumour strategies aimed to reverse their hyper-glycolytic state and 
lead them to cell death (Gill et al., 2016). Specifically, the attempt consists in the 
selective inhibition of the glycolytic pathway to sensitize tumour cells to anticancer 
agents. An example is represented by 2-deoxy-d-glucose (2DG), a calorie 
restriction mimetic that inhibits the glycolytic pathway by competitively inhibiting 
the synthesis of glucose-6-phosphate from glucose through the 
phosphoglucoisomerase. 2DG significantly intensifies the cytotoxicity of various 
anti-tumour drugs, by enhancing oxidative stress, such as in Cisplatin treatment of 
human head and neck cancer cells (Simons et al., 2007), as well as in Doxorubicin 
and Paclitaxel treatments in human osteosarcoma and non-small cell lung cancers 
(Maschek et al., 2004). Furthermore, in breast cancer cell lines, 2DG acts 
synergistically with DNA damaging chemotherapeutic agents and causes cell death 
(Zhang and Aft, 2009). In tumours characterized by impaired mitochondrial 
bioenergetics, a similar approach consists in the stimulation of mitochondrial 
activity to overcome the upregulation of the glycolytic pathway and restore ATP 
production mechanism used by non-malignant cells. This kind of strategy has been 
implemented, as an example, by inhibiting PDK1 by dichloroacetate, to readdress 
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the pyruvate metabolism and shift metabolism from glycolysis to glucose oxidation 
(Bonnet et al., 2007).  
A similar approach takes advantage of the presence of nuclear-encoded Krebs 
cycle enzymes mutations in cancer cells. Tumours with defective mitochondrial 
functions show a different metabolism compared with most normal tissues, as an 
example, by up-regulating this pathway to satisfy energy requirement. To exploit 
this metabolic vulnerability is possible to inhibit the glucose uptake. To this aim, 
the activity of mutant IDH has been investigated as a potential therapeutic target in 
glioma cells and human leukaemia (Rohle et al., 2013; Wang et al., 2013). 
Similarly, in SDH-associated malignancies, the loss of SDH activity induces a 
block of Krebs cycle and drives proliferating cells to aerobic glycolysis. This event 
represents a very interesting metabolic vulnerability that can be a targeted therapy. 
SDH activity lack leads cells, on the one hand, to consume the extracellular 
pyruvate needed to sustain glycolytic flux and, on the other hand, to divert glucose-
derived carbons into aspartate biosynthesis, thus sustaining cell growth (Cardaci et 
al., 2015).  
The mitochondrial contribution to molecules biosynthesis is being investigated 
too. Glutamine metabolism, for example, is being explored since cancer cells 
usually increase its uptake and utilization. Glutamine metabolism requires the 
activity of the mitochondrial enzyme, glutaminase (GLS), for the production of 
glutamate. This enzyme, in cancer cells, is the predominant Krebs cycle fuel and it 
is involved in the production of intermediates for fat synthesis (Zong et al., 2016). 
Interestingly, GLS expression is induced by the proto-oncoprotein c-Myc (Gao et 
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al., 2009). Furthermore, it has been described that glutamine deprivation leads Myc-
expressing cells to apoptosis (Yuneva et al., 2007). Consequently, as 
pharmacological inhibition of GLS suppresses tumour growth in renal cell 
carcinoma in mouse models, targeting glutaminase might be a good strategy to 
explore in suppressing Myc-driven cancer therapy (Shroff et al., 2015).  
Recent reports suggest that cancer cells are highly susceptible to the inhibition 
of oxidative phosphorylation. The anti-diabetic drug known as Metformin, is an 
inhibitor of complex I of the electron transport chain, which is used by cells to 
produce energy. Recently metformin has been investigated for its anticancer 
activity (Evans et al., 2005; Chae et al., 2016; Wheaton et al., 2014). In xenograft 
models of Ras-driven colon cancer, Metformin impairs tumour growth by blocking 
tumour-intrinsic metabolism, since a tumour is dependent on oxidative 
phosphorylation to make ATP. At least two ways have been proposed for 
Metformin activity on tumour growth (Wheaton et al., 2014).  The first one suggests 
that the slower rate of tumor growth represents the side-effect of the Metformin 
activity of reducing the blood amount of insulin, which, in turns, stimuluses cancer 
cells division.  On the other side, it has been proposed that Metformin targets cancer 
cells by reducing the mitochondria-produced energy supply. Moreover, low 
glucose-sensitive cell lines are not able to up-regulate the OXPHOS in low glucose 
conditions. This impairment, which is the result of mtDNA mutations in Complex 
I genes or impaired glucose utilization, induces cell sensitivity to Metformin, and, 
in general, to OXPHOS inhibitors (Birsoy et al., 2014). 
 Introduction 
 39 
 
Additionally, inhibitors of mitochondrial translation can also act as sensitizers to 
cancer therapeutics and chemotherapy (Kuntz et al., 2017), especially in a tumour 
characterized by high level of mitochondrial biogenesis (Tan et al., 2017). The 
antibiotic Tigecycline –a mitochondrial protein translation inhibitor - has been 
shown as selectively acting against hepatocellular carcinoma (HCC) by inducing 
mitochondrial dysfunction and oxidative damage, via decreasing mitochondrial 
membrane potential, complex I and IV activities, mitochondrial respiration and 
ATP levels. Similar results have been observed in chronic myeloid leukaemia 
(CML), in which the combined treatment with the c-Abl-specific Tyrosine kinase 
inhibitors, Imatinib and Tigecycline, selectively destroy leukemic stem cells in a 
xeno-model of human CML.  
1.3 Forkhead box protein family 
Forkhead box (Fox) protein family has been described first in Drosophila (Weigel 
et al., 1989). This heterogenic protein family includes more than 100 transcription 
factors, which can be divided into 19 subclasses based on phylogenetic analysis. To 
classify the numerous member of Fox family, the term “Fox” is used as the root 
symbol, followed by a letter (from A to S) that indicates the subclass, and a number 
that identifies each protein. Fox proteins share a conserved DNA-binding domain, 
a sequence of 80 to 100 amino acids named Forkhead domain (FD). A “winged-
helix” motif characterizes the Forkhead motif, due to the butterfly-like appearance 
of the loops in the protein structure of the domain, with three α helices and two 
large disordered loops (Clark et al., 1993). Fox transcription factors are involved in 
 Introduction 
 40 
 
a plethora of diverse functions, including development regulation, metabolism, 
tumorigenesis, and cognition. Their function is tightly regulated through the 
interaction with various binding partners, including co-activators, co-repressors and 
other transcription factors (Carlsson and Mahlapuu, 2002).  
The FoxO proteins have been identified in many species, including nematode 
(Caenorhabditis elegans), Zebra fish (Danio rerio), fruitfly (Drosophila 
melanogaster), mouse and human (Arden, 2004; Arden, 2006). Mammalian FoxOs 
are orthologues of the transcription factor DAF-16, identified in C. elegans, 
involved in insulin signalling and longevity (Van der Horst and Burgering, 2007). 
The FoxO class is made of four members, FoxO1 (previously known as FKHR), 
FoxO3A (previously known as FKHRL1), FoxO4 (previously known as AFX) and 
FoxO6. Most of them are ubiquitously expressed, even though they can differ in 
tissues or organs. Additionally, it has been recently unravelled that the human 
FoxO3A pseudogene FoxO3B is a true human gene, which encodes a FoxO3A-
related protein product (Santo and Paik, 2018). 
FoxO proteins share high sequence homology. Their subcellular localisation 
defines their activity. Their structure consists of four common main domains 
(Figure 1.3): the Forkhead DNA binding domain (DBD), a nuclear localisation 
signal (NLS) downstream of the DBD, a nuclear export sequence (NES) and a C-
terminal trans-activation domain (Greer and Brunet, 2005). To exert their role as 
transcription factors, FoxO proteins bind, through their DBD, to the consensus 
motif (Forkhead Response Element, FHRE), 5’-TTGTTTAC-3’, within the target 
promoter sequence (Van der Horst and Burgering, 2007). Once they are bound to 
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DNA, the C-terminal trans-activation domain initiates gene transcription, working 
as a transcriptional activator or repressor, possibly depending on the range of 
associated co-factors that they recruit. 
 
Figure 1.3 –Domains contained in mammalian FoxO proteins.  
The following are indicated: locations of the forkhead domain (FD), nuclear 
localisation sequence (NLS), nuclear export sequence (NES) and helical motif 
(LXXLL). Adapted from Sanchez et al. 2013. 
FoxO proteins are not equally expressed in all tissues, suggesting that individual 
proteins may have specificity in regards to cellular function (Fu and Tindall, 2008). 
As an example, the FoxO1 transcript is highly expressed in adipose tissues, while 
FoxO4 is expressed mostly in skeletal muscle.  The formating transcript is abundant 
in brain, heart, kidney and spleen, while FoxO6 is predominantly found in the brain, 
FoxO3A 
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suggesting an important role for this FoxO to control cognitive and motor function 
(Figure 1.4)
 Introduction 
 43 
 
 
Figure 1.4- Types of FoxO and their involvement in various diseases. 
Image adapted from Farhan et al., 2017.
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1.3.1 FoxO target and functions 
Through its transcription factor activity, FoxO proteins differentially affect 
cell fate in a downstream target-specific manner (Figure 1.5). Indeed, as their ability 
to bind a large number of gene promoters containing the DBD (Xuan and Zhang, 
2005), they present a great diversity in function. In invertebrates, the homologous 
DAF-16 has been proven to increase lifespan and regulate nutrient sensing. These 
functions are conserved in Drosophila, where dFoxO is also involved in insulin 
signalling. In mammals, the members of the FoxO family play a role in stress 
resistance, proliferation/arrest, survival/death, metabolism and autophagy. FoxO 
proteins have been shown to get involved in tumour suppression, regulation of 
energy metabolism and development in some tissues. (Van de Horst A & Burgering 
BM, 2007).  Interestingly, FoxO3A has also been described to regulate ovarian 
follicular development and fertility, glucose uptake after fasting and muscle 
regeneration (Castrillon et al., 2003; Sanchez et al. 2014). 
One of the functions explored of FoxO is the regulation of cell cycle. In 
particular, FoxO is involved in the two important checkpoints for stress response, 
G1/S and G2/M. On the first point, it can block the G1 progression by repressing 
cyclin D1 and D2 either directly (Ramaswamy et al. 2002) or indirectly through 
Bcl6/STAT5 (Fernandez de Mattos et al. 2004). FoxO also promotes cell cycle 
arrest at the G1/S phase by up-regulating the CDK cyclin-dependent kinase 
inhibitors p21Cip1 (Seoane et al. 2004) and p27Kip1 (Medema et al. 2000). 
Furthermore, FoxO3A can act on p27Kip1 directly - by disrupting the cyclin 
D/CDK4 and Cyclin E/CDK2 complexes and causing an arrest at the G1 cellular 
checkpoint (Medema et al. 2000, Schmidt et al., 2002),  or indirectly, through the 
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modulation activity exerted by c-Myc on FoxO3A (Bouchard et al., 2004). FoxO 
can also induce cell cycle arrest at the G2/M checkpoint by induction of growth-
arrest and DNA-damage inducible protein GADD45α (Furukawa-Hibi et al. 2002, 
Tran et al. 2002), which is important in DNA-damage repair, maintaining genetic 
integrity, and promoting cell survival. Induced by FoxO, GADD45α interacts with 
the cdc25/Cyclin B complex and the CDKI p21, promoting the activation of the 
G2/M checkpoint, and the initiation of DNA repair mechanisms (Furukawa-Hibi et 
al. 2002). Moreover, by modulating GADD45α FoxO proteins participate to DNA 
conservation and repair, (Tran et al., 2002), to maintain the genomic integrity and 
reduce the accumulation of oncogenic mutations (Alekseyev et al. 2008).  
FoxO proteins protect cells from ROS accumulation through the regulation 
of genes involved in cell detoxification and cell survival. Notably, FoxO3A is up-
regulated in response to ROS accumulation. This event leads to an increase in the 
expression of its downstream transcriptional targets, such as the manganese 
superoxide dismutase (SOD2) and the Catalase (Kops et al. 2002). 
FoxO proteins have various target genes in cell death pathways, which 
differentially express, through combinatory effects, ensure an efficient result. FoxO 
regulates the transcription of the tumour necrosis factor-related apoptosis inducing 
ligand, TRAIL (Modur et al., 2002), and of the tumour necrosis factor receptor-
associated death domain, TRADD (Rokudai et al., 2002). Moreover, it has been 
widely explored that FoxO3A regulates the pro-apoptotic Bcl-2 family member 
Bcl-2-like protein 11 (Bim) expression (Dijkers et al., 2000a). Treatment of chronic 
myelogenous leukaemia (CML) cell lines driven by the BCR-ABL chimeric 
oncogene, with a BCR-ABL inhibitor, showed the activation of FoxO3A-dependent 
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Bim expression, resulting in apoptosis. (Essafi et al., 2005). FoxO3A has been 
widely shown to act as a tumour suppressor not only in leukaemia but also in breast 
and prostate cancers (Dansen and Burgering, 2008). Moreover, somatic deletion of 
FoxO1, FoxO3A, or FoxO4 in mice results in a cancer-prone phenotype, such as 
thymic lymphomas and haemangiomas (Paik et al., 2007).  
Interestingly, the first identified FoxO member, DAF-16, which regulates 
the larva formation in C.elegans, is related to longevity (Kenyon et al., 1993). This 
function is evolutionally conserved. In recent years, the relationship between 
FoxO3A genotype and human longevity has been explored. Numerous single 
nucleotide polymorphisms (SNPs), located in intronic regions of the gene, are 
associated with longevity with statistical significance in different human 
populations (Willcox et al., 2008, Flachsbart et al., 2009, Anselmi et al., 2009). 
FoxO proteins play a major role also in cellular differentiation. As an 
example, in mice models the absence of FoxO3A causes a deficiency in the ability 
of haematopoietic stem cells to repopulate the bone marrow, suggesting its possible 
role in promotion and maintenance of undifferentiated haematopoietic stem cells 
(Miyamoto et al., 2007). 
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Figure 1.5 -FoxO target genes and cellular roles. 
Adapted from Greer and Brunet, 2005. 
1.3.2 Regulation of FoxO 
A complex cascade of post-translational modifications (PTMs), including 
phosphorylation, acetylation and ubiquitination, regulates FoxOs’ transcriptional 
activity and protein-protein interactions (Figure 1.6). These modifications, known 
as “FoxO code” (Calnan and Brunet, 2008), are the result of the integration of 
cellular stimuli acting on FoxO. Notably, they determine the cellular localisation 
and the activity of FoxO proteins, since nuclear FoxOs can perform their typical 
transcriptional regulator activity, while cytoplasmic FoxOs are inactive and 
undergo proteasomal degradation. As a result, PMTs on FoxO influence the cell 
fate. 
ATM 
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Figure 1.6 -Post-translational modifications of FoxO. 
Effect: (−), Inhibition of FoxO; (+), activation of FoxO.  Black, PTMs verified in 
cells; blue, expected site based on sequence alignment with other FoxO family 
members; green, PTMs verified in cells for the mouse FoxO; red, removal of PTMs. 
Italics—PTMs identified in vitro, not verified in cells. Adapted from Calnan and 
Brunet, 2008. 
Phosphorylation of FoxO3A 
Negative and positive regulation of FoxO3A involves principally 
phosphorylation events, mainly related to evolutionarily conserved signalling 
pathways, sensitive to metabolic and oxidative conditions of the cell. The main 
negative regulator of FoxO3A is represented by the insulin signalling pathway, 
constituted by phosphoinositide-3 kinase (PI3K) and the oncogenic protein kinase 
B (PKB), also known as the Serine/Threonine kinase 1AKT (Brunet et al. 1999, 
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Brownawell et al. 2001). Furthermore, two other main oncogenic kinases, like the 
inhibitor of NFκB signalling IKKβ and the mitogen-activated protein kinase 
MAP3K (also known as ERK, Extracellular-signal-regulated kinases) are also 
involved in the regulation FoxO3A nuclear localisation and activity (by 
phosphorylation), supporting the critical role of FoxO3A in cancer cells survival 
(Figure 1.7). 
Activation of PI3K is induced by insulin-like growth factor (IGF-1) bound 
to its Tyrosine kinase-receptor IGF-1R. Activated PI3K phosphorylates the 
phosphatidylinositol-4,5-biphosphate (PIP2) membrane lipid to 
phosphatidylinositol-3,4,5-triphosphate (PIP3), offering the binding site on cell 
membrane for AKT, to localise it next to PDK1 (Phosphoinositide-Dependent 
protein Kinase 1). In this position, PDK1 can bind and activate AKT, leading to the 
phosphorylation of numerous substrates, including Threonine 32 and Serine 253 on 
FoxO3A (Greer and Brunet 2005). As a consequence, FoxO3A interacts with the 
chaperone proteins 14-3-3. This event blocks the FoxO3A nuclear import through 
interfering with its NLS region in the FHRE domain and shifts its localisation into 
the cytoplasm, leading to FoxO3A activity inhibition (Rena et al. 1999). Similar to 
AKT, Serum and Glucocorticoid-regulated Kinase (SGK) is also activated by PI3K 
and phosphorylates FoxO3A on the same residues of AKT (Brunet et al. 2001). 
IKKβ phosphorylates FoxO3A on S644 leading to its nuclear exclusion and 
promoting its degradation by an ubiquitin-proteasome-dependent pathway (Hu et 
al., 2004; Greer and Brunet 2005; Arden et al. 2004, Tezil et al. 2012).  
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The involvement of the RAS-ERK axis, one of the main actors in 
differentiation, proliferation and tumour progression in FoxO3A activity 
modulation, is performed by the direct interaction of ERK with the transcription 
factor and phosphorylation on its S294, S344 and S425. This post-translational  
modification results in FoxO3A stability suppression and nuclear exclusion (Yang 
et al., 2008). Moreover, the increase of FoxO3A cytoplasmic distribution improves 
its susceptibility to degradation via a murine double minute 2 (MDM2)-mediated 
ubiquitin-proteasome pathway, which serves as an E3 ligase. As a consequence, 
FoxO3A down-regulation promotes cell proliferation and tumorigenesis. 
Notably, not all the phosphorylation events targeting FoxO3A lead to its 
negative regulation and cytoplasmic localisation. In fact, in response to oxidative 
stress, FoxO3A is phosphorylated by other kinases promoting its nuclear 
accumulation. As an example, the upstream activator of MAPK pathway, MST-1, 
can phosphorylate FoxO3A, disrupting the interaction with 14-3-3 and promoting 
its nuclear translocation (Lehtinen et al. 2006). Similarly, as a response to oxidative 
stress, the June-terminal kinase (JNK)-mediated phosphorylation results in 
FoxO3A nuclear localisation promotion and, consequently, its transcriptional 
activity (Eijkelenboom and Burgering, 2013). JNK can also modulate FoxO3A 
activity indirectly, by repressing the PI3K/Akt activity (Sunters et al. 2006, Ho et 
al. 2012). A similar pathway involves the MAPK p38, which promotes FoxO3A 
phosphorylation at S7 and its re-localisation to the nucleus, in response to 
chemotherapy treatment (Ho et al., 2012).   
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Figure 1.7 - Schematic representation of the major oncogenic signalling pathways 
linked with FoxO3A. 
The phosphorylation mediated by AKT, ERK or IKK leads to FoxO3A inactivation 
and degradation, as described in several cancer types (as indicated). Image 
adapted from Coomans de Brachène and Demoulin, 2013. 
Similarly, in response to metabolic stress, the AMP-responsive kinase mediates 
FoxO3A phosphorylation and induces qualitative changes in the protein, 
influencing the shuttling between nucleus and cytoplasm and the transcriptional 
activity of the transcription factor (Greer et al. 2007b). AMPK is a central player in 
glucose and lipid metabolism, acting in response to nutrient and intracellular energy 
levels alterations. Interestingly, it phosphorylates FoxO3A on at least six specific 
sites, while experimental evidence suggesting that AMPK also acts on other sites 
(Greer et al. 2007b). Moreover, under metabolic stress, AMPK indirectly modulates 
FoxO3A transcriptional activity by activating the NAD+-dependent deacetylase, 
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Sirtuin1 (SIRT1, Canto et al. 2009, Brunet et al. 2004). Furthermore, AMPK can 
be triggered by mitochondrial ROS, through an alternative pathway that involves 
FoxO3A and its target genes such as SOD, catalase, and the peroxisome 
proliferator-activated receptor-γ coactivator-1α (PGC1α) (Colombo et al. 2009, 
Chiacchiera and Simone 2010). Remarkably, AMPK-phosphorylation is required 
for FoxO3A mitochondrial translocation, in normal cells (Peserico et al. 2013).  
Acetylation/deacetylation of FoxO3A 
Acetylation/deacetylation events represent another important post-translational 
modification to regulate FoxO3A transcriptional activity, especially under 
oxidative stress (Figure 1.8). These events are evolutionarily conserved as in 
C.elegans, DAF-16 is positively regulated by acetylation (Tissenbaum and 
Guarente 2001, Motta et al. 2004). FoxO3A acetylation is performed by the 
acetyltransferases p300 and the cyclic-AMP responsive element binding (CREB)-
protein, while the deacetylation is performed by NAD+-dependent deacetylases, 
like SIRT1 and SIRT3, which are parts of Sirtuin family (Brunet et al. 2004, Calnan 
and Brunet 2008, Kobayashi et al. 2005, Daitoku et al. 2014). Seven Sirtuins are 
known in humans, named as hSIRT1–7, mainly characterized by a NAD-dependent 
deacetylase activity (Schwer et al., 2002).  
The acetylation/deacetylation status of FoxO3A results in the activation of 
different transcription programmes, such as apoptosis, through the strong activation 
of pro-apoptotic genes transcription, such as Bim, p21 and FASL6 (Brunet et al. 
2004). Conversely, FoxO3A deacetylation by SIRT1 results in cell survival and 
FoxO3A-dependent apoptosis suppression, through the activation of downstream 
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targets involved in cell cycle arrest, DNA repair and antioxidant activity like 
GADD45α, SOD and p27 (Brunet et al. 2004). Therefore, SIRT1-mediated 
FoxO3A deacetylation can be considered as a cell-dependent cytoprotective 
mechanism (Greer and Brunet, 2005).   
 
Figure 1.8 - Key regulators of post-translational modification of FoxO3A. 
Stimulation with insulin or growth factors induces the phosphorylation of FoxO3A 
through PI3K pathway, leading to the association with 14-3-3 factors and nuclear 
export. The hypo-phosphorylated status of FoxO3A leads to Sirtuin recruitment and 
to the DNA binding promotion. Image adapted from Myatt et al., 2007. 
Genes transcription 
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Besides SIRT1, even SIRT3, the main mitochondrial Sirtuin, can efficiently 
deacetylate FoxO3A (Kim et al., 2010). SIRT3 interacts directly with FoxO3A in 
mitochondria and nucleus. In the first case, the interaction promotes the 
transcription of oxidative stress response genes, such as catalase and SOD2 (Jacobs 
et al.  2008, Peserico et al. 2013, Tseng et al. 2013). Notably, the mitochondrial 
interaction between SIRT3 and FoxO3A will be discussed in the paragraph 1.3.3. 
In nucleus, SIRT3-FoxO3A interaction results in the nuclear localisation of 
FoxO3A and enhances the transcription of its nuclear target genes (Sundaresan et 
al. 2008). These events modulates FoxO3A ability to regulate cellular ROS 
accumulation. In mice, SIRT3-FoxO3A interaction ameliorates cardiac 
hypertrophy by ROS modulation, through FoxO3A nuclear localisation promotion 
and antioxidant genes transcription activation. (Sundaresan et al. 2008, Scher et al. 
2007). 
Ubiquitination of FoxO3A 
FoxO3A protein levels and activity can be mediated among others by 
ubiquitin-dependent protein degradation (Tzivion et al., 2014). Two kinds of this 
PTM are possible: mono-ubiquitination (reversible) and poly-ubiquitination (not 
reversible), which results in the proteasome-mediated degradation (Figure 1.9). The 
poly-ubiquitination is performed in two steps: firstly, the target protein is covalently 
attached to the ubiquitin molecules, with the help of an ubiquitin-activating enzyme 
(E1-3). Then the 26S proteasome complex degrades the protein (Nakayama et al., 
2006). The identified E3 ligases that mediate FoxO3A poly-ubiquitination is the S-
phase kinase-associated protein 2 (SKP2) and MDM2, ubiquitin-ligases. MDM2 
can both induce FoxO mono-ubiquitination as well as poly-ubiquitination. The 
 Introduction 
 55 
 
latter is related to AKT phosphorylation on Ser-253 of FoxO3A. On the other hand, 
ERK-phosphorylation induces FoxO3A mono-ubiquitination by MDM2 (Yang et 
al., 2008). IKK phosphorylation of FoxO3A induces its proteasome degradation. 
As IKK expression promotes cancer cell proliferation and tumorigenesis, FoxO3A-
IKK phosphorylation might represent a promoting mechanism of tumorigenesis 
(Hu et al., 2004). 
 
Figure 1.9 -ERK interaction and phosphorylation of FoxO3A. 
The post-translational modification increases FoxO3A-MDM2 interaction and its 
degradation through a MDM2-dependent ubiquitin-proteasome pathway, 
promoting tumorigenesis. Adapted image from Yang et al., 2008. 
Poly-ubiquitination 
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Methylation of FoxO3A 
Lysine methylation of FoxO3A is not well-characterised. It has been 
reported that the methyl-transferase SET9 directly methylates FoxO3A, in vitro and 
cells, on the lysine 271. The methylation decreases the stability of FoxO3A. 
Howeverm it increasease FoxO3A transcriptional activity, upon stress stimuli 
(Calnan et al., 2012). 
1.3.3 FoxO3A as tumour suppressor: a cancer therapy 
opportunity 
To prevent the progression of cancer, surgery, radiotherapy, chemotherapy 
or their combinations are employed, depending on the stage and type of cancer. The 
aim of the chemotherapy focuses on promoting cancer cell death, preferably 
apoptosis, by changing the intracellular signalling pathways. Understanding how 
different therapeutic agents affect different cell types is instrumental to design more 
efficient and specific drugs. Worldwide, therapeutics in use is only 50% successful. 
In fact, varoius therapeutic resistance mechanisms interfere with the effect of drugs 
or/and desensitise the cells against cellular death signals. This phenomenon, known 
as chemo-resistance, can be acquired from cancer cells in the course of therapy or 
they can already be innate resistant genotypically. Currently, alongside the 
cytotoxic chemotherapies, targeted therapies that can modulate specific molecular 
oncogenic target (e.g. tumour suppressors), are taking holds, such as monoclonal 
antibodies and small molecules.  
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As briefly explained before, in mammals, FoxO proteins are involved in cell 
cycle arrest, DNA repair and apoptosis. The involvement in these function supports 
the idea of FoxOs as tumour suppressors. Indeed, loss of FoxO function decreases 
the ability to induce cell cycle arrest and to repair damaged DNA, subsequently 
leading to genomic instability and tumour development. Moreover, since apoptosis 
induction ability is compromised, in the absence of FoxOs, abnormal cells succeed 
to survive, resulting in tumour expansion. Simultaneous genetic deletion of five 
FoxOs alleles, correspondent to somatic FoxO1, FoxO3A, or FoxO4 in mice, 
resulted in a cancer-prone phenotype (Paik et al., 2007). The further deletion of all 
of the FoxOs alleles induces progressive cancers, late in life, such as thymic 
lymphomas and haemangiomas. Anyway, carcinoma has not been observed. 
Together, these data suggested FoxOs as putative tumour suppressors. However, 
genetic alterations inactivating FoxO loci in human cancers are quite rare. This 
evidence might explain why the tumour suppressor activity is visible only after 
inactivation of four to six alleles of FoxO. Furthermore, FoxO inactivation at 
protein and mRNA levels in cancer cells is efficiently performed via different 
oncogenic signalling pathways. 
FoxO3A was one of the first FoxO factor recognised as a tumour suppressor 
in human breast cancer tissue samples, since its absence correlated with poor 
survival of patients (Hu et al., 2004). Additionally, low levels of FoxO3A protein 
expression are  associated with poor prognosis in several types of cancers, including 
ovarian cancer, hepato-cellular carcinoma, gastric cancer, and lung adenocarcinoma 
(Fei et al., 2009; Jiang et al., 2013; Habashy et al., 2011; Yang et al., 2013; Yu et 
al., 2016;  Liu et al., 2015). 
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During tumour development, inhibition of the transcriptional activity of 
FoxO3A promotes cell transformation, tumour progression and angiogenesis, while 
its over-expression inhibits a breast tumour (Greer & Brunet 2005; Potente et al., 
2005; Hu et al., 2004). In many types of human cancers, down-regulation of 
FoxO3A results from post-translational regulation by on-kinases, such as AKT, 
IKKβ and ERK, as well as from the over-activation of upstream regulatory 
pathways, like the Phosphatase And Tensin Homolog, PTEN.  
FoxO factors tumour suppressor activity have been investigated as 
therapeutic targets in various cancers, especially as mediators of the cytostatic and 
cytotoxic effects of chemotherapeutic agents. Different strategies have been 
implemented to activate FoxO3A. As an example, Paclitaxel - a chemotherapeutic 
agent used in the treatment of breast carcinoma- activates FoxO3A by reducing the 
activity of its upstream kinase AKT (Sunters et al., 2005). Therefore, the interaction 
between FoxO3A with the 14-3-3 protein is impaired (Tzivion et al., 2011), as well 
as the 14-3-3-mediated FoxO3A nuclear export. Paclitaxel can modulate FoxO3A 
activation also through JNK, resulting in FoxO3A-DNA binding promotion and 
activation of the transcriptional programme (Sunters et al., 2006; Eijkelenboom and 
Burgering, 2013).  Doxorubicin treatment induces p38-mediated FoxO3A nuclear 
re-localisation (Ho et al., 2012) in MCF breast carcinoma cell line. On the other 
hand, in sensitive leukemic cells, doxorubicin leads FoxO3A to induce the 
expression of the multidrug resistance gene ABCB1 in K562 doxorubicin-sensitive 
leukemic cells (Hui et al., 2008). Additionally, Imatinib, a drug used for chronic 
myelogenous leukaemia (CML) and acute lymphocytic leukaemia, activates 
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FoxO3A (Essafi et al., 2005) and induces Bim-dependent apoptosis through 
inhibition of BCR-ABL in CML, as briefly mentioned in the paragraph 1.2.4.  
Another strategy for targeting FoxO3A in cancer therapy is represented by 
the modulation of the FoxO3A-FOXM1 transcriptional axis (Figure 1.10). The 
Forkhead box protein M1 (FOXM1) is a proto-oncogene acting as a transcriptional 
activator, which is involved in cell proliferation by regulating the expression of cell 
cycle genes, like cyclin B1 and cyclin D1. Its up-regulation is frequent in several 
human cancers, including liver, breast, lung, prostate, uterus, colon, and pancreas. 
Furthermore, FoxO3A directly repress the activity of FOXM1 (Wilson et al., 2011; 
Yao et al., 2017). Various anticancer drugs like the “tinibs” agents (Lapatinib, 
Imatinib and Gefitinib), Paclitaxel, Cisplatin and Doxorubicin can be used to 
modulate FoxO3A-FOXM1 axis. Intriguingly, their cytostatic and cytotoxic effects 
are mediated through the activation of FoxO3A and/or the inhibition of FOXM1 
(Yao et al., 2017; Farhan et al., 2017). 
Lapatinib, Imatinib and Gefitinib interfere with the PI3K-AKT-FoxO3A-
FOXM1 axis by blocking the auto-phosphorylation of receptor-Tyrosine kinases 
and downstream signalling. On the other hand, as briefly described above, the JNK-
triggering ability of Paclitaxel leads to the nuclear accumulation of FoxO3A and, 
consequently, to the inhibition of FOXM1. Similarly, Doxorubicin, promotes the 
nuclear translocation of FoxO3A by phosphorylating of p38 MAP kinase. 
Moreover, at the same time, it can directly down-regulates FOXM1 expression, as 
well as Cisplatin and Epirubicin (Yao et al., 2017; Farhan et al., 2017). Furthermore, 
in cancer cells in which Sirtuins activity is up-regulated (i.e. SIRT4, SIRT5, SIRT6 
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and SIRT7), the combined treatment with Sirtuins inhibitors, such as Sirtinol, 
Salermide or EX527 and Doxorubicin or Epirubicin helps cells to overcome chemo-
resistance, by mediating the deacetylation and inhibition of FoxO3A (Yao et al., 
2017). 
 
Figure 1.10 - Example of anticancer drugs interfering with FoxO3A pathway. 
Image modified and adapted from Farhan et al., 2017. 
1.3.4 FoxO3A and chemo-resistance 
Even if chemotherapy and radiotherapy are often successful in inducing cell 
death of tumours or reducing the tumour mass, many cancer patients develop 
resistance to cancer therapeutics, experience recurrence and die. A fascinating 
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therapeutic opportunity is represented by the combination of the FoxO3A tumour 
suppressor activity and other therapeutic agents, to sensitize resistant tumour cells.  
In colorectal cancer (CRC) cells, FoxO3A is a mediator of the cytotoxic 
effect of Cisplatin. Inhibition of FoxO3A de-phosphorylation and nuclear 
translocation induced by Cisplatin in the PI3K/AKT/FoxO3A axis causes 
chemoresistance of CRC to the drug (Fernández de Mattos et al., 2008). Similarly, 
the PI3K/AKT/FoxO3A pathway activation plays an important role in 5-
Fluorouracil (5-FU) resistance in CRC. The co-treatment of CRC cells with 5-FU 
and the PI3K/mTOR inhibitor, NVP-BEZ235, induces AKT survival pathway 
inhibition and the activation of FoxO3A-mediated transcription of genes target 
related to cell death (Wang et al., 2015). Additionally, the p38-FoxO3A axis can be 
targeted to overcome chemo-resistance of CRC cells to chemotherapeutics. In vitro 
co-treatment with a p38 inhibitor, SB202190 and Cisplatin induces FoxO3A 
activation and apoptosis mediated by FoxO3A-target genes. Moreover, in vivo, the 
same co-treatment results in tumour regression in xenograft mouse model (Germani 
et al., 2014). In ER-negative breast cancer, the activation of FoxO3A through the 
inhibition of the PDK-1/AKT pathway results in the sensitization of chemo-
resistant cells to Tamoxifen (Weng et al., 2008). 
Another opportunity of combined therapy involves the epidermal growth 
factor receptor/human epidermal growth factor receptor2 (EGFR/HER2) blocking 
agents, currently employed in clinical trials against breast, prostate, kidney, ovarian 
and lung cancers (Myatt et al., 2007). Especially, the inhibition of the EGFR family 
by monoclonal antibodies such as Trastuzumab or Cetuximab impairs the PI3K 
pathway and promotes FoxO3A activity (Real et al., 2005). Furthermore, the 
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reconstitution of active FoxO3A results in sensitisation of resistant cancer cells to 
EGFR/HER2 inhibitors like Lapatinib and Gefitinib (Myatt et al., 2007). 
Additionally, in osteosarcoma model, FoxO3A activation induces Bim and 
apoptosis in cells exposed to ionizing radiation (Yang et al., 2006). Thus, the 
combination of radiation with chemotherapy targeting FoxO3A may improve 
tumour cells sensibility to radiation therapy. 
1.3.5 FoxO3A at the interface between cell death and survival 
As briefly explained before, in cancer energy metabolism reprogramming, 
key mitochondrial functions are usually preserved in the majority of cancer cells 
and are required for the acquisition of a fully malignant phenotype. In this context, 
proteins usually considered as genuine tumour suppressors are sometimes required 
to be functional for full malignant phenotype acquisition depending on the cellular 
context, such as FoxO3A (Gomes et al., 2008; Zhang et al., 2011; Chiacchiera and 
Simone, 2010). 
FoxO3A activity as tumour suppressors have been extensively explored and 
linked not only to its pro-apoptotic and anti-proliferative actions but also to its 
involvement in angiogenesis, resistance to oxidative stress and control of cell 
invasion (Figure 1.11). However, further experimental evidence suggested a dual 
role for FoxO3A at the crossroad between cell survival and death. Although its 
activity and expression are unaltered in different cancers, numerous studies 
performed in the last decade demonstrated that FoxO3A also has an unexpected 
function in the promotion of cancer and in modulating responses to cancer 
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treatment, through a variety of mechanisms (Storz et al., 2009; Scisci et al., 2013; 
Liang et al., 2013; Ahn et al., 2018). 
Indeed, it has been recently proposed that FoxO3A can be involved in 
promotion of cancer cell survival, tumour expansion, and metastasis. As an 
example, in breast cancer, FoxO3A plays a pro-invasion role by regulating the 
expression matrix metalloproteinase (MMP), such as MMP-9 or MMP-13 (Storz et 
al., 2009; Scisci et al., 2013). In this context, any therapy under development to 
inactivate FoxO3A might be a candidate to block tumour expansion and metastasis 
(Storz et al., 2009; Scisci et al., 2013). Pro-oncogenic functions have been 
investigated in hepatocellular carcinoma (HCC) too, where FoxO3A activates 
serotonin-induced cell proliferation in serum-deprived HCC cells (Liang et al., 
2013; Ahn et al., 2018). A more recent study showed the association between the 
over-expression of FoxO3A and aggressive phenotypes with a poor prognosis in 
patients with HCC. 
Furthermore, the down-regulation of FoxO3A expression in HCC cell line 
inhibits cell proliferation and migration. Similarly, FoxO3A protein expression has 
been associated with progression and poor prognosis in glioblastoma (GBM) 
patients. Indeed, FoxO3A over-expression considerably promoted the colony 
formation and invasion ability in GBM cells, by activating of c-Myc, microtubule-
associated protein 1 light chain 3 beta (MAP1LC3B) and Beclin1 (Qian et al., 
2017). Consistently, FoxO3A knockdown strongly inhibited tumour progression.  
Other studies suggested that, at least in some types of cancer, like leukaemia, 
activation of FoxO3A is initially required for induction of apoptosis in response to 
chemotherapy, whereas its prolonged activity promotes drug-resistance by 
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increasing anti-oxidant defences and DNA damage repair (Hui et al., 2008). 
Furthermore, not surprisingly, FoxO3A has emerged as a major sensor for 
metabolic stress and chemotherapeutic drug response in cancer cells. As it will be 
exploited in section 1.3.2, in metabolically stressed cancer cells (colorectal, ovarian, 
prostate), activation of the FoxO3A-dependent transcriptional programme first 
leads to autophagy and cell cycle arrest as an attempt to retain energy and increase 
ATP levels to survive, but then triggers cell death under conditions of persistent 
stress (Chiacchiera and Simone, 2009).  
 
Figure 1.11- Dual role of FoxO protein in cancer. 
FoxO plays a major role in a plethora of cellular functions (e.g. cell cycle arrest, 
apoptosis) aimed to the tumour development prevention and cancer cell death 
induced by various drugs (green leafs). By contrast, some FoxO3A functions 
appear as ambiguous (e.g., angiogenesis, oxidative stress resistance, 
differentiation, cancer stem cell maintenance and control of cell invasion and 
PROTEINS 
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metastasis, orange leafs). The explicitly pro-tumour roles of FoxO, which as an 
example causes the resistance to certain treatments are indicated in the red leafs. 
Key target genes are indicated in smaller letters, while the repressed ones are 
crossed. Image adapted from Coomans de Brachène and Demoulin, 2013. 
Taken together, these contradictory findings suggest that FoxO3A may have 
opposing roles in different tumour types, based on the extracellular stimuli or the 
specific cell type. 
1.4 The AMPK-FoxO3A axis 
As briefly mentioned above, the increase of the AMP/ATP ratio leads to the 
activation of the energy sensor pathway and consequently leads to the 
phosphorylation of FoxO3A by AMPK (Greer et al., 2007a-b).  Experimentally, in 
mammalian cells, AMPK phosphorylates FoxO3A in response to stimuli associated 
with dietary restriction (DR) (Greer EL et al., 2007a-b). 
1.4.1 AMPK activation 
AMPK is a Serine/Threonine protein kinase complex, which forms a 
heterotrimer consisting of a catalytic α-subunit (α1 and α2), a scaffolding β-subunit 
(β1 and β2) and a regulatory γ-subunit (γ1, γ2 and γ3). AMPK is involved in various 
cell functions, such as cell growth regulation, reprogramming metabolism, 
autophagy and cell polarity modulation. Indeed, upon activation, AMPK “re-
programmes” cell metabolism to turn on catabolic pathways, such as glycolysis and 
fatty acid oxidation, to generate ATP and inhibits ATP-consuming anabolic 
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processes not necessary for the immediate survival of the cell (Canto and Auwerx, 
2010). Furthermore, to this aim, AMPK increases mitochondrial content and 
mitochondrial substrates as an energy source, by modulating the expression of the 
transcriptional coactivator PGC1-α, of the Oestrogen-related receptor alpha 
(ERRα), the nuclear respiratory factors 1-2 (NRF1, NRF2) and the Peroxisome 
proliferator-activated receptors (PPARs) (Reznick and Shulman, 2010). Therefore, 
as a cellular energy sensor, a variety of physiological and pathological conditions 
that deplete cellular energy levels, such as prolonged exercise, nutrient starvation, 
hypoxia, exposure to toxins that inhibit the mitochondrial respiratory chain and 
disease conditions, stimulate the AMPK signalling (Hardie et al., 2012; Mihaylova 
and Shaw et al., 2011).  Specifically, in the presence of lowered intracellular ATP 
levels, AMP or ADP directly binds the γ-regulatory subunits, inducing a 
conformational change aimed to protect the phosphorylation of AMPK. The α-
catalytic subunit contains the Thr172, which is phosphorylated by three known 
upstream kinases: the tumour suppressor Serine/Threonine kinase 11 (STK11, also 
known as LKB1), the MAPKKK family member transforming growth factor-β-
activated kinase 1 (TAK1/MAP3K7), and the Ca2+/calmodulin-dependent protein 
kinase kinase β (CAMKKβ) kinase, which is triggered in response to calcium flux. 
Additionally, several pharmacological agents can activate AMPK (Figure 1.12). 
These drugs can act in two different ways: directly, by inducing activating 
conformation changes in the AMPK complex, without any significant change in 
cellular ATP, ADP or AMP levels, or indirectly, through the AMP or calcium 
accumulation modulation (Kim et al., 2016). The first group includes the AMPK 
activator 5-aminoimidazole-4-carboxamide riboside (AICAR). Upon 
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phosphorylation by adenosine kinase, AICAR monophosphate (ZMP) binds to the 
AMPKγ subunits. The group of indirect activators of AMPK includes Biguanides, 
Thiazolidinediones, Ginsenosides, α-Lipoic acid and Polyphenols (Kim et al., 
2016). As an example, the polyphenol Resveratrol, which is abundant in the skin of 
red grapes, activates AMPK by increasing the AMP/ATP ratio as the result of the 
F1F0 mitochondrial ATPase inhibition. Similarly, quercetin, which is abundant in 
fruits, vegetables, grains and curcumin, from Curcuma longa, also is capable of 
activating AMPK by modulating AMP levels (Kim et al., 2016; Mihaylova and 
Shaw et al., 2011).  
Metformin and other biguanides are classified as indirect activators of 
AMPK since they modulate ATP levels, through the inhibition of the Complex I of 
the respiratory chain. Metformin is a biguanide drug commonly used in the 
treatment of diabetes, which has been proven to have anticancer activity in diabetic 
patients (Evans et al., 2005; Chae et al., 2016). 
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Figure 1.12 - The endogenous and exogenous stimuli activating AMPK. 
Image modified and adapted from Andrade and Pires de Carvalho, 2014. 
Several phase II/III clinical trials are currently evaluating the efficacy of 
Metformin in association with chemotherapeutic agents as well as its 
chemoprevention activity as a single agent. However, the Metformin anticancer 
properties are still under debate, as briefly mentioned before (Paragraph 1.1.5). Of 
note, Metformin inhibits the activity of Complex I of the mitochondrial machinery 
responsible for oxidative phosphorylation, the same mechanism inducing AMPK 
activation in cultured cells (Wheaton et al., 2014). 
AMPK activation in dietary restriction (DR) 
The shortage of caloric intake nearly doubled the lifespan of rats (Mc Cay 
et al., 1989). Since that moment DR, meant as the reduction of food intake without 
inducing malnutrition, has been investigated with the aim to extend longevity and 
 Introduction 
 69 
 
lifespan. In various species, such as worms, flies and mice, a longevity effect 
correlated with DR (Masoro, 2005). Moreover, in mice, DR can reduce the 
incidence of major diseases (Fontana and Kline, 2007). In monkeys, DR can 
“halve” the incidence of neoplastic mass development compared with the control 
animals (Colman et al., 2009), while in humans, DR decreases the incidence of age-
dependent diseases, including cancer (Michels and Ekbom, 2004).  
AMPK plays a central role as a modulator of lifespan extension by DR 
(Cantó and Auwerx, 2011). AMPK activation increases lifespan in C. elegans and 
D. melanogaster through the mitochondrial metabolism remodelling in peripheral 
tissues. Similarly, Metformin treatment promotes healthy ageing in mice (Weir et 
al., 2017). In mammals subjected to DR, decreased levels of glucose and leptin 
activates AMP, in the brain but not in the liver (Greer et al., 2007b). AMPK-FoxO 
axis has been proposed as a mediator of lifespan- DR induced in C. elegans (Greer 
et al. 2007b). 
1.4.2 AMPK-FoxO axis in cancer and longevity 
So far, six mammalian FoxO3A residues are known to be phosphorylated 
by AMPK in vitro: T179, S399, S413, S555, S588, and S626 (Figure 1.13). Five of 
them are located in the transactivation domain (Greer et al., 2007b; Greer et al., 
2009). Experimental evidence showed that the substitution of all six residues in 
FoxO3A with non-phosphorylatable amino acids, still partially retains (16%) the 
potential of AMPK to phosphorylate FoxO3A, strongly suggesting the existence of 
additional phosphorylation sites in the protein sequence. 
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Figure 1.13–AMPK phosphor-sites in FoxO3A. 
Alignments of the AMPK consensus phosphorylation motif with putative 
phosphorylation sites (in red) in human FoxO3A and sites in known substrates of AMPK. 
Boldface and italic: sites identified as being phosphorylated in vitro by AMPK by LC-
MS/MS. Green: sites identified as being phosphorylated in cells by LC-MS/MS. Blue: sites 
phosphorylated in cells identified by using phosphospecific antibodies. Hydrophobic 
residues are indicated in dark blue. Basic ones in light blue. Image modified and adapted 
from Greer et al. 2007. 
Notably, the substitution of all six residues is not able to affect the ability of 
FoxO3A to shuttle between the nucleus and the cytoplasm, depending on nutrient 
condition. However, the nuclear transcriptional activity of FoxO3A is impaired 
(Greer et al., 2007b).  
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The AMPK-FoxO axis is required for dietary restriction-dependent health 
and lifespan extension (Greer et al., 2007b; Greer et al., 2009). As briefly mentioned 
before, in nematodes DR extends lifespan. This effect on longevity is blunted in 
AMPK defective nematodes and significantly reduced in FoxO mutant strains. 
Notably, FoxO involvement in DR-lifespan extension is not dependent on its 
transcriptional activity, since FoxO is not able to shuttle into the nuclei from the 
cytoplasm. On the other hand, the mutation of the insulin receptor extends lifespan 
in nematodes. DR further enhance lifespan (Greer et al., 2007b). The AMPK-FoxO 
axis plays a major role also in oxidative stress resistance in nematodes, which is 
strictly related to longevity and lifespan, through the modulation of its target gene 
SOD-3. 
At least in human colorectal and ovarian cancers, AMPK/FoxO3A pathway 
is maintained as a functional metabolic switch capable of sensing variations in the 
AMP/ATP ratio. As an example, the decreased glycolysis caused by inhibition of 
the p38α/HIF1α pathway, activates FoxO3A transcriptional programme, in an 
AMPK-dependent way (Chiacchiera and Simone, 2009). Notably, pharmacological 
inhibition of p38α is a challenging strategy used in that kind of tumours, like CRC, 
in which p38α is required for cell proliferation and survival (Comes to et al., 2007; 
Chiacchiera et al., 2009). For example, in CRC, the combined use of the selective 
p38 inhibitor, SB202190, and a kinase inhibitor, Sorafenib, approved for the 
treatment of renal cell carcinoma and hepatocellular carcinoma enhances the anti-
cancer activity of Sorafenib, by inducing apoptosis (Grossi et al., 2012). In CRC, 
p38α signalling pathway inhibition significantly impairs the intracellular levels of 
ATP and decreases the HIF1α protein stability and the expression of key enzymes 
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involved in aerobic glycolysis. The metabolic stress activates AMPK, which 
promotes the nuclear accumulation of FoxO3A and the sequential transcription of 
its target genes related to autophagy, cell metabolism, cell cycle arrest and cell death 
(Chiacchiera et al., 2009).  
FoxO3A activation leads first to the transcription of genes related to the 
autophagic flux, such as the GABA type A receptor-associated protein 
(GABARAP), GABA type A receptor-associated protein-like 1 and 2 
(GABARAPL1 and GABARAPL2), and MAP1LC3. The autophagic flux consists 
of sequential steps, controlled by the ATG proteins (ATG6, ATG7 and ATG12), 
which lead to the degradation of cytoplasmic amino acids and fatty acids, to sustain 
cell metabolism. To this aim, FoxO3A-target genes involved in metabolisms, such 
as PGC1α, the PhosphoEnolPyruvateìCarboxyKinase (PEPCK) and the 
mitochondrial Uncoupling Protein (UCP2) are induced to convert the fatty acids 
and amino acids produced by the autophagic flux in ATP. Subsequently, FoxO3A 
induces the up-regulation of the cyclin D transcriptional repressor, Bcl-6, and of the 
CDK inhibitors, p21 and p27, to block the G1/S transition, leading the cell to exit 
from the cell cycle and trigger cycle arrest. If metabolic stress conditions persist, 
cell undergoes cell death, mediated by the FoxO3A-dependent activation of the 
transcription of the Autophagy-related 6, 7 and 12 genes (ATG6, ATG7 and 
ATG12), and of BH3-only proteins, such as the p53 up-regulated modulator of 
apoptosis (PUMA), Bim, the BCL2 Interacting Protein 3 (BNIP3) and the BCL2 
Interacting Protein 3 Like (BNIP3L).  
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 AMPK-dependent activation of FoxO3A transcriptional programme in 
metabolic stress conditions causes tumour growth inhibition, both in vitro and in 
vivo (Chiacchiera and Simone, 2009), suggesting that the pharmacological 
manipulation of the AMPK-FoxO3A axis is a interesting approach for cancer 
treatment. 
 
Figure 1.14 - AMPK-dependentFoxO3A transcriptional profile. 
Gene transcription profile in response to p38α inhibition, SB202190-mediated. 
Adapted from Chiacchiera and Simone, 2009. 
1.4.3 The mitochondrial arm of AMPK-FoxO3A axis 
Recently, a mitochondrial arm of AMPK-FoxO3A axis has been proposed (Figure 
1.16). A growing body of evidence highlights the involvement of FoxO3A in 
 Introduction 
 74 
 
various mitochondrial functions, such as ROS detoxification, mitochondrial fission, 
biogenesis and morphology control (Ferber et al. 2012: Zhou et al., 2017). As an 
example, upon hypoxia, the increase of the mitochondrial ROS production required 
for the stabilisation of HIF-1α induces FoxO3A activation, which counteracts the 
hypoxia-dependent ROS increase and the accumulation of HIF-1α, through the 
modulation of c-Myc stability (Ferber et al., 2012).     
 
Figure 1.15–Mitochondrial target of AMPK. 
AMPK phosphorylates mitochondrial fission factor (MFF) to regulate 
mitochondrial fission, which is required to degrade damaged mitochondria by 
mitophagy. During energy stress, AMPK also activates mitochondrial biogenesis 
genes through interaction with proliferator-activated receptor-γ PPARγ or 
oestrogen-related receptors (ERRs), though the co-activator 1α (PGC1α). Adapted 
from Herzig and Shaw, 2017. 
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Recent studies have focused on the ability of AMPK to promote mitochondrial 
homeostasis, by regulating mitochondrial fission, mitophagy and transcriptional 
control of mitochondrial biogenesis, upon stress conditions (Herzig and Shaw, 
2017). Furthermore, the presence of substrates of AMPK in the mitochondrial outer 
membrane, the mitochondrial fission factor (MFF) and the acetyl-CoA carboxylase 
2 (ACC2), suggests that a pool of freely floating cytosolic AMPK can localise at 
least close to mitochondria in response to changes in energy status (Figure 1.15). In 
support of this hypothesis, it has recently been observed that a myristoylated form 
of AMPK is recruited to the mitochondria in response to mitochondrial damage, to 
mediate autophagy-dependent mitochondrial removal (Liang et al., 2015).  
The mitochondrial AMPK-FoxO3A axis can modulate the balance between 
oxidative phosphorylation and glycolysis in response to metabolic stress (Peserico 
et al., 2013). Recently, a mitochondrial fraction of FoxO3A has been proposed 
(Jacob et al., 2008; Peserico et al., 2013; Caballero-Caballero et al., 2013). In 
mammalian cells -myotubes and fibroblasts -, FoxO3A can accumulate into the 
mitochondria upon glucose restriction (GR) (Peserico et al. 2013). This event 
requires AMPK activation, which is regulated by nutrient conditions, through the 
energy sensor pathway.  Inside the organelles, FoxO3A physically interacts with 
mtRNA Polymerase and SIRT3, the main mitochondrial Sirtuin (Schwer et al., 
2002).  
SIRT3 is a soluble mitochondrial protein highly expressed in tissues rich in 
mitochondria, such as muscle and liver (Lombard et al., 2007). It is expressed as a 
full-length 44kDa protein that is targeted to the mitochondria by its N-terminal 
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localisation sequence (Schwer et al., 2002). The long form of SIRT3, located in the 
nucleus, has been considered as an inactive precursor for a long time. The 
importance of its nuclear form of SIRT3 is related to ROS detoxification activity 
(Sundaresan et al., 2008). The long form of SIRT3 is transported from the cytosol 
to the mitochondrial matrix, where the mitochondrial matrix processing peptidase 
(MPP) releases a cleaved 28kDa protein. In the mitochondria, SIRT3 regulates a 
plethora of functions (Alhazzazi et al. 2014, Haigis et al. 2010). It is primarily 
involved in the control of global mitochondrial protein acetylation (Lombard et al. 
2007) in ATP production (Ahn et al. 2008), anti-oxidative response (Huang et al. 
2010, Schwer and Verdin, 2008) cell death (Sundaresan et al., 2008; Allison et al., 
2007; Verma et al.,2013) and human longevity (Park et al., 2013). Importantly, 
SIRT3 opposes the Warburg effect in cancer cells through HIF-1α destabilization 
(Finley et al., 2011). Interestingly, also for SIRT3, a dual role in tumour suppression 
and tumour promotion is still under intense debate (Alhazzazi et al., 2011; Chen et 
al., 2014). Indeed it seems to operate as both a tumour suppressive and oncogenic 
factors depending on the conditions. As an example, loss of SIRT3 induces a 
tumorigenic phenotype in vivo (Ferber et al., 2012), and SIRT3 KO mice 
spontaneously form oestrogen/progesterone receptors (ER/PR)-positive mammary 
tumours later in life (Ferber et al., 2012). Interestingly, SIRT3 levels are decreased 
in human breast cancer (Desouki et al., 2014), and this event is associated with poor 
prognosis in breast cancer patients. In contrast, SIRT3 is over-expressed in several 
human oral cancer cells, as an example in the Oral Squamous Cell Carcinoma 
(OSCC) where its down-regulation inhibits cancer cell growth and proliferation 
(Alhazzazi et al., 2011; Torrens-Mas et al., 2017). 
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Figure 1.16 - The mitochondrial arm of AMPK-FoxO3A pathway. 
The mitochondrial AMPK-FoxO3A-SIRT3 pathway induces mitochondrial 
transcription and respiration upon glucose restriction. Adapted from Peserico et 
al., 2013. 
Remarkably, the SIRT3-FoxO3A mitochondrial interaction allows the formation of 
a FoxO3A-SIRT3-mtRNAPol complex, which binds the mtDNA and activates the 
transcription of mitochondrial-encoded catalytic subunits of the OXPHOS 
machinery (Jacob et al., 2008; Peserico et al., 2013). Therefore, this event results in 
increased respiration and cell energy metabolism support. Importantly, accordingly 
to the proposed role of acetylation in the impairment of FoxO-chromatin interaction 
(Glucose Restriction) 
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in the nucleus, SIRT3 activity is required for FoxO3A recruitment on FHRE sites 
in the D-loop regulatory region and mtDNA binding. Notably, SIRT3 is not 
required for FoxO3A mitochondrial localisation (Figure 1.16). 
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2 Aims 
 
FoxO transcription factors are involved in several cellular processes, including 
proliferation, apoptosis, stress resistance and metabolism. Their activity is finely 
regulated through specific post-translational modifications functioning as a 
“molecular FoxO code”. Recently, it has been described a novel mitochondrial arm 
of the AMPK-FoxO3A axis acting as a recovery mechanism to sustain energy 
metabolism upon nutrient shortage. 
The research programme of my PhD is aimed to deepen the mechanisms underlying 
FoxO3A mitochondrial localisation and activity, through the identification of 
molecular mediators and partners involved. Considering the well-establish role of 
nuclear FoxO3A as a tumour suppressor, and its emerging function as a tumour cell 
migration and proliferation promoter, which is still under debate, the study is 
pointed to understand the role of mitochondrial FoxO3A in cancer cells and its 
possible contribution to nuclear FoxO3A activity. Data collected will be 
instrumental in devising novel pharmacological strategies aimed at manipulating 
cellular metabolism to counteract cancer.
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3 Material and methods 
 
3.1 Experimental model and subject details 
3.1.1 Cells culture and reagents 
NIH3T3, MEFs, HEK293, HT29, IMR90, HeLa, LS174T, SW-480, Caco2, 
MDA-MB-468, BT474, OVCAR3, A549 and DU145 cells were obtained from the 
American Type Culture Collection (ATCC). EFM19 cells were obtained from the 
Leibniz-Institute DSMZ. NIH-3T3 and MEF: murine fibroblasts. HEK293: human 
kidney epithelial cells. IMR90: human lung normal. , LS174T, SW-480, Caco2, 
HT29, and HCT116: human colorectal cancer; MDA-MB-468, BT474 and EFM19: 
human breast cancer. OVCAR3: human ovarian carcinoma. A549: human lung 
adenocarcinoma. DU145: human prostate cancer.  
HT29 Rho0 were kindly provided from Dr. Gaetano Villani’s Lab 
(University of Bari – Department of medical sciences, neurosciences and sense 
organs). HCT116 FoxO3A-/- were generated for this project. 
HCT116, HCT116 FoxO3A-/-,NIH3T3, MEFs, HT29, HT29 Rho0, IMR90, 
HeLa, LS174T, MDA-MB-468, OVCAR3, A549 and SW-480 cells were cultured 
in DMEM high glucose (HG), without pyruvate (Gibco) with 10% FBS (Gibco) 
and 100 IU/ml penicillin-streptomycin (Gibco). BT474, EFM19 and Caco2 cells 
were maintained in the same conditions with 5% and 20% FBS, respectively. 
HEK293 cells were supplemented with 1% each of pyruvate and non-essential 
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amminoacids (NEAA, Sigma). DU145 cells were cultured in RPMI high glucose 
(HG), without pyruvate (Gibco) with 10% FBS (Gibco) and 100 IU/ml penicillin-
streptomycin (Gibco). All media were prepared with 100 IU/ml penicillin and 100 
µg/ml streptomycin, and cells were grown in a humidified incubator at 37°C and 
5% CO2 avoiding confluence at any time. All cell lines were glucose restricted by 
using DMEM containing 0.75 mM glucose (LG, low glucose). The final glucose 
concentration in the HG and LG medium should be considered as 40 and 15.75 mM, 
respectively (according to Li and Tollefson, 2011). 
Compound C, PD98059, 2-Deoxy-D-glucose (2DG), Iodoacetic acid (IA), 
Metformin (MET), 5-Fluorouracile (5-FU), Cisplatin (cis-diammineplatinum 
dichloride, CDDP), Etoposide (VP-16), Irinotecan (CTP-11) and Nicotinamide 
(NAM) were purchased from SIGMA. Trametinib was from Selleckchem. 
3.1.2 Animal husbandry 
For in vivo studies reported in paragraph 4.7, C57/Bl6J male strain mice 
were bred on a 12-hour light/dark cycle and fed with standard diet. 8-10-week-old 
mice were divided in two experimental groups (fed/fasted) including at least five 
mice: free food access group (fed) and 18-hour fasted group. To minimize the effect 
of circadian variation on gene expression profile, mice were sacrificed at the 
beginning of the light cycle. Brain, kidney, lung, pancreas, colon, and liver were 
chopped into small pieces with a razor blade and then disaggregated using a 
Medimachine (Becton Dickinson). Cells were harvested and processed for total 
protein analysis and/or mitochondria isolation, as previously described (Frezza et 
al. 2007) and as briefly explained in the section 3.2.4. 
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For in vivo studies reported in the sections 4.2.5 and 4.3.3-5, female CD-1 
athymic nude mice (6-8-week-old) were obtained from Charles River Laboratories. 
To develop xenograft tumours, 10x106 HCT116 cells were injected subcutaneously 
into the flanks (0.2 ml per flank) of CD-1 mice. The volume of the tumours was 
measured every 2–3 days and calculated using the following formula: 
!"#$%&	(%%)) = ,-./ℎ1		 ∗ 	#&34ℎ/ ∗ 	0.5. 
When the tumour volume reached 60 mm3, mice were randomized into 
different treatment groups. Cisplatin (2 mg/kg) or 2-deoxygluocose (100 mg/kg) 
were given intra-peritoneally once every three days. Control groups received the 
vehicle only (normal saline). Mice were treated twice every 3 days. At the end of 
the treatment, mice were sacrificed and tumours explanted for immunoblot analysis. 
Animals were maintained in the animal colony at the University of Bari, following 
the institutional guidelines, in compliance with national, international laws, and 
policies. In vivo studies were performed in collaboration with Dr. Gadaleta and Dr. 
Scialpi of the Laboratory of “Medicina Interna Universitaria Frugoni”, at the 
Department of Interdisciplinary Medicine of University of Bari Aldo Moro. 
3.1.3 Bacterial strains 
NEB5-alpha bacterial strains were grown in Luria-Bertani (LB) medium 
(Tryptone, Yeast extract and NaCl, Sigma) in the presence of Ampicillin (25 µg/ml, 
Sigma). Briefly, liquid LB was added to a 500 ml Erlenmeyer flask and the 
appropriate antibiotic to the correct concentration was added. With a sterile pipette 
tip, a single colony from each experimental agar plate was selected and the tip was 
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dropped into the Erlenmeyer flask and swirl. The culture was loosely covered with 
sterile aluminum foil and incubated at 37°C for 12-18 hours in a shaking incubator. 
3.2 Methods Details 
3.2.1 Cloning 
The plasmids described in the manuscript were obtained, with specific 
primers, as previously described (Nakatani et al., 2003). Briefly, to prepare vector 
DNA for cloning, 2-5 µg vector DNA were digested by using restriction enzymes 
needed for the insert DNA. Then, gel purification of digested vector DNA was 
performed. To prepare insert DNA for cloning by using PCR, primers are been 
designed and obtained from CARLO ERBA Reagents S.r.l. Insert DNA was 
amplified from a template by PCR. Gel purification of insert DNA was performed. 
Ligation of insert and vector reaction was performed by using 1 mole of vector and 
5 or more moles of insert, at 37°C for 30 minutes. Then, chemically competent cells 
(NEB 5-alpha Competent E. coli) were tarsformed with 1 µl ligation product  by 
using heat-shock method. Briefly, after a short incubation in ice, a mixture of 
chemically competent bacteria and the ligation product is placed at 42°C for 90 
seconds and then placed back in ice. Thus, the mixture is spread on LB agar plates 
with Ampicillin (25 µg/ml) and incubated at 37°C overnight. About 12-16 hours 
later colonies are picked. To screen for plasmids carrying the correct insert, colony 
PCR and consequent sequencing of the plasmid.was perfomed. 
Site-directed mutagenesis was performed using the Q5® Site-Directed 
Mutagenesis Kit (New England Biolabs) according to the manufacturer’s 
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instructions. Briefly, double-stranded plasmid DNA is exponentially amplified 
using standard primers and a master mix formulation of Q5 Hot Start High-Fidelity 
DNA Polymerase. The product is then incubated with an enzyme mix (containing 
a kinase, a ligase and DpnI) to allow the circularization of the PCR product and 
removal of the template DNA. Thus, chemically competent cells (NEB 5-alpha 
Competent E. coli) are transformed with the PCR product. 
A list of the constructs generated and/or used in this thesis, as well as the 
list of site-directed mutagenesis primer sequences used are available in Appendix 
Tables 1 and 2. 
3.2.2 Cell transfection and RNA interference 
HCT116, HCT116 FoxO3A-/- and HEK293 cells were transiently 
transfected with mammalian expression plasmids using TransIT-LT1 Transfection 
Reagent (Mirus) according to the manufacturer’s instruction.  
For RNA interference, HCT116 cells were transfected with 50 nM validated 
Silencer® Select Pre-Designed siRNA (Thermo Fisher Scientific) directed against 
FoxO3A by using the HiPerfect reagent (QIAGEN) according to the manufacturer's 
instructions. On-TARGET-plus control siRNAs (Thermo Scientific) were used as 
a non-silencing negative control. siRNA sequences used in this study: 
FoxO3A siRNA1:  5’ CUCACUUCGGACUCACUUAtt 3’,  
5’ UAAGUGAGUCCGAAGUGAGca 3’ 
FoxO3A siRNA2:  5’ GCCUUGUCGAAUUCUGUCAtt 3’, 
5’UGACAGAAUUCGACAAGGCac 3’ 
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3.2.3 Protein expression and purification 
NEB5-alpha bacterial strains transformed with different pGEX-4T3-GST-
FoxO3A constructs were grown in Luria Bertani medium in the presence of 
Ampicillin (25 µg/ml, Sigma). When bacteria reached the optical density of 0.6 
(exponential growth phase), they were induced with 0.5 mM IPTG at 37°C, for 4 
hours. Cells were then collected by centrifugation and pellets were lysed with B-
PER lysis buffer (Thermo Fisher), according to the manufacturer's instructions. 
Then, the lysate was centrifuged at 15.000 x g for 5 min at 4°C. Recombinant 
protein expression was confirmed by SDS-PAGE. GST-fused proteins were 
purified by affinity chromatography using the GST Bulk Kit (GE Healthcare) 
according to the manufacturer’s instructions. Briefly, Glutathione Sepharose slurry 
is resuspended and transferred to the appropriate tube. After slurry draining, the 
Glutathione Sepharose is washed by adding PBS. Thus, the sample is applied to the 
column and 2 washes with binding buffer are performed. Then, the protein is eluted 
by applying the elution buffer to the column. The obtained product were evaluated 
and quantified by SDS–PAGE.  
3.2.4 Mitochondria isolation and treatment 
Mitochondria-enriched fractions were obtained as previously described 
(Frezza et al., 2007). Briefly, cells were harvested and centrifuged at 600g at 4 °C 
for 10 min. Then, the pelleted cells were re-suspended in ice-cold IBc buffer (0.1M 
Tris–MOPS, 0.1M EGTA/Tris, 1 M sucrose) and homogenized by using a Teflon-
glass pestle. The homogenate was centrifuged at 600 xg for 10 min at 4 °C and the 
supernatant was collected and centrifuged at 7,000 x g for 10 min at 4 °C. The pellet 
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was re-suspended in ice-cold IBc and centrifuged at 7,000 xg for 10 min at 4 °C. 
Eventually, the obtained mitochondria were treated with proteinase K 4 U/ml 
(Ambion) in order to degrade the outer mitochondrial membrane protein and/or 
TritonX-100 (0.25%) and analysed by immunoblotting. Notably, TritonX-100 
tratment is performed as control of antibody specificity. 
3.2.5 Proteinase K protection assay 
Mitochondrial fractions, obtained as described in section 3.2.4, were re-
suspended in an isotonic buffer (0.1M Tris–MOPS, 0.1M EGTA/Tris, 1 M sucrose) 
and incubated with various concentrations of proteinase K (1, 10 or 50 µg/ml, PK) 
for 20 minutes on ice, to minimize the enzymatic effect of PK.  
Specifically, increasing concentrations of PK were used to degrade each 
layers of mitochondria.  Memebrane degradation was followed by using specific 
mitochondrial markers. Digestion was stopped by adding 2 mM 
phenylmethylsulfonyl fluoride (PMSF) to the samples (Ryan et al., 2001). 
Mitochondrial proteins were analysed by immunoblot. 
 
 
 
 
 
Figure 2.1–Proteinase K (PK) protection assay.  
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MCL1: outer membrane marker; CYTOCHROME C: inter-membrane space 
marker; COX4: inner membrane marker; VDAC1: inner membrane marker; 
HSP60: matrix marker.  
3.2.6 Mitochondrial swelling experiments 
Mitochondrial fractions obtained as described in section 3.2.4 were re-
suspended in a hypotonic buffer (10 mM MOPS-KOH) and incubated on ice for 15 
min (Ryan et al., 2001). To obtain mitoplasts, part of the samples was incubated 
with proteinase K (25 µg/ml), on ice, for 20 min. To stop the protease activity, 2 
mM PMSF was added. Mitochondria and mitoplasts were re-centrifuged at 7,000 
xg for 10 min at 4 °C and analysed by SDS-PAGE. 
3.2.7 Nuclear extraction 
Nuclear extraction was performed using Nuclear Extraction Kit according 
to the manufacturer’s instructions (#ab113474, Abcam, Cambridge, MA). Briefly,  
cells were grown to 70-80% confluency on a 100 mm culture plate. Then, the 
growth medium was removed and cells were washed twice with PBS. Then,  3 mL 
of fresh PBS were added to the plate and cells were scraped in a 15 mL tube and 
centrifuged for 5 minutes at 1000 rpm. Once discarded the supernatant, the pellet 
was resuspended in 100µL of 1X Pre-Extraction Buffer (per 106) cells, and 
transferred to a micro-centrifuge vial. Then, the sample was incubated on ice for 10 
min., vortexed vigorously for 10 seconds and centrifuged for 1 minute at 12,000 
rpm. The supernant were recovered as cytoplasmic extract, while the pellet was 
recovered as nuclear one. The protein fractions were analysed by western blot. 
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3.2.8 Chromatin immunoprecipitation (ChIP) 
To perform the Chromatin Immunoprecipitation of mitochondrial DNA, 
mitochondrial fractions obtained as described in section 3.2.4, were processed to 
eliminate genomic DNA contamination. Specifically, DNase I (Ambion, 4 U/100 
mg wet mitochondria, 10 min, 4°C), was added to the mitochondrial fractions re-
suspended in ice-cold IBc buffer (0.1M Tris–MOPS, 0.1M EGTA/Tris, 1 M 
sucrose) in the presence of 2.5 mM MgCl2.The reaction was stopped by the adding 
of EDTA (final concentration 50 mM) into the mixture. Further ChIP analysis was 
performed as previously described (Peserico et al. 2013). Briefly, formaldehyde 
(Sigma) was added directly to mitochondrial fraction to a final concentration of 1%. 
Cross-linking was allowed to proceed for 15 min at room temperature and then 
stopped by the addition of glycine (Sigma) to a final concentration of 0.125 M. 
Cross-linked mitochondria were lysed in CLB buffer (10 mM Tris pH 8.0, 10 mM 
NaCl, 0.2 % NP40) plus protease inhibitors (Roche). Then, the mitochondrial 
fraction was enriched by differential micro-centrifugation. The chromatin solution 
was sonicated, cleared by centrifugation and the supernatant was divided into 
aliquots. 1% of the supernatant was taken as input. Four micrograms of antibody 
for each experimental group were used to immunoprecipitate chromatin-bound 
complexes. Immunoprecipitation was performed on a rotating platform overnight 
at 4°C with the indicated antibodies. IgG was used as unrelated antibodies. 
Immuno-complexes were pulled down using protein G (GE-healthcare). Following 
extensive washing, bound DNA was reverse cross-linked, purified using 
phenol:chloroform (Sigma) and analysed by quantitative real-time PCR. 
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ChIP assays on nuclear DNA were performed using the MAGnify 
Chromatin Immunoprecipitation System (Life Technologies) according to the 
manufacturer’s instructions. Briefly, adherent cells (100 mm dish) were washed 
with PBS twice and then they were treated with with formaldehyde 37% (final 
concentration 1%) to generate protein-protein and protein-DNA crosslinks between 
molecules in close proximity within the chromatin complex. The cross-linking 
reaction was stopped by adding 1.25 M glycine. Then the sample was lysed by 
adding PBS twice and by performing centrifuge. Therefore, the cells were lysed, by 
adding Lysis Buffer with Protease Inhibitors to the cell pellet obtained from the 
previous step. Thus, the chromatin was released from the nuclei and sheared by 
sonication to reduce the average DNA fragment size to 200–500 bp for analysis by 
quantitative real-time PCR (qPCR) or 100–300 bp for analysis by massive parallel 
DNA sequencing. In order to immunoprecipitate and isolate the crosslinked protein 
of interest, specific ChIP-qualified antibodies conjugated to Dynabeads® Protein 
A/G were used. Specifically, 1 µg of indicated antibodies were used for each 
assay.IgG antibodies, used as ChIp-control, were included in the kit. The 
formaldehyde crosslinking was reversed by heat treatment, specifically by 
incubating the samples tubes and the input control tubes at 55°C for 15 minutes in 
a thermal cycler. Finally, the DNA associated with that protein was purified by 
adding DNA Purification Buffer to the sample and the, after sequential washing 
with DNA Washing Buffer, by eluting DNA by addinf DNA Elution Buffer. The 
obtained DNA DNA was analysed by quantitative real-time and PCR Primer 
sequences used are available in Appendix Table 5. 
 Material and methods 
 92 
 
3.2.9  In vitro kinase assays 
Purified AMPK (Millipore) and/or ERK (Active Motif) were incubated with 
various recombinant substrates (0.5 µg) in kinase reaction buffer [HEPES (32 mM) 
pH 7.4, dithiothreitol (650 µM), Mg(CH3COO)2 (10 mM), BriJ-35 (0,012%), non-
radioactive ATP (50 µM)] and 0,9-1,8 µCi of [γ-32P]ATP (Perkin Elmer), at 30°C 
for 30 min. For AMPK, AMP (100 µM) was added to the reaction. Phosphorylation 
was detected by incorporation of radiolabeled [γ-32P] ATP. Radioactivity-Based 
Assays were performed in collaboration with Dr. Signorile and Dr. De Rasmo of 
the Department of Basic Medical Sciences, Neurosciences and Sense Organs, at the 
University of Bari Aldo Moro, 
3.2.10 Immunoblotting 
Protein extracts were obtained by treating cells or mitochondrial fractions 
with total lysis buffer (50 mM Tris-HCl pH 7.4, 250 mM NaCl, 5 mM EDTA, 0,1% 
TritonX-100, 1 mM DTT, 1 mM PMSF) supplemented with protease and 
phosphatase inhibitors (Roche). Protein concentration was determined using the 
Micro BCA Protein Assay Kit (Thermo Fisher), Briefly, Micro BCA Working 
Solution is prepared as instructed by the manufacturer. Then, 1 µl of protein lysate 
is diluted in 499 µl of diluent buffer and thus 500 µl of Micro BCA Working 
Solution is added to the tube. After 60 min incubation at 65°C, absorbance was read 
at 562 nm for each of the experimental samples. Protein concentrations were 
determined by using a Micro BCA-standard curve previously generated. 
SDS gels consisted of a lower resolving gel and an upper stacking gel, were 
made using the acrylmide/bis stock solution. 25% percent ammonium persulphate 
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(APS) and Tetramethylethylenediamine (TEMED) were used as polymerisation 
catalysts. The percentage of the resolving gel used depended on the size of the 
protein of interest -Lower percentage gels are used in case of proteins of higher 
molecular weight and vice versa. To separate the proteins, 15-20 µg of protein 
lysate was added to an equal volume of 5X SDS loading buffer [4% (w/v) SDS, % 
(v/v) glycerol, 0.01% (w/v) bromophenol blue] and boiled for 5 minutes at 95ºC. 
Samples were then spin-down and the appropriate volume of sample was loaded 
into the gel wells. SDS-PAGE gels were run in running buffer (BIORAD) at 80V 
through the stacking gel and then 150V through the resolving gel. Once the proteins 
had been separated by SDS-PAGE, proteins were electrotransferred on  
nitrocellulose membranes (GE Healthcare) by using Trans-Blot TurboTransfer 
System (BIORAD) for 7-10 minutes. Accordingly on antibodies’ requirement, 
membranes were then blocked in either 5% milk or 5% Bovine Serum albumin 
(BSA) in TBS plus 1% Tween (TBST) for 45 minutes at room temperature and then 
incubated with specific primary antibodies (see Appendix Table 3) for 16 hours at 
4°C. Membranes were then washed every 10 minutes with 5 ml of TBST for 30 
minutes at room temperature. They were then incubated with their respective 
peroxide-conjugated secondary antibody (anti-rabbit or anti-mouse – see Appendix 
Table 3) for one hour at room temperature. The membranes were then washed every 
10 minutes with 5 ml of TBST for 30 minutes at room temperature.  
The membranes were developed with the ECL-plus chemiluminescence 
reagent (GE Healthcare) in ChemiDoc™ Touch Imaging System (BIORAD), as 
manufacturer’s instructions. The densitometric evaluation was performed by 
ImageJ software. 
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3.2.11 Microscopic quantification of viability and cell death 
Cell viability and cell death of the reported cell lines were scored by 
counting, as previously described (Germani et al. 2014). Briefly, the supernatants 
(containing dead/floating cells) were collected, and the remaining adherent cells 
were detached by Trypsin/EDTA (SIGMA). Cell pellets were resuspended in 1X 
PBS and an aliquote (10 µl) was mixed with an equal volume of 0.01% Trypan blue 
solution for cell counting. Viable cells (unstained, Trypan blue negative cells) and 
dead cells (stained, Trypan blue positive cells) were counted with a phase contrast 
microscope. The percentages of viable and dead cells were calculated, as below: 
8&##	!-9:-#-/;/="3/>"# = (?!&>94&	"@	!-9:#&	=&##A)BCDEFG(?!&>94&	"@	!-9:#&	=&##A)HIJKLIF ∗ 100 
8&##	.&9/ℎ/="3/>"# = (?!&>94&	"@	.&9/ℎ	=&##A)BCDEFG(?!&>94&	"@	.&9/ℎ	=&##A)HIJKLIF ∗ 100 
3.2.12 Immuno-gold labelling 
The immuno-gold labelling assay was performed as previously described 
(Peserico et al. 2013). Briefly, cells were fixed with 4% formaldehyde and 0.005% 
glutaraldehyde, rinsed with PBS, incubated with the primary antibody overnight, 
and then with Nanogold conjugated Fab fragments of the secondary antibodies 
(Nanoprobes) for 2 hours. Nanogold particles were developed using the 
Goldenhance kit (Nanoprobes). TEM images were acquired from thin sections 
under a Philips Tecnai 10/12 electron microscope (Philips) using an ULTRA VIEW 
CCD digital camera (Soft Imaging Systems GmbH). Quantification of gold 
particles was carried out using the AnalySIS software (Soft Imaging Systems 
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GmbH). For each experimental condition, 20 cells were analysed. In each cell, 15 
areas (mean3* 106 nm2) were randomly selected. Data presented in the Results 
section were obtained by scoring the percentage of FoxO3A-positive cells and 
counting the number of gold particles per single mitochondria. Immuno-gold 
labelling analyses were performed in collaboration with the Advanced Light and 
Electron Microscopy Facility of the Consorzio Mario Negri Sud (Santa Maria 
Imbaro, Chieti, Italy). 
3.2.13 Real-time PCR 
RNA extraction and real-time PCR were performed as previously described 
(Peserico et al. 2014). Briefly, total RNA was extracted with Trizol reagent 
(Invitrogen) following manufacturer’s instructions. Samples were then treated with 
DNase-1 (Ambion) and 4 µg of total RNA was retro-transcribed using iScript™ 
cDNA Synthesis Kit (BIORAD) following manufacturer’s instructions. cDNAs  
were used as template and gene expression was measured using RT-qPCR, which 
was performed using a QuantStudio3 Real-Time PCR System (Applied Biosystem), 
using the SYBR Green PCR Master Mix (BIORAD) according the the 
manufacturers instructions. As a control the established housekeeping genes were 
used to normalise gene expression between samples. The reaction mix contained 
1,5 µl of sample and 7,5 µl of SYBR PCR Master Mix, primers and water were 
added to a final volume of 10 µl. All measurements were performed in triplicate.  
Relative quantification was performed by using the ΔΔCt method. Primer 
sequences used in this study are listed in Appendix Table 4. 
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3.2.14 Co-immunoprecipitation (Co-IP) 
For co-IP, cells or mitochondria were lysed in IP lysis buffer (50 mM Tris 
HCl pH 7.4, 250 mM NaCl, 5 mM EDTA, 0,1% TritonX-100), supplemented with 
protease inhibitors (Pierce). Lysates were cleared by centrifugation and incubated 
overnight at 4°C with 1 µg of anti-FLAG, anti-FoxO3A, anti-SIRT3, anti-
acetylLysine and/or IgG covalently bound to Protein G-Sepharose (GE 
Healtcare)/Protein A-Sepharose (GE Healtcare). Immunocomplexes were washed 
twice with IP lysis buffer, boiled in 5X SDS loading buffer [4% (w/v) SDS, % (v/v) 
glycerol, 0.01% (w/v) bromophenol blue] and boiled for 5 minutes at 95ºC. Samples 
were analysed by immunoblot as described in section 3.2.  
3.2.15 Deacetylation assay 
The deacetylation assay was performed as previously described (Hirschey 
et al. 2009). Briefly, the mitochondrial fraction isolated from HCT116 previously 
transfected with p3x-CMV14-FoxO3A-FLAG was immune-precipitated with anti-
FLAG antibody and then incubated with GST-SIRT3 recombinant protein, in 
presence/absence of Sirtuin inhibitor Nicotinamide (NAM, 10 mM).  Subsequently 
immunocomplexes were washed twice with IP lysis buffer (50 mM Tris HCl pH 
7.4, 250 mM NaCl, 5 mM EDTA, 0,1% TritonX-100), boiled for 5 minutes at 95ºC. 
Samples were analysed by immunoblot as described in section 3.2. 
3.2.16 Prediction analysis 
Analysis of the N-terminal region of FoxO3A (corresponding to positions 
1-148) was performed using the NetPhos (available at 
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http://www.cbs.dtu.dk/services/NetPhos) and DISPHOS 1.2 (available at 
http://www.dabi.temple.edu/disphos)prediction tools. The KinasePhos 
2.0prediction server (available at http://kinasephos.mbc.nctu.edu.tw)was employed 
in consensus phosphorylation motifs investigation. 
3.2.17 Citotoxicity assay 
Citotoxicity assays were performed as previously described (Germani et al. 
2014). Briefly, 1*105 cells were seeded in 60 mm dishes and after 24 hours they 
were treated with the indicated drugs. After 24 hours, media were discarded and 
cells were washed twice with 1X PBS. Therefore, 2 ml of Coomassie brilliant blue 
(Bradford) were added into each dish for 5 minutes. Eventually, cells were washed 
with ethanol 70% to remove the excess of Coomassie. Plates were dried at room 
temperature. Percent cell growth-inhibition at each concentration was quantified by 
densitometric evaluation using ImageJ software. 
3.2.18 Mitochondrial membrane potential assay (TMRE staining) 
and immunofluorescence 
Mitochondrial membrane potential assay was performed using 
tetramethylrhodamine ethyl ester perchlorate (TMRE, Sigma), according to the 
manufacturer's instructions. Nuclei were counterstained using DAPI (300 nM in 
PBS, Invitrogen).  
HCT116 FoxO3A-/- cells were transiently transfected with eGFP-tagged 
mammalian expression plasmids. After transfection and treatment with the 
indicated drugs, cells were fixed with 4% paraformaldehyde, permeabilized with 
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1% TritonX-100, and then stained as described above. Nuclei were counterstained 
using DAPI (300 nM in PBS, Invitrogen).  
Images were acquired using an Axio Observer Z1 microscope (Zeiss) in 
single-plan. For both TMRE staining and immunofluorescence, quantification of 
mitochondrial TMRE fluorescence in GFP+ cells was performed using ZEN 
imaging software (Zeiss). Moreover, for quantification of the staining, an area 
containing each staining signal was select and measured. Another set of 
measurements has been obtained from the same areas in a region outside the cell 
(background) and subtracted by the intensities previously measured. All the images 
contained in this manuscript have been obtained by using a 63X objective.  
3.2.19 CRISPR/Cas9 genome editing system 
The CRISPR/CAS9 reporter vector (GeneArt CRISPR Nuclease Vector Kit, 
Invitrogen) was used according to the manufacturer’s instructions. Oligonucleotide 
sequences used to create the gRNA vector were designed to target the exon 2 of 
FoxO3A for “indel” mutation.  The sequences are reported below: 
gRNA	top	strand	oligo:	GTCTTCATCGTCCTCCTCCT	
gRNA	bottom	strand	oligo:	AGGAGGAGGACGATGAAGAC	
CHOPCHOP web tool was used for determining gRNAs off-targets. 
HCT116 cells were transfected using Lipofectamine 3000 (Thermo Fischer 
Scientific) according to the manufacturer’s instruction. Isolation of clonal 
populations was performed with agarose-based cloning rings (Sigma). Cell clones 
were tested for site-specific deletions by PCR. Sequencing products were purified 
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using the Dye Ex 2.0 Spin Kit (QIAGEN) and sequenced on an ABI PRISM 310 
Genetic Analyzer (Applied Biosystems). A scheme of gRNA location in FoxO3A 
locus, proto-spacer adjacent motifs (PAMs) and deleted region is reported in Figure 
4.22. 
3.2.20 Glucose restriction resistance assay 
Glucose restriction resistance assays were performed on several cell lines. 
For each of them, a preliminary experiment was performed to determine the glucose 
restriction end-point. Specifically, 2.5 × 104 cells were plated for each cell line on 
a 12-well dish and switched 24 hours later to low glucose medium (0.75 mM 
glucose). Every 24 hours, the supernatants (containing dead/floating cells) were 
collected, and the remaining adherent cells were detached by Trypsin/EDTA 
(Sigma). Cell pellets were resuspended in 1X PBS and 10 µl were mixed with an 
equal volume of 0.01% trypan blue solution. Viable cells (unstained, trypan blue 
negative cells) and dead cells (stained, trypan blue positive cells) were counted with 
a phase contrast microscope. For each cell line, the glucose restriction end-point 
was established as the time point in which the amount of dead cells was at least 
50% of the total. To investigate the correlation between glucose restriction 
resistance and FoxO3A protein levels, 2 × 105 cells were plated on 60-mm dishes 
and switched 24 hours later to low glucose medium (0.75 mM glucose). For each 
cell line, cells were harvested at the glucose restriction end-point preliminarily 
established as described above. Then, cell pellets were lysed and total proteins were 
analysed by immunoblot with a FoxO3A antibody. Densitometric evaluation of 
FoxO3A protein levels was performed by ImageJ software. The correlation index 
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between cell resistance (days) and FoxO3A protein levels was calculated by using 
Excel as: 
8">>&#(N, P) = 	 ∑(	R − RD) ∗ (; − ;D)T∑(R −	RD)1 ∗ 	T∑(; − ;D)1 
3.3 Quantification and statistical analysis 
Results are expressed as mean ± SEM and n ≥ 3. Student’s t test was used 
to define p values. A p value<0.05 was considered statistically significant. Multiple 
comparisons are accounted for via the Hochberg’s method using PROC 
MULTTEST in SAS (Hochberg et al., 1988).
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4 Results 
 
4.1 The mitochondrial import and localisation of 
FoxO3A 
Recently, it has been described a novel mitochondrial arm of the AMPK-
FoxO3A axis in murine and human normal cells, and it is nutrient shortage-
dependent (Peserico et al., 2013). Specifically, upon glucose restriction (GR) 
FoxO3A accumulates into the mitochondria in murine C2C12-derived myotubes 
and NIH-3T3 fibroblasts. In line with these findings, transmission electron 
microscope (TEM) analysis showed that specific immuno-gold signals revealed 
FoxO3A mitochondrial localisation also in metabolically stressed HeLa human 
cervix adenocarcinoma cells (Figure 4.1). 
 
 
Figure 4.1 - FoxO3A accumulates into the mitochondria 
Immuno-gold labelling of HeLa cells cultured in high glucose (HG) or switched to 
low glucose (LG, 0.75 mM glucose) for 24 h. On the left, black dots represent gold 
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particles recognizing FoxO3A immunocomplexes (Celestini et al., 2018). On the 
right, data were quantified by counting the number of gold particles per single 
mitochondria and scoring the total number of FoxO3A-positive particles. 
As the mitochondrial form of FoxO3A (mtFoxO3A) has been little explored (Jacob 
et al., 2008; Peserico et al., 2013; Caballero-Caballero et al., 2013), the mechanism 
underlying FoxO3A mitochondrial localisation is still not clear yet. 
4.1.1 Characterization of the intra-mitochondrial form of FoxO3A 
To characterise the mitochondrial translocation mechanism of FoxO3A, 
mitochondrial-enriched fractions have been isolated from several normal and 
cancer cell lines of different origin (Caco2, HT29, SW-480 and LS-174T: human 
colorectal cancer; HEK293: human kidney epithelial cells; BT474 and EFM19: 
human breast cancer; NIH-3T3 and MEF murine fibroblasts) for a deep molecular 
analysis. Since it has been reported that GR triggers FoxO3A accumulation into 
mitochondria of normal cells (Peserico et al. 2013), the selected cell lines were 
cultured in the presence of high (HG) or low (LG) glucose concentrations. Then, 
the mitochondrial fraction was processed by using a proteinase K (PK) protection 
assay to distinguish proteins localised at the outer membrane or inside the 
mitochondria. In LG conditions, anti-FoxO3A antibodies recognised two bands in 
the whole mitochondria fraction: one migrating at around 90kDa –the expected 
molecular weight of FoxO3A- and a second band migrating at around 70kDa.  At 
the same time, the analysis of mitochondria treated with proteinase K detects only 
the 70kDa band into the organelles of all cell lines tested. These results indicate that 
FoxO3A antibodies recognised the full-length protein (resulting in the 90kDa band) 
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bound outside of the mitochondria and a shorter intra-mitochondrial form with the 
molecular weight of 70kDa (Figure 4.2). The obtained evidence was further 
confirmed by treating colorectal cancer cells (HCT116) with two diverse calorie 
restriction (CR) mimetics, 2-deoxyglucose (2DG) and iodoacetic acid (IA), that act 
by interfering with different limiting steps of the glycolytic cascade (Figure 4.3). 
To ensure that these findings were not due to a cell culture artefact, 
mitochondria purified from different mouse tissues were analysed with anti-
FoxO3A antibodies. Immunoblot images allowed to detect a migration pattern 
similar to the one obtained in human cancer cells (Figure 4.4a). Furthermore, to 
obtain an in vivo validation of these data, mitochondrial fractions purified from 
murine liver and kidney were treated with PK and analysed, demonstrating the 
presence of the FoxO3A full-length form on the outer mitochondrial membrane and 
the shorter 70kDa protein inside the organelles (Figure 4.4b). Notably, as it has 
been reported that FoxO3A co-localise into the mitochondria in complex with the 
NAD+¬-dependent deacetylase SIRT3 (Jacob et al., 2008; Peserico et al., 2013), its 
expression has been investigated in the same models, as a control (Figure 4.5). 
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Figure 4.2 - FoxO3A accumulates into the mitochondria of glucose-restricted cells. 
Immunoblot analysis of mitochondrial fractions isolated from different cell lines 
(Caco2, HT29, SW-480 and LS-174T: human colorectal cancer; HEK293: human 
embryonic kidney epithelial cells; BT474 and EFM19: human breast cancer; NIH-
3T3 and MEF murine fibroblasts) upon low glucose (LG, 0.75mM glucose) 
treatment. Mitochondrial fractions were treated with PK alone – in order to 
degrade the mitochondrial outer membrane proteins - or with PK and Triton X-100 
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to permeabilise mitochondria and degrade all mitochondrial proteins, as control of 
the antibody specificity. BCL2: outer membrane control; PDH: mitochondrial 
matrix control. The presented results are representative of at least three 
independent experiments (Celestini et al., 2018). 
 
Figure 4.3- FoxO3Amitochondrial accumulation upon metabolic stress 
Immunoblot analysis with the indicated antibodies of mitochondrial fractions 
isolated from HCT116 cells treated with (a) low glucose (LG, 0.75mM glucose) for 
24 h, (b) 2-deoxy-glucose (2DG, 1 mM, 6 h) and (c) iodoacetic acid (IA, 0,5 mM, 
5h), which are use as metabolic stress mimetics. Mitochondrial fractions were 
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treated with proteinase K (PK) to degrade outer mitochondrial membrane proteins. 
PDH: loading control. The presented results are representative of at least three 
independent experiments (Celestini et al., 2018).. 
 
Figure 4.4–FoxO3Aaccumulates into murine mitochondria 
(a) Immunoblot analysis of mitochondria purified from different murine organs 
with the indicated antibodies. PDH was used as a loading control. (b) Western blot 
analysis of mitochondria-enriched fractions isolated from murine kidney and liver. 
Mitochondrial samples were treated with PK alone – in order to degrade the 
mitochondrial outer membrane proteins - or with PK and Triton X-100 to 
permeabilise mitochondria and degrade all mitochondrial proteins, as control of 
the antibody specificity. PDH: mitochondrial matrix control. The presented results 
are representative of at least three independent experiments (Celestini et al., 2018). 
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Figure 4.5 – SIRT3 accumulation into the mitochondria of different cell lines and 
in murine tissue. 
(a) Immunoblot analysis of mitochondrial fractions isolated from different cell lines 
(HT29, human colorectal cancer; HEK293: human epithelial kidney; BT474, 
human breast cancer; NIH-3T3, murine fibroblasts) upon low glucose (LG, 
0.75mM glucose) treatment.  Mitochondrial fractions were treated with PK alone 
to degrade MOM proteins or with PK and Triton X-100 to permeabilise 
mitochondria and degrade all mitochondrial proteins, as control of antibody 
specificity. BCL2: outer membrane control; PDH: mitochondrial matrix control. 
(b) Western blot analysis of mitochondria-enriched fractions isolated from murine 
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kidney and liver and subjected to PK or combined PK and Triton X-100 treatment. 
PDH: mitochondrial matrix control. (c) Immunoblot analysis of different murine 
organs with the indicated antibodies. PDH was used as a loading control. The 
presented results are representative of at least three independent experiments. 
4.2 Requirements for the mitochondrial import 
and accumulation of FoxO3A 
Experimental evidences described above supported for the first time the 
existence of a shorter, intra-mitochondrial form of FoxO3A, which may result from 
a processing mechanism similar to the one involving the canonical mitochondrial 
proteins. To exclude the possibility that the 70kDa band could represent another 
protein cross-reacting with FoxO3A antibodies, a plasmid DNA coding for 
FoxO3A FLAG-tagged at the C-terminal domain (Figure 4.6a) was transfected in 
glucose-restricted HCT116, and HEK-293 cells and the mitochondrial fraction 
obtained from transfected cells were analysed. In both cell lines, anti-FLAG 
antibodies revealed two bands, migrating at around 90kDa and 70kDa, which 
corresponded to exogenous FoxO3A in the purified mitochondrial fraction. Only 
the 70kDa band was detected after PK addition (Figure 4.6b).  
It is well-established that mitochondrial nuclear-encoded proteins have a 
mitochondrial import signal (MTS) in their primary or secondary structure, required 
to direct them into the mitochondria. Several mitochondrial localisation signals 
have been described, and the 70% of them are localised in the N-terminal domain 
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of the protein. MTS allows proteins destinated to the mitochondrial matrix, to bind 
the surface of the organelle and translocate them across the mitochondrial 
membranes (OMM and IMM), through a general translocation apparatus. Upon 
mitochondrial import, MTS is proteolytically cleaved by the mitochondrial 
processing peptidase (MPP) and the released proteins folded in the matrix (Neupert 
and Herrmann, 2007, Chacinska et al., 2009). As experimental evidence 
demonstrates the ability of FoxO3A to bind mtDNA (Peserico et al., 2013), it is 
possible to speculate that mtFoxO3A can reach the mitochondrial matrix. However, 
as FoxO3A is not a canonical mitochondrial protein, a FoxO3A-mitochondrial 
targeting sequence has never been described before.  
4.2.1 FoxO3A N-terminus cleavage upon mitochondrial 
translocation 
Various preliminary in silico attempts aimed to identify putative cleavable 
N-terminal mitochondrial targeting signals in FoxO3A sequence failed (Fukasawa 
et al. 2015; Smith et al., 2016). Furthermore, the N-terminal of FoxO3A has been 
poorly characterised and defined, until today, as a “chromatin remodelling” domain 
of the protein (Calnan and Brunet, 2008). Therefore, to determine the presence of 
such an extension even in the FoxO3A structure, a new FoxO3A vector tagged both 
with HA - at the N-terminus - and with FLAG -at the C-terminus- (Figure 4.6a) was 
generated and transfected in glucose-restricted HCT116 cells. Results obtained 
showed the presence of both tags (HA and FLAG) at around 90kDa in purified 
mitochondria. Importantly, only one band running at around 70kDa was detected 
by anti-FLAG antibodies after PK treatment (Figure 4.6c), supporting the 
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hypothesis of a FoxO3A N-terminal domain cleavage event, occurring upon the 
mitochondrial translocation. These results corroborate those obtained with 
endogenous proteins, suggesting that exogenous full-length FLAG-tagged FoxO3A 
can localise at the outer mitochondrial membrane. Inside the mitochondria, it is 
present a shorter form that is still tagged at the C-terminus. 
Moreover, genetic silencing using two siRNAs specific for FoxO3A showed 
that the 70kDa band detected inside the mitochondria is a shorter form of 
endogenous FoxO3A (Figure 4.7a). Therefore, a newly generated FLAG-tagged 
FoxO3A plasmid (Figure4.7b), deleted of the entire N-terminal domain (amino 
acids 1-148) was transfected in HCT116 cells, and the ability of this mutant to 
localise at the mitochondria was assessed. The collected data indicate that amino 
acids 1-148 are required for FoxO3A localisation and translocation into the 
mitochondria, functioning as an N-terminal mitochondrial import signal (Figure 
4.7b). To get further confirmation, additional immunoblot analysis was performed 
on mitochondria isolated from metabolically stressed HCT116 and HEK-293 cells, 
using two distinct antibodies detecting the endogenous form of FoxO3A. The first, 
raised against the N-terminus recognised only a single band of around 90kDa in the 
whole mitochondria. The other targeting the C-terminal domain recognized both 
the 90kDa and the 70kDa bands in whole mitochondria and only the 70kDa inside 
the organelles (Figure 4.7c). 
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Figure 4.6– FoxO3Ais cleaved upon translocation into the mitochondria. 
(a) Scheme of plasmids used. (b-c) Cells were transfected with (b) FoxO3A-FLAG 
and (c) HA-FoxO3A-FLAG for 48 h; upon LG (0.75mM glucose, 24 h), total and 
mitochondrial proteins were analysed by immunoblot with the indicated antibodies, 
upon PK treatment alone –to degrade the outer membrane proteins- or in 
combination with Triton X-100 to permeabilise mitochondria and degrade all 
 Results 
 113 
 
mitochondrial proteins, as control of the antibody specificity. β-ACTIN and PDH 
were used as total lysate and mitochondrial fraction controls, respectively. N-term. 
N-terminal domain, FKH-DBD forkhead DNA-binding domain, NLS nuclear 
localisation signal, TAD transactivation domain, C-term. C-terminal domain. The 
presented results are representative of at least three independent experiments 
(Celestini et al., 2018). 
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Figure 4.7 – N-terminus of FoxO3A is required for its mitochondrial accumulation. 
(a) HCT116 cells were transfected with control (siNC) or FoxO3A-specific siRNAs 
for 48 h. Upon LG (0.75mM glucose, 24 h), FoxO3A mitochondrial levels were 
evaluated by immunoblot. PDH: loading control. (b) HCT116 cells transfected with 
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FoxO3A-WT-FLAG or FoxO3A-Δ1–148-FLAG. Upon LG (0.75mM glucose, 24 h), 
total and mitochondrial proteins were analysed by immunoblot with the indicated 
antibodies. β-ACTIN and PDH were used as total lysate and mitochondria controls, 
respectively. (c) Immunoblots performed with two different anti-FoxO3A antibodies 
in mitochondria isolated from HCT116 and HEK293 cells cultured in LG (24 h). 
Mitochondrial fractions were subjected to PK treatment to degrade outer 
membrane protines. β-ACTIN and PDH were used as total lysate and mitochondrial 
fraction controls, respectively (Celestini et al., 2018). 
4.2.2 Exploring the N-terminal domain of FoxO3A for the 
mitochondrial processing sequences 
Upon import into mitochondria, the sequences of the most protein destined 
to the matrix are cleaved off by the heterodimer mitochondrial processing 
peptidases. Among them, mitochondrial processing peptidase (MPP) cleaves the 
majority of mitochondrial proteins, while the mitochondrial intermediate peptidase 
(MIP) processes only specific groups of precursor polypeptides. These proteases 
are structurally and functionally conserved across species, and their human 
homologues have been identified as potential players in mitochondrial diseases. 
Three mitochondrial protease recognition site motifs are reported:  
“R-2 motif” [xRx(↓)x(S/x)], recognized by MPP 
“R-3 motif” [xRx(Y/x)(↓)(S/A/x)x)], recognized by MIP 
“R-10” motif [Rx(↓)(F/L/I)xx(T/S/G)xxxx], (Gakh et al.,2002; Mossmann 
et al., 2012), which are “merged” motifs recognizable by both MPP and MIP. 
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Although various in silico tools exist to predict these cleavage sites (Fukasawa et 
al. 2015), they failed in FoxO3A sequence analysis. Therefore, to extensively 
characterise the N-terminal region of FoxO3A, MPP and MIP consensus motif-like 
peptide probes were used to search exact matches in positions 1-148. Interestingly, 
in region 98-108 there is the sequence ARVLAPGGQD, which matches MPP and 
MIP consensus motifs R-2, R-3 and R-10. Of note, these motifs are partially 
overlapping in this region. This observation suggests that cleavage events mediated 
by mitochondrial processing peptidases may occur in region 98-108 of FoxO3A 
(Figure 4.8a). Thus, FLAG-tagged vector encoding for a mutant form of FoxO3A 
lacking residues 80-108 was generated (Figure 4.8b).  The resulting protein was 
able to localise at the mitochondria, but was impaired in translocating into the 
mitochondria (Figure 4.8c). 
Further proteinase K protection assays (see Figure 4.9a) confirmed that 
endogenous FoxO3A is translocated into the mitochondria and reaches the matrix 
in its cleaved form (Figure 4.9b, FoxO3A-cl.). These results were corroborated by 
immunoblot analysis of mitoplasts from swollen mitochondria treated with 
proteinase K (Figure 4.9c). Importantly, these data indicate that FoxO3A N-
terminus, which is required for proper recruitment to the mitochondria, contains the 
key residues necessary for FoxO3A cleavage by mitochondrial peptidase and 
import into the mitochondrial matrix. Interestingly, alignment of the N-terminal 
region of FoxO3A with other human FoxO proteins, performed by using the 
CLUSTALW (1.83) tool -available on the Multiple Sequence Alignment server-, 
revealed that the region 98-108 is specific to FoxO3A since it is not conserved in 
other human FoxO proteins (Fig 4.10a). On the other hand, this region is 
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evolutionarily conserved across species, as revealed by phylogenetic analysis 
performed from Caenorhabditis elegans to Homo sapiens, through the T-Coffee 
tool-mediated multiple sequence alignment of the region including the 
mitochondrial processing peptidase consensus motifs R-2, R-3 and R-10 (aa: 98-
108, Fig 4.10b). 
 
Figure 4.8- The cleavage region of FoxO3A. 
(a) Alignment of FoxO3A N-terminal sequence and cleavable mitochondrial pre-
sequences. R-2 (XRXXS) and R-3 (XRXXSX) motifs are cleavage sites recognized 
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by the mitochondrial processing peptidase (MPP). The R-10 motif 
(XRXLXXGXXXX) is sequentially cleaved by MPP and MIP (mitochondrial 
intermediate peptidase). (b-c) HCT116 cells were transfected with FoxO3A-FLAG 
and truncated FoxO3A (Δ80-108)-FLAG plasmids for 48 h. Total and 
mitochondrial proteins were analysed by immunoblot with the indicated antibodies. 
The cleaved FoxO3A mitochondrial band is not detectable into the mitochondria of 
cells transfected with FoxO3A (Δ80-108)-FLAG.β-ACTIN and PDH were used as 
total lysate and mitochondrial fraction controls, respectively. N-term. N-terminal 
domain, FKH-DBD forkhead DNA-binding domain, NLS nuclear localisation 
signal, TAD transactivation domain, C-term. C-terminal domain. fl.: full-length 
FoxO3A; cl.: cleaved FoxO3A. The presented results are representative of three or 
more independent experiments (Celestini et al., 2018). 
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Figure 4.9- FoxO3A localise into the mitochondrial matrix. 
(a) Proteinase K (PK) protection assay scheme, as described in section 3.2.5. (b) 
Immunoblot analysis with the indicated antibodies of mitochondrial fractions 
isolated from HCT116 cells, subjected to PK protection assay upon glucose 
restriction (LG, 0,75 mM glucose, 24h). (c) Immunoblot analysis with the indicated 
antibodies of mitoplasts obtained from HCT116 cells upon glucose restriction (LG, 
24h). (B, C). MCL1: outer membrane marker; CYTOCHROME C: inter-membrane 
space marker; COX4: inner membrane marker; VDAC1: inner membrane marker; 
HSP60: matrix marker. fl.: full-length FoxO3A; cl.: cleaved FoxO3A. The 
presented results are representative of at least three independent experiments 
(Celestini et al., 2018).
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Figure 4.10 – Analysis of the 98-108 region 
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(a) Alignment of the N-terminal region of human FoxO proteins annotated with specific UniProtKB/Swiss-Prot accession numbers and entry 
names (http://www.uniprot.org). (b)  Multiple sequence alignment of the region the region encompassing residues 98-108, performed by 
using the T-Coffee tool available on the MSA (Multiple Sequence Alignment) server (http://www.ebi.ac.uk/Tools/msa/tcoffee/). 
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4.2.3 Mitochondrial FoxO3A import requires Serine 12 and Serine 
30 phosphorylation 
So far, the N-terminal domain of FoxO3A – encompassing residues 1-148 – has 
been poorly characterised, except for Threonine 32, which is evolutionarily 
conserved and represents a well-known target of AKT, involved in FoxO3A 
subcellular compartments-shuttling (Brunet et al., 1999). Specifically, the AKT-
dependent phosphorylation of FoxO3A on this amino acid, together with the 
modification of the Serine 253 and Serine 315, leads to FoxO3A nuclear exclusion, 
mediated by 14-3-3 proteins and, consequently, to FoxO3A transcriptional 
programme inhibition (Brunet et al., 1999). 
With the support of various bioinformatics tools, the 1-148 region has been 
analysed in the search for novel amino acids (Serines, Threonines, Tyrosines) that 
could be potential targets for signalling pathways transducing extracellular stimuli. 
In silico analyses were performed by using NeTPhos 2.0 and DISPHOS 1.3. 
Specifically, NeTPhos server can predict Serine, Threonine or Tyrosine 
phosphorylation sites in eukaryotic proteins, by using ensembles of neural networks 
(Blom et al., 1999). Also, DISPHOS (Disorder-enhanced Phosphorylation Sites 
Predictor) performs the computational prediction of Serine, Threonine and Tyrosine 
phosphorylation sites in proteins, based on thousands of non-redundant 
experimentally confirmed protein phosphorylation sites, promising an accuracy 
around 80% (Iakoucheva et al., 2004). In silico analysis revealed the presence of 
only six residues that reached a significant threshold score (>0.6) with both tools, 
such as to be considered a high confident, positive prediction. These residues are 
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all Serines and are located at positions 12, 26, 30, 43, 48 and 55 of FoxO3A 
sequence (Table 4.1). Furthermore, although the involved kinases (or signalling 
pathways) have not been identified yet, these Serines have all been previously 
described to be phosphorylated in vivo by mass-spectrometry analysis of human 
samples of patients with different types of cancer (Pan et al., 2009; Kiyotsugu et 
al., 2014; Klammer et al., 2012; Mertins et al., 2014; Mertins et al., 2016; Olsen et 
al., 2010; Sharma et al., 2014). 
 
 
 
 
 
 
 
 
 
 
Table 4-1 - Phosho-profile prediction di FoxO3A 
*: NetPhos 2.0 score (http://www.cbs.dtu.dk/services/NetPhos/). **: Disphos score 
(http://www.dAbi.temple.edu/disphos/).  §:All kinase orphan residues that show 
threshold score >0.6. 
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As widely discussed in the Introduction chapter, phosphorylation events precisely 
regulate the transcriptional activity of FoxO3A and, importantly, its shuttling 
between cell compartments. Therefore, the prediction of six Serine phosphorylation 
sites in the N-terminus of FoxO3A is important for extending the characterisation 
of this domain to ascertain whether these residues could be involved in the 
signalling pathways inducing accumulation of FoxO3A into the mitochondria, 
under metabolic stress conditions. To test this hypothesis, all the indicated Serines 
have been mutagenised to non-phosphorylatable alanine residues (Figure 4.11a). 
Then, the indicated FoxO3A FLAG-tagged proteins have been expressed in 
glucose-restricted cancer cells, and the mitochondrial fractions isolated from them 
were analysed by immunoblot. Alanine substitution at positions 12 or 30 impaired 
the ability of full-length FoxO3A (90kDa form, FoxO3A-fl.) to be recruited at the 
outer membrane and then processed (70 kDa cleaved form, FoxO3A-cl.) to localise 
inside the mitochondria (Figure 4.11b-c). 
Interestingly, the concomitant replacement of both Serines with Alanines 
(S12A/S30A) strongly decreases FoxO3A mitochondrial localisation (Figure 
4.12a-b). Taken together this evidence suggests that S12 and S30 are both required 
by the signal transduction machinery to direct FoxO3A to mitochondria in 
metabolically stressed cancer cells. Furthermore, the transfection of a vector 
encoding for a FoxO3A mutant lacking the initial 30 residues (Figure 4.12c) of the 
N-terminal domain – encompassing both S12 and S30- showed that the deletion of 
this portion severely impaired the mitochondrial localisation of FoxO3A in 
metabolically stressed cancer cells, confirming the main role of the two Serines in 
FoxO3A mitochondrial translocation. 
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Figure 4.11 -PTMs required for FoxO3A mitochondrial accumulation. 
(a) Scheme of FoxO3A-FLAG and mutated FoxO3A-FLAG plasmids obtained by 
site-directed mutagenesis. (b,c) HCT116 cells were transfected with the indicated 
FoxO3A-FLAG plasmids for 48 h and then subjected to a low glucose regimen for 
a 
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24 hours (LG, 0,75 mM glucose, 24h). Total and mitochondrial proteins were 
analysed by immunoblot with the indicated antibodies. N-term. N-terminal domain, 
FKH-DBD forkhead DNA-binding domain, NLS nuclear localisation signal, TAD 
transactivation domain, C-term. C-terminal domain. The presented results are 
representative of three or more independent experiments (Celestini et al., 2018). 
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Figure 4.12 –S12 and S30 are both required to direct FoxO3A to mitochondria in 
metabolically stressed cancer cells. 
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(a - c)  HCT116 cells were transfected with the indicated FoxO3A-FLAG plasmids 
for 48 h and then subjected to a low glucose regimen for 24 hours (LG, 0,75 mM 
glucose, 24h). (a, c) Total and mitochondrial proteins were analysed by 
immunoblot with the indicated antibodies. β-ACTIN and TFAM were used as total 
lysate and mitochondrial fraction controls, respectively. (b) Mitochondrial 
fractions were subjected to PK treatment to degrade the outer membrane proteins. 
BCL-2 and TFAM were used as outer membrare and inner mitochondrial 
membranes markers, respectively. fl.: full-length FoxO3A; cl.: cleaved FoxO3A. 
The presented results are representative of three or more independent experiments 
(Celestini et al., 2018). 
4.2.4 Signalling involved in FoxO3A mitochondrial translocation 
The finding of two major players for FoxO3A mitochondrial translocation 
required a more detailed investigation on the N-terminal domain of FoxO3A. The 
published evidence shows that genetic silencing of AMPK abolished FoxO3A 
accumulation into the mitochondria of normal cells under glucose shortage 
(Peserico et al., 2013). This suggests that AMPK could be a physiological kinase 
for N-terminus FoxO3A phosphorylation. In the literature, various approaches have 
been described - synthetic peptides, or mutational analyses of AMPK substrates- 
that elucidated the AMPK motif, in the effort to find novel substrates of AMPK 
(Gwinn et al., 2008; Marin et al., 2015). Mainly, as a highly selective kinase, AMPK 
prefers sites that have at least one basic side chain (usually R, but can be K or H), 
usually at the −3 or −4 positions, and hydrophobic residues at the −5 position and/or 
the +4 (usually L or M, but I, V or F in some cases). However, AMPK targets often 
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contain minor variants of the consensus sequence, such as the lack of the basic 
residues in the −4/-6 positions.  
To determine whether AMPK is one of the kinases required for the 
phosphorylation of FoxO3A at S30, alignment has been performed between the 
AMPK phosphorylation sites sequence in the best-established in vivo substrates of 
the kinase and the amino acid sequence surrounding S30. The results of the 
comparative analyses revealed that the analysed region does carry AMPK signature 
sequence and, consequently, the S30 is likely an authentic substrate of AMPK 
(Table 4.2). 
Furthermore, in the light of the previous in silico and in vivo results, 
KinasePhos 2.0, a web server aimed to the identification of protein kinase-specific 
phosphorylation sites, was questioned to predict which kinase might be required in 
the signalling pathway involving Ser12 (Wong et al., 2007). Specifically, this tool 
investigates uncharacterised protein sequences by exploiting known 
phosphorylation sites, categorised in the server by substrate sequences and their 
corresponding protein kinase classes. The KinasePhos analysis performed of N-
terminus of FoxO3A suggested that S12 could be a part of an ERK consensus 
phosphorylation motif (Ser-Pro). Of note, experimental evidences showed that both 
AMPK and ERK kinases were phospho-activated in glucose-restricted HCT116 
cells (Figure 4.13a) and that they can be localised at the mitochondria together with 
FoxO3A (Figure 4.13b). Importantly, pharmacological inhibition of the mitogen-
activated protein kinase kinase (MEK)/ERK or the AMPK pathway by PD98059 or 
compound C (CC), respectively, significantly prevented FoxO3A localisation at 
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(FoxO3A-fl.) and accumulation into (FoxO3A-cl.) the mitochondria (Figure 4.14a-
b). Moreover, consistent with previous reports (Peserico et al., 2013), activation of 
AMPK by AICAR significantly induced mitochondrial processing and import of 
FoxO3A, as shown by the levels of its cleaved form (FoxO3A-cl.) even in the 
presence of high glucose concentration in culture (Figure 4.14b). 
 
 
 
 
 
 
 
 
 
 
 
Table 4-2. - Signalling involved in FoxO3A mitochondrial translocation- 
Protein alignment between N-terminus of FoxO3A and AMPK phosphorylation 
sites established in AMPK substrates. Grey boxes indicates similarity (polarity 
and/or hydropathy properties) among FoxO3A amminoacids surrounding S30 and 
the AMPK target sites residues. 
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Figure 4.13- Signalling involved in FoxO3A mitochondrial translocation. 
(a) Total proteins were extracted from HCT116 cells grown in standard (HG, 24 h) 
and low glucose conditions hours (LG, 0,75 mM glucose, 24h) and analysed by 
immunoblot with the indicated antibodies. β-ACTIN was used as a loading control. 
(b) Upon glucose restriction, HCT116 cells were transfected with FoxO3A-FLAG 
for 48 hours and mitochondrial fractions were isolated and analysed by co-
immunoprecipitation. pAMPK: phospho-AMPK; pERK: phospho-ERK. fl: full-
length FoxO3A; cl: cleaved FoxO3A. The presented results are representative of 
three or more independent experiments (Celestini et al., 2018). 
 Results 
 132 
 
 
Figure 4.14–The pharmacological modulation of MEK/ERK and AMPK pathway 
influence FoxO3A mitochondrial translocation 
(a) Pharmacological inhibition of MEK using PD98059 in HCT116 cells cultured 
in LG (24 h). (b) Pharmacological inhibition or activation of AMPK using 
compound C (CC, 5 µM) or AICAR (5 mM), respectively, in HCT116 cells cultured 
in LG (24 h). Total and mitochondrial proteins were analyzed by immunoblot. (a-
b) PD98059, compound C and AICAR concentrations were defined accordingly on 
dose-response curve previously performed. β-ACTIN and TFAM  were used as total 
lysate and mitochondrial fraction controls, respectively. pACC: phospho-ACC; 
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pERK: phospho-ERK; fl: full-length FoxO3A; cl: cleaved FoxO3A. The presented 
results are representative of three or more independent experiments (Celestini et 
al., 2018). 
Collectively, these data strongly propose that S12 and S30 are targeted by ERK and 
AMPK, respectively. To confirm this hypothesis, two newly GST-FoxO3A 
constructs were generated, one encoding for the N-terminal domain [GST-
FoxO3A(1-148)] and the other for a region encompassing residues 385-525 [GST-
FoxO3A(385-525)], which contains residues previously shown to be targeted by 
both AMPK (at S399 and S413, Calnan and Brunet, 2008) and ERK (S425, Yang 
et al., 2008). Moreover, the GST-FoxO3A (1-148) vector was mutagenized by 
Serine/alanine substitution at positions 12 and/or 30 to obtain the constructs GST-
FoxO3A (1-148) S12A, GST-FoxO3A (1-148) S30A and GST-FoxO3A (1-148) 
S12A/S30A (Figure 4.15a). The indicated purified proteins were subjected to a 
kinase assay to test the ability of AMPK and ERK to phosphorylate their candidate 
residues in vitro directly. Data presented in Figure 4.15b show that ERK could 
efficiently phosphorylate GST-FoxO3A (1-148) as well as the positive control 
[GST-FoxO3A (385-525)] and that the S12A substitution is sufficient to decrease 
P32 incorporation in GST-FoxO3A (1-148) significantly. By in silico prediction, 
similar results were obtained with the S12A/S30A double mutant, indicating that 
ERK directly phosphorylates FoxO3Aat S12. To ascertain whether AMPK could 
phosphorylate S30, GST-FoxO3A (1-148) and GST-FoxO3A (385-525) were 
assayed with AMPK. The results demonstrated that AMPK efficiently 
phosphorylated the N-terminus of FoxO3Ain vitro (Figure 4.15b, right panel). 
Serine-to-Alanine substitution at position 30 impaired the radioactive labelling, 
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indicating that AMPK phosphorylates FoxO3Aat S30. Indeed, also, in this case, 
similar results were obtained with the S12A/S30A double mutant. 
Furthermore, the alignment of the N-terminal region of human FoxO proteins 
obtained by using the CLUSTALW (1.83) tool revealed that S30 is evolutionarily 
conserved from humans to nematodes (Figure 4.16a), and this is located in a part of 
a highly conserved subdomain which is shared by other human FoxOs. Moreover, 
the phylogenetic analysis performed by using the T-Coffee tool for sequence 
alignment showed homology of FoxO3A sequences surrounding S30 from 
Caenorhabditis elegans to Homo sapiens. Interestingly, S12 is less conserved 
across species and is not present in the other members of the human FoxO family 
(Figure 4.16b). 
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Figure 4.15 - The AMPK and MEK/ERK signalling pathways regulate 
mitochondrial FoxO3A 
(a) Scheme of GST-FoxO3A recombinant constructs generated.  In vitro kinase 
assays performed with the indicated GST-FoxO3A (1–148) and mutant 
recombinant proteins as substrates, in the presence of recombinant ERK (a) or 
recombinant AMPK (b). In both assays, GST-FoxO3A (386–525) was used as a 
positive control. GST-empty protein was used as a negative control. Coomassie gel 
staining (lower panels) was used as a loading control. fl. full-length FoxO3A, cl. 
 Results 
 136 
 
cleaved FoxO3A, N-term. N-terminal domain, FKH-DBD forkhead DNA-binding 
domain, NLS nuclear localization signal, TAD transactivation domain, C-term. C-
terminal domain. The presented results are representative of at least three 
independent experiments (Celestini et al., 2018).
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Figure 4.16 – Analysis of the 1-30 region 
(a) Alignment of the N-terminal region of human FoxO proteins performed by using the CLUSTALW (1.83). Human FoxO proteins were 
annotated with specific UniProtKB/Swiss-Prot accession numbers and entry names (http://www.uniprot.org). (b) Phylogenetic analysis 
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showing homology of the FoxO3A region encompassing residues S12 and S30. Sequences were aligned by using the T-Coffee tool available 
on the MSA (Multiple Sequence Alignment) server (http://www.ebi.ac.uk/Tools/msa/tcoffee/).  
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4.2.5 FoxO3A mitochondrial accumulation requirements in 
normal cells and tissues upon nutrient shortage 
In normal cells, glucose restriction induces only AMPK activation, while ERK is 
not phosphorylated (Figure 4.17a). To explore the “mitochondrial code” of 
FoxO3A in normal model, NIH-3T3 normal murine fibroblasts were transfected 
with FoxO3A-wt, FoxO3A-S12A and FoxO3A-S30A. Interestingly, our data 
showed that the replacement of S30 with a non-phosphorylatable Alanine is 
sufficient to prevent FoxO3A mitochondrial localisation under glucose restriction 
(Figure 4.17b). These data indicate that normal fibroblasts require only AMPK 
activation to induce FoxO3A mitochondrial accumulation, whereas MEK/ERK 
signalling pathway is not involved. 
To get further insight into the mechanism observed in cell culture, two group of 
mice were subjected to overnight fasting (18 h), a procedure known to significantly 
lower plasma glucose levels (Andrikopoulos et al., 2008). Upon their sacrifice, 
mitochondria from kidney and liver, two tissues containing a significant amount of 
both FoxO3A-fl. and -cl. in the previous analysis (Figure 4.4), were isolated and 
purified. Immunoblot analysis revealed the accumulation of both forms of FoxO3A 
in fasted mice, suggesting that nutrient shortage caused localisation of the 
transcription factor at the outer mitochondrial membrane (FoxO3A-fl.) and its 
subsequent import, cleavage and translocation into the mitochondrial matrix 
(FoxO3A-cl.). Treatment of murine mitochondria with proteinase K confirmed that 
the cleaved form (FoxO3A-cl.) is detectable also in vivo into the mitochondrial 
matrix (Figure 4.18b-c). To get the full picture, the status of AMPK and ERK in 
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kidney and liver of mice upon fasting was analysed (Figure 4.18a). Consistent with 
results obtained in the NIH-3T3 cell line, only AMPK was found to be significantly 
activated in the animal tissue under nutrient shortage conditions, which supports its 
role in the signal transduction pathways leading to mitochondrial translocation of 
FoxO3A. 
 
Figure 4.17 - FoxO3A accumulation into the mitochondria only requires the AMPK 
signal in normal cells 
(a) Immunoblot analysis of total proteins isolated from murine NIH3T3 cells upon 
LG (0.75 mM glucose, 24 h). β-ACTIN: loading control. (b) Immunoblot analysis 
of total and mitochondrial proteins isolated from NIH3T3 cells transfected with the 
indicated plasmids for 48 h and subjected to LG (24 h). β-ACTIN and HSP60 were 
used as total lysate and mitochondria controls, respectively. fl. full-length FoxO3A, 
cl. cleaved FoxO3A. The presented results are representative of at least three 
independent experiments (Celestini et al., 2018). 
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Figure 4.18 -FoxO3A accumulation into the mitochondria only requires the AMPK 
signal in tissues under nutrient shortage 
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(a) Left panel: immunoblot analysis of total proteins isolated from kidney and liver 
of fed or fasted (18 h) mice (1 and 2). β-ACTIN: loading control. Right panel: 
densitometric analysis of the phosphorylated forms of AMPK and ERK normalized 
against total AMPK and ERK, respectively, and the loading control. (b) 
Immunoblot analysis of mitochondrial proteins isolated from the liver of fed or 
fasted (18 h) mice in the presence or absence of PK. BCL2: outer membrane 
control, HSP60: mitochondrial matrix control. (c) Left panel: immunoblot analysis 
of mitochondrial proteins isolated from kidney and liver of fed or fasted (18 h) mice. 
HSP60: loading control. Right panel: densitometric analysis of full-length and 
cleaved FoxO3A normalized against the mitochondrial fractionation loading 
control. fl. full-length FoxO3A, cl. cleaved FoxO3A. The presented results are 
representative of at least three independent experiments. Where applicable, data 
are presented as mean ± SEM and significance was calculated with Student’s t test; 
*p < 0.05, **p < 0.01, and ***p < 0.001 (Celestini et al., 2018). 
4.3 Role of mitochondrial FoxO3Ain stressed 
cancer cells 
As a shorter form of FoxO3A originated by the cleavage of its N-terminus has never 
been described to date, in the light of data previously published by Peserico and 
colleagues, this novel FoxO3A form needs to be characterised in its ability to bind 
mtDNA and induce the expression of the mitochondrial genome in nutrient shortage 
conditions. 
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4.3.1 Mitochondrial FoxO3A regulates the mtDNA expression in 
metabolically stressed cancer cells 
To characterise the ability of the cleaved form of FoxO3A to modulate the 
mitochondrial genome fate, an HA-FoxO3A-FLAG vector was expressed in 
HCT116 cancer cells, followed by chromatin immunoprecipitation (ChIP) analysis, 
performed on mitochondrial fraction by using an anti-HA antibody or an anti-
FLAG. Only the latter was able to recognise the cleaved form, which could 
efficiently bind the D-loop of mtDNA at FRHE consensus sites (FHRE#1: bp 
14,963–15,110; FHRE#2: bp 15,400–15,469) under metabolic stress conditions 
(Figure 4.19a). Further ChIP analyses performed on endogenous proteins from 
mitochondria purified from different cell lines (HCT116 and HT29 human 
colorectal cancer cells; HEK-293 immortalized human embryonic kidney epithelial 
cells) confirmed that endogenous FoxO3A-cl. is recruited at FHRE#1-2 sites 
together with SIRT3, TFAM and mtRNApol in glucose-restricted cells (Figure 
4.19b, d, f, h). The specificity of immunoprecipitation was ensured by a parallel 
analysis carried out on mitochondria purified from mtDNA-depleted (rho0) HT-29 
cells (Schubert et al., 2015) which served as a proper negative control (Figure 
419d). 
Importantly, FoxO3A-cl., SIRT3, TFAM and mtRNApol form a multiportion 
complex in the mitochondrial matrix (Figure 4.21a), that is enriched in nutrient 
shortage conditions. Interestingly, it is worth noting that the glucose deprivation 
does not influences SIRT3 expression in HCT116 cell lines (Fig 4.20a). On the 
other hand, SIRT3 phosphorylation is enriched upon low glucose (Fig 4.20b). 
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However, few data are available about the regulation of SIRT3 function by PMTs 
(Flick et al. 2012). Of note, the presence of FoxO3A-SIRT3-mtRNAPol-TFAM 
complex (Figure 4.21a) on mtDNA well correlates with increased expression of all 
mitochondrial transcripts, as shown by quantitative real-time analysis of mtRNA in 
cell lines subjected to glucose restriction (Figure 4.19c, e, g, i). These results are 
consistent with the previous reports (Peserico et al., 2013). Interestingly, upon 
nutrient shortage, the acetylation of FoxO3A decreases in HCT116 (Figure 4.21b). 
SIRT3 deacetylatesFoxO3A in the nucleus (Sundaresan et al., 2009), an in vitro 
deacetylation assay was performed on the mitochondrial fraction obtained from an 
HCT116 cell transfected with FoxO3A-FLAG, in the presence of a newly generated 
GST-SIRT3 purified protein. To modulate the activity of SIRT3, the Sirtuin 
inhibitor, Nicotinamide (NAM), was added to the reaction. The assay confirmed 
that SIRT3 is required for FoxO3A mitochondrial deacetylation (Figure 4.21c). 
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Figure 4.19 - GR-dependent FoxO3A mitochondrial import leads to increased 
mitochondrial gene expression. 
(a) ChIP analysis of exogenous FoxO3A recruitment at FHRE #1–2 sites on mtDNA 
(FHRE #1: bp 14,963–15,110; FHRE #2: bp 15,400–15,469) upon LG (0.75 mM 
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glucose, 24 h) in HCT116 cells transfected with HA-FoxO3A-WT-FLAG. (b, d, f, h) 
ChIP analysis of endogenous FoxO3A recruitment at FHRE #1–2 sites on mtDNA 
in HCT116 (b), HT29 and Rho0 HT29 (negative control, d), SW480 (f) and HEK293 
(h) cells upon LG (24 h). Anti-IgGs were used as controls. (c, e g, d) Mitochondrial 
gene regulation in HCT116 (c) HT29 and Rho0 HT29 (negative control, e), SW480 
(g) and HEK293 (i) upon LG (0.75 mM glucose, 24 h) assessed by RT-PCR. Black 
bars: ATPase 6 and 8 genes; white bars: COX1, COX2, and COX3 genes; gray 
bars: ND1, ND2, ND3, ND4, ND4L, ND5, and ND6 genes; light gray bar: 
CYTOCHROME B gene. The dotted line corresponds to the expression levels 
detected in cells cultured in HG. The presented results are representative of at least 
three independent experiments. Where applicable, data are presented as 
mean ± SEM and significance was calculated with Student’s t test; *p < 0.05, 
**p < 0.01, and ***p < 0.001(Celestini et al., 2018). 
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Figure 4.20 - SIRT3 phosphorylation increases upon glucose restriction 
(a) Immunoblot analysis with the indicated antibodies of mitochondrial fraction 
isolated from HCT116 cells treated with low glucose (LG, 0.75mM glucose) for 
24h. Mitochondrial fractions were treated with proteinase K (PK) to degrade outer 
mitochondrial membrane proteins. PDH: loading control. (b) Immunoprecipitation 
analysis with the indicated antibodies of HCT116 mitochondrial fractions upon LG 
(24h. The presented results are representative of at least three independent 
experiments. 
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Figure 4.21 - SIRT3 deacetylates mtFoxO3A. 
(a) Co-immunoprecipitation analysis with the indicated antibodies of PK-treated 
HCT116 mitochondrial fractions upon LG (0.75 mM glucose, 24 h). (b) Upon 
glucose restriction, HCT116 cells were transfected with FoxO3A-FLAG and 
mitochondrial fraction was isolated and analysed by immunoprecipitation with 
anti-acetylLysine antibody. (c) In vitro deacetylation assay. FoxO3A-WT-FLAG 
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was transfected in HCT116 cells. Upon LG (24h), the mitochondrial enriched-
fraction was purified and treated with Proteinase K to degrade the outer membrane 
protein. Then it has been immunoprecipitated with anti-FLAG antibody and 
incubated with recombinant GST-SIRT3, in presence/absence of the Sirtuin 
inhibitor Nicotinamide (NAM). cl: cleaved FoxO3A-FLAG. The presented results 
are representative of at least three independent experiments. 
4.3.2 Characterization of FoxO3A localisation mutants in a 
FoxO3A-/- cancer cell line 
To further explore FoxO3A function in cancer cells under metabolic stress, and, 
particularly, to dissect the role of mitochondrial FoxO3A and its possible 
contribution to nuclear FoxO3A activity, by using the CRISPR/Cas9 system for 
genome editing (Figure 4.22a), a FoxO3A knockout HCT116 cell line (HCT116 
FoxO3A-/-) was generated. To validate it, immunoblot analysis was performed on 
mitochondria isolated from metabolically stressed HCT116 FoxO3A-/-cells, with 
two antibodies detecting the endogenous form of FoxO3A, one directed against the 
N-terminus, and the other targeting the C-terminal domain.  None of them was able 
to recognize the 90kDa or the 70kDa bands in whole mitochondria of HCT116 
FoxO3A-/-cells (Figure 4.22b). Additionally, further confirmation was obtained by 
performing an RT-PCR with specific FoxO3A primers (data not shown). 
After the validation of the FoxO3A knock-out model, FoxO3A expression was 
reconstituted in these cells by transfecting them with different plasmids: the 
FoxO3A-WT, the non-phosphorylatable mutant FoxO3A-S12A/S30A plasmid and 
with a newly generated mutant plasmid, FoxO3A-S12D/S30D, where Ser12 and 
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Ser30 were replaced with aspartic acid residues to mimic Phosphoserines (Figure 
4.23a). As shown in Figure 4.23, the phospho-mimetic mutant (FoxO3A-
S12D/S30D) is strongly accumulated in the mitochondria, also in the absence of 
stress (HG). This mutated FoxO3A bound to mtDNA and induced the expression 
of mitochondrial genes, while the unphosphorylatable mutant (FoxO3A-
S12A/S30A) failed to do so (Figure 4.23b-f and 4.24). Importantly, both FoxO3A 
mutants were still able to enter in the nucleus and bound FHRE sites at the 
promoters of two well-known FoxO3A target genes, p21 and p27, under metabolic 
stress (Figure 4.23d).  
In the same cellular system, another FoxO3A mutant, FoxO3A-D242/271, lacking 
the nuclear localisation signals (NLS, Tsai et al., 2007), was introduced. This 
protein was unable to enter in the nucleus (Figure 4.23c) to bind the FHRE sites of 
p21 and p27 (Figure 4.23e), but was still capable of entering into the mitochondria 
and bound the FHRE#1-2 sites at the D-loop of mtDNA in metabolically stressed 
cancer cells (Figure 4.23g). 
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Figure 4.22 -Generation of HCT116 FoxO3A-/- by using Crispr-Cas9 system. 
(a) Scheme of gRNA location in human FoxO3A locus. Targeting sites and proto-
spacer adjacent motifs (PAMs) and the deleted region are indicated. (b) 
Immunoblot analysis of total lysate obtained from HCT116 FoxO3A+/+ and 
HCT116 FoxO3A-/- cells with different anti-FoxO3A antibodies upon 2DG (1 mM, 
6h) treatment (Celestini et al., 2018). 
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Figure 4.23-Mitochondrial-FoxO3A regulates mitochondrial gene expression in 
metabolically stressed cancer cells. 
HCT116 FoxO3A-/- cells were transfected with the indicated FoxO3A plasmids for 
48h and treated with 2DG (1 mM, 6h), to induce metabolic stress. (a) Immunoblot 
C
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analysis of total and mitochondrial proteins. (d-g) ChIP analysis of exogenous 
FoxO3A recruitment at FHRE p21-p27 sites on nuclear DNA (d,e) and FHRE #1-
2 sites on mtDNA (f,g). (c) Immunoblot analysis of nuclear and mitochondrial 
proteins. (d-g) Anti-IgGs were used as controls. (b,c) β-ACTIN, TFAM and LAMIN 
B were used as total, mitochondrial and nuclear lysate controls, respectively, as 
appropriate. fl.: full-length FoxO3A; cl.: cleaved FoxO3A; N-term.: N-terminal 
domain; FKHDBD: forkhead DNA-binding domain; NLS: nuclear localisation 
signal; TAD: transactivation domain; C-term.: C-terminal domain. The presented 
results are representative of at least three independent experiments. Where 
applicable, data are presented as mean±SEM and significance was calculated with 
Student’s t test; *p value < 0.05, **p < 0.01 and ***p < 0.001 (Celestini et al., 
2018). 
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Figure 4.24 – Mitochondrial-FoxO3A regulates mitochondrial gene expression in 
metabolically stressed cancer cells (2) 
(a, b) HCT116 FoxO3A-/- cells were transfected with the indicated plasmids for 48h 
and treated with 2-deoxy-glucose (2DG, 1 mM, 6h). (a) Mitochondrial gene 
regulation assessed by RT-PCR. Black bars: ATPase 6 and 8 genes; white bars: 
COX1, COX2 and COX3 genes; grey bars: ND1, ND2, ND3, ND4, ND4L, ND5, 
and ND6 genes; light grey bar: cytochrome b gene. (b) Immunoblot analysis of total 
proteins with the indicated antibodies. HSP60 was used as loading control. The 
presented results are representative of at least three independent experiments. 
Where applicable, data are presented as mean ± SEM and significance was 
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calculated with Student’s t test. *p value < 0.05 was considered statistically 
significant (Celestini et al., 2018). 
4.3.3 Role of mtFoxO3A in cancer cell response to metabolic stress 
As discussed above, a nuclear transcriptional programme of FoxO3A regulates a 
plethora of functions, such as triggering apoptosis through the expression of genes 
necessary for cell death.  Moreover, its role as tumour suppressor has been widely 
discussed (Hu et al., 2004; Fei et al., 2009; Han et al., 2018; Jiang et al., 2013; 
Habashy et al., 2011; Yang et al., 2013; Yu et al., 2016;  Liu et al., 2015).  
In the effort to dissect FoxO3A nuclear and mitochondrial activities in cancer cells 
under metabolic stress and chemotherapy, HCT116 FoxO3A+/+ and HCT116 
FoxO3A-/- cells were cultured in glucose shortage conditions or the presence of 
drugs currently administered to colorectal cancer patients. The chemotherapic 
reagents were selected on the bases of the fact that their activity has been shown to 
involve FoxO3A in cellular models, such as Metformin, Cisplatin, Irinotecan, 5-
Fluorouracil and Etoposide (Chiacchiera and Simone, 2010; Fernández de Mattos 
et al., 2008; Wang et al., 2015; Yu et al., 2016; Germani et al., 2014). 
Surprisingly, relative cell viability and relative cell death evaluations revealed that 
HCT116 FoxO3A-/- cells were more sensitive to metabolic stress and 
chemotherapeutics than their wild-type isogenic counterparts were. This evidence 
suggested that the presence of FoxO3A in HCT116 cell line results in resistance 
and survival. Of note, treatment with Metformin showed opposite results, with 
HCT116 FoxO3A+/+ cells being more sensitive to its administration than HCT116 
FoxO3A-/- cells (Figure 4.25a). Moreover, several human cancer cell lines 
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(HCT116 and HT-29 colorectal cancer cells, DU145 prostate cancer cells, A549 
lung cancer cells, MDA-MB-468 breast cancer cells and OVCAR-3 ovarian cancer 
cells) and HEK-293 cells have been cultured in low glucose conditions to assay 
their resistance under metabolic stress. Collected results showed that the higher the 
amount of mtFoxO3A they accumulated, the more they resisted and survived in LG 
cultures (Figure 4.25b), and supporting the hypothesis that mtFoxO3A could 
represent a survival factor in cancer cells under metabolic stress. Therefore, 
FoxO3A expression in HCT116 FoxO3A-/- cells were reconstituted by transfecting 
them with various FLAG-tagged vectors, encoding for FoxO3A-WT or non-
phosphorylatable double mutant FoxO3A-S12A/S30A (impaired in its 
mitochondrial localisation, but still able to localise into the nucleus and bind target 
genes, see Figure 4.23), or FoxO3A-D242/271 which lacks the NLS (but still able 
to enter the mitochondria and bind FHRE sites at the mtDNA, see Figure 4.23). 
Upon transfection, cells were cultured in LG conditions. 
Interestingly, the obtained results showed that reconstitution of FoxO3A-WT 
expression increased cell survival (Figure 4.26a), by results obtained in HCT116 
FoxO3A+/+ (Figure 4.25a). Of note, FoxO3A-D242/271 was still able to rescue 
metabolic stress-dependent cell death, while the mutant impaired in mitochondrial 
localisation failed to do so (Figure 4.26a). Furthermore, the analysis of FoxO3A 
mitochondrial target genes expression (ND6, Cox1)  revealed that both the wild-
type form and the D242/271 mutant were able to activate mitochondrial 
transcription in surviving cells. Moreover, the FoxO3A-S12A/S30A mutant 
possibly contributed to apoptosis induction in metabolically stressed cancer cells 
by promoting the transcription of Bim and the PARP cleavage (Figure 4.26a-b). 
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This scenario, strongly suggested that the mitochondrial form of FoxO3A in 
HCT116 cell line is linked to survival. 
 
Figure 4.25 - mtFoxO3A is involved in cancer cell response to metabolic stress. 
(a) HCT116 FoxO3A+/+ and HCT116 FoxO3A−/− cells were subjected to different 
treatments: glucose restriction (LG, 0.75 mM glucose, 24 h), Metformin (MET, 
10 µM, 72 h), Cisplatin (CDDP, 30 µM, 48 h), Irinotecan (CPT-11, 30 µM, 24 h), 5-
fluorouracil (5-FU, 2 µM, 24 h) and etoposide (VP-16, 40 µM, 24 h). 
Chemoterapeutic drugs selected are commonly used in CRC. The selected drug 
dose have been previously defined by performing dose-response curves and 
defining the IC50 for each drug. Cell viability/control and cell death/control were 
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calculated as described in Material and Methods. (b) Correlation between LG-
resistance (days) and mitochondrial FoxO3A (mtFoxO3A) protein levels in 
different human cell lines (HCT116 and HT29 colorectal cancer cells, HEK293 
embryonic kidney cell, DU145 prostate cancer cells, A549 lung cancer cells, MDA-
MB-468 breast cancer cells and OVCAR3 ovarian cancer cells). a.u. arbitrary 
units. The presented results are representative of at least three independent 
experiments. Where applicable, data are presented as mean ± SEM and 
significance was calculated with Student’s t test; *p < 0.05, **p < 0.01, and 
***p < 0.001 (Celestini et al., 2018). 
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Figure 4.26 - mtFoxO3A as a survival factor in cancer cells under metabolic stress 
(a) HCT116 FoxO3A−/− cells were transfected with the indicated plasmids (48 h) 
and subjected to LG (24 h). Upper panel: cell viability/control and cell 
death/control calculated as described in Material and Methods. Lower panel: 
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immunoblot analysis of total proteins. β-ACTIN: loading control. (b) Transcription 
analysis of selected mitochondrial (ND6 and COX1) and nuclear (BIM) genes by 
RT-PCR in HCT116 FoxO3A−/− cells transfected with the indicated plasmids (48 h) 
and subjected to LG (24 h). The presented results are representative of at least three 
independent experiments. Where applicable, data are presented as mean ± SEM and 
significance was calculated with Student’s t test; *p < 0.05, **p < 0.01, and 
***p < 0.001 (Celestini et al., 2018). 
Subsequently, to confirm these experimental observations, FoxO3A knockout cells 
were transfected with GFP-tagged vectors encoding for FoxO3A-WT, FoxO3A-
S12A/S30A and FoxO3A-D242/271, and then subjected to metabolic stress by 
treating them with the calorie mimetic 2DG. Then, TIME staining was performed 
to visualise the polarisation status of mitochondrial membranes in GFP-positive 
cells. TMRE failed to stain mitochondria of HCT116 FoxO3A-/- cells transfected 
with the FoxO3A-S12A/S30A mutant (Figure 4.27a), as they were undergoing 
apoptosis (Figure 4.27a). The maintenance of polarised membrane potential, 
together with functional electron chain transportation, demonstrate that the healthy 
and functionally active state of mitochondria in metabolically stressed cancer cells 
is sustained. These results highlighted the functional importance of FoxO3A S12 
and S30 residues and of the activation of pathways dictating their phosphorylation 
(see Figure 4.26a), in cancer cell resistance to metabolic stress. This evidence 
suggested to assess the effect of the inhibition of the MEK/ERK and/or the AMPK 
pathway in HCT116 FoxO3A+/+ cells cultured in LG conditions. Of note, 
Trametinib (a MEK inhibitor approved by the FDA for clinical use) and compound 
C (an AMPK inhibitor) co-treatment was tested on the wild-type HCT116, by using 
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a citotoxicity assay. Increasing concentrations of both drugs showed a cytotoxic 
effect in metabolically stressed cancer cells (Figure 4.27b).  
To confirm these results in vivo, HCT116 FoxO3A+/+ cells were injected in nude 
mice. Then, growing tumours were treated with 2DG (100 mg/kg) intra-peritoneally 
to induce metabolic stress. At the end of the treatment, mice were sacrificed, and 
tumours were explanted for immunoblot analysis. The results obtained (shown in 
Figure 4.28) reveal that the metabolic stress induced the activation of both the 
MEK/ERK and the AMPK pathways in tumour tissues. Moreover, the stress stimuli 
induced also the mitochondrial localisation of FoxO3A, similar to what was 
observed in cancer cells in culture. 
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Figure 4.27– mtFoxO3A as a survival factor in cancer cells under metabolic stress 
(2) 
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(a) HCT116 FoxO3A−/− cells, transfected with the indicated plasmids (48 h), were 
subjected to metabolic stress with 2DG (1 mM, 6 h). The graph reflects the 
quantification of tetramethylrhodamine ethyl ester (TMRE) fluorescence of active 
mitochondria in transfected cells. (b) Citotoxicity assay on HCT116 FoxO3A+/+ 
cells cultured in LG (24 h) and treated with increasing concentrations of 
Trametinib and/or compound C, as indicated, for 24 h. Cell growth percent 
inhibition at each drug concentration is shown. The presented results are 
representative of at least three independent experiments. Where applicable, data 
are presented as mean ± SEM and significance was calculated with Student’s t test; 
*p < 0.05, **p < 0.01, and ***p < 0.001 (Celestini et al., 2018). 
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Figure 4.28-mtFoxO3A accumulation in vivo under metabolic stress 
Left panel: immunoblot analysis of total and mitochondrial proteins isolated from 
tumours (n ≥ 7 for each group) derived from HCT116-xenografted nude mice 
subjected to 2DG treatment (100 mg/kg, 6 days). β-ACTIN and HSP60 were used 
as total and mitochondrial loading control, respectively. fl. full-length FoxO3A, cl. 
cleaved FoxO3A. Right panel: densitometric analysis of full-length and cleaved 
FoxO3A normalized against the mitochondrial loading control and the results of 
the densitometric analysis of the phosphorylated-AMPK and ERK normalized 
against total AMPK and ERK, respectively, and the loading control. The results are 
representative of at least three independent experiments. Data are presented as 
mean ± SEM and significance was calculated with Student’s t test; *p < 0.05, 
**p < 0.01, and ***p < 0.001(Celestini et al., 2018). 
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4.3.4 Role of mtFoxO3A in cancer cell response to 
chemotherapeutic agents 
The results gathered in metabolically stressed cancer cells, the role of FoxO3A-
WT, FoxO3A-S12A/S30A and FoxO3A-D242/271 in the response of reconstituted 
HCT116 FoxO3A-/- cells to chemotherapeutic agents was evaluated. Specifically, 
FoxO3A knockout HCT116 cells were transfected with the relevant FLAG-tagged 
vectors and then cultured in the absence or the presence of Irinotecan (CTP-11), 
Cisplatin (CDDP), 5-Fluorouracil (5-FU) or Etoposide (VP-16). Consistent with 
data obtained in the multi-drug screening performed in HCT116 FoxO3A-/- vs 
HCT116 FoxO3A+/+ cells (see Figure 4.25a), reconstitution of FoxO3A-WT 
expression resulted in increased survival (Figure 4.29). Moreover, in line with what 
was observed in metabolically stressed cells, the evaluation of the mitochondrial 
localisation-impaired non-phosphorylatable mutant (FoxO3A-S12A/S30A) 
revealed that it was unable to rescue chemotherapy-induced apoptosis (4.29a-b, 
4.30). On the other hand, the mutant could activate Bim transcription to contribute 
to the apoptotic response (Figure 4.29b). Of note, the DNLS mutant (FoxO3A-
D242/271) behaved similar to FoxO3A-WT, and both were able to activate 
mitochondrial gene expression in chemotherapy-induced cellular stress (4.29b).  
Importantly, the molecular analysis of transfected HCT116 FoxO3A-/- cells showed 
activation of the MEK/ERK, but not the AMPK pathway, in response to 
chemotherapy (Figure 4.29a, lower panel). Indeed, only Serine 12 of FoxO3A is 
required to elicit chemoresistance in these conditions (Figure 4.29c). Of note, the 
FDA-approved MEK inhibitor Trametinib and CPT-11 co-treatment was tested on 
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the wild-type HCT116. Results obtained showed a additive cytotoxic effect in 
HCT116 FoxO3A+/+ cancer cells (Figure 4.31b). 
To validate the obtained experimental observation in vivo, HCT116 FoxO3A+/+ 
cells were injected in nude mice to generate HCT116-xenograft tumour model. The 
mice were treated with Cisplatin (2 mg/kg) that was given intra-peritoneally once 
every three days. At the end of the treatment, mice were sacrificed and tumours 
explanted for immunoblot analysis. Consistently with the observation made in cell 
culture, the analysis revealed that chemotherapy-induced the accumulation of 
FoxO3A into the mitochondria and, at the same time, the activation of the 
MEK/ERK. On the other hand, the AMPK pathway is not activated (Figure 4.31a).  
Briefly, the data collected show that, in metabolically stressed cancer cells, the 
activation of MEK/ERK and AMPK - which phosphorylate Serine 12 and 30 
respectively- induces the recruitment and import of FoxO3A to the mitochondria. 
Here, the protein is cleaved to reach mitochondrial DNA and activate its expression 
to support mitochondrial metabolism and cell survival. 
 
  
 Results 
 167 
 
 
Figure 4.29 - mtFoxO3A is involved in chemoresistance. 
HCT116 FoxO3A−/− cells were transfected with the indicated plasmids for 48 h and 
then treated with Irinotecan (CPT-11, 30 µM, 24 h). (a) Upper panel: r Cell 
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viability/control and cell death/control calculated as described in Material and 
Methods. Lower panel: immunoblot analysis of total proteins. β-ACTIN: loading 
control. (b) Transcription analysis of selected mitochondrial (ND6 and COX1) and 
nuclear (Bim) genes by RT-PCR. (c) HCT116 FoxO3A−/− cells were transfected 
with the indicated plasmids for 48 h and then treated with Irinotecan (CPT-11, 
30 µM, 24 h). (c) HCT116 FoxO3A-/- cells were transfected with the indicated 
plasmids for 48h and then treated with Irinotecan (CPT-11, 30 µM, 24h). Cell 
viability/control and cell death/control were calculated as described in Material 
and Methods. The presented results are representative of at least three independent 
experiments. Data are presented as mean ± SEM and significance was calculated 
with Student’s t test. *p value < 0.05 and **p < 0.01 were considered statistically 
significant (Celestini et al., 2018). 
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Figure 4.30 - mtFoxO3A is involved in cancer cell response to chemotherapeutic 
agents. 
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HCT116 FoxO3A-/- cells were transfected with the indicated plasmids for 48h. 
Upon treatment with 5-Fluorouracil (5-FU, 2 µM, 24h) (A), Etoposide (VP-16, 40 
µM, 24h) (B) or Cisplatin (CDDP, 30 µM, 48h) (C), Cell viability/control and cell 
death/control were calculated as described in Material and Methods. The drugs 
concentrations selected have been previously defined by using dose-response 
curves. The presented results are representative of at least 3 independent 
experiments. Data are presented as mean ± SEM and significance was calculated 
with Student’s t test. *p value < 0.05 and **p < 0.01 were considered statistically 
significant (Celestini et al., 2018). 
  
 Results 
 171 
 
 
Figure 4.31- mtFoxO3A is involved in cancer cell response to chemotherapeutic 
agents (2) 
(a) Left panel: immunoblot analysis of total and mitochondrial proteins isolated 
from tumours (n ≥ 7 for each group) derived from HCT116-xenografted nude mice 
subjected to Cisplatin treatment (CDDP, 2 mg/kg, 6 days). β-ACTIN and HSP60 
were used as total lysate and mitochondrial fraction controls, respectively. Right 
panel: densitometric analysis of full-length and cleaved FoxO3A normalized 
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against the mitochondrial fractionation loading control and the results of the 
densitometric analysis of the phosphorylated forms of AMPK and ERK normalized 
against total AMPK and ERK, respectively, and the loading control. (b) Citotoxicity 
assay on HCT116 FoxO3A+/+ cells treated with increasing concentrations of 
Trametinib (24 h) and/or Irinotecan (24 h), as indicated. The drug concentrations 
used have been previously defined by using a dose-response curve. Cell growth 
percent inhibition at each drug concentration is presented. The presented results 
are representative of at least three independent experiments. Data are presented as 
mean ± SEM and significance was calculated with Student’s t test. *p value < 0.05 
and **p < 0.01 were considered statistically significant (Celestini et al., 2018). 
 
4.3.5 Role of mtFoxO3A in cancer cell response to 
chemotherapeutic agents: the response to Metformin 
The characterisation of HCT116 FoxO3A+/+ and HCT116 FoxO3A-/- cells revealed 
an opposite behaviour for Metformin treatment compared with metabolic stress and 
chemotherapeutic agents (4.25a). Moreover, molecular analysis of HCT116 
FoxO3A+/+ cells indicated that Metformin only activates AMPK and induces cells 
to undergo apoptosis (Figure 4.32a). Therefore, further investigation was required. 
As prevoiusly, in HCT116 FoxO3A-/- cells were transfected with various FLAG-
tagged vectors: FoxO3A-WT, the non-phosphorylatable double mutant FoxO3A-
S12A/S30A and FoxO3A-DNLS (Figure 4.23). 
Interestingly, the reconstitution of FoxO3A expression with the wild-type form or 
the DNLS mutant significantly increased cell death (Figure 4.32b), supporting the 
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preliminary observations and suggesting that mtFoxO3A is required for the 
Metformin-induced apoptosis. Indeed, reconstitution with a vector encoding for the 
FoxO3A-S30A mutant was sufficient to reduce cell death to the levels of mock-
transfected cells. These results indicate that Metformin can induce apoptosis via the 
AMPK-mtFoxO3A axis. Furthermore, the co-treatment of Metformin with a 
chemotherapeutic drug (Irinotecan) was assessed by performing a citotoxicity 
assay. Consistently with data obtained in FoxO3A knockout cells transfected with 
FoxO3A mutants, results obtained showed a additive cytotoxic effect of Metformin 
with Irinotecan in HCT116 FoxO3A+/+ cells (Figure 4.32c). 
To summerize, in cancer cells treated with chemotherapeutic agents, accumulation 
of FoxO3A into the mitochondria promoted survival and chemo-resistance in a 
MEK/ERK-dependent manner. Moreover, mitochondrial FoxO3A seems to be 
required for apoptosis induction by Metformin. 
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Figure 4.32-mtFoxO3Ais required for Metformin-induced apoptosis 
(a) Immunoblot analysis of total proteins isolated from HCT116 FoxO3A+/+ cells 
upon Metformin treatment (MET, 10 µM, 72 h). β-ACTIN: loading control. (b) 
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HCT116 FoxO3A−/− cells were transfected with the indicated plasmids for 48 h and 
then treated with Metformin (MET, 10 µM, 72 h). Cell viability/control and cell 
death/control were calculated as described in Material and Methods. (C) 
Citotoxicity assay on HCT116 FoxO3A+/+ cells treated with increasing 
concentrations of Metformin (24 h) and/or Irinotecan (24 h), as indicated. Cell 
growth percent inhibition at each drug concentration is presented. The data 
presented are the mean of at least three independent experiments. Where 
applicable, data are presented as mean ± SEM and significance was calculated with 
Student’s t test; *p < 0.05, **p < 0.01, and ***p < 0.001 (Celestini et al., 2018)
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5 Discussion 
 
FoxO transcription factors activity plays a major role in several biological 
processes, including cell cycle progression, proliferation, DNA damage-repair, 
oxidative stress resistance, metabolism and cell death. Therefore, as a key element 
of the molecular machinery driving cells towards survival or death, the regulation 
of FoxOs activity in response to extracellular cues is fundamental in lifespan, aging 
and cancer. A wide range of external stimuli controls FoxOs, including insulin, 
growth factors, nutrients, cytokines and oxidative stress, which affect FoxO protein 
amount, subcellular localisation, binding to the DNA and transcriptional efficiency. 
These regulation mechanisms are mediated by signalling pathways that eventually 
induce changes in PTMs on FoxO proteins, which, in turn, result in changes in 
subcellular localisation. In 2008, Calnan and Brunet proposed a fascinating model 
which interprets the combinations of the PTMs acting on FoxOs as a functional 
“FoxO code”, modulating their functions. Among multiple PTMs, the main one is 
phosphorylation, which is an evolutionarily conserved mechanism from 
invertebrates to humans. Specifically, it is often considered as the most critical one 
for FoxO and cell fate. For instance, AKT, SGK, Casein kinase-1 (CK1), Dual-
specificity Tyrosine (Y)-phosphorylation-regulated kinase (DYRK1A) and IKKα 
directly phosphorylate FoxOs thus promoting their binding to the 14-3-3 nuclear 
export protein. On the other hand, JNK1 phosphorylates the 14-3-3 protein thereby 
inhibiting its binding to FoxOs and promoting their nuclear localisation (Calnan 
and Brunet, 2008). 
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Interestingly, novel subcellular localisation of one of the four members of 
the human FoxO family, FoxO3A, is described (Peserico et al., 2013). Glucose 
restriction triggers the AMPK-dependent mitochondrial accumulation of FoxO3A. 
Once into the mitochondria, FoxO3A can form a transcriptionally active complex 
with mtRNAPol and SIRT3, the latter of which is the primary mitochondrial protein 
deacetylase and can efficiently deacetylate FoxO3A (Sundaresan et al., 2009). This 
event finally leads to increased mitochondrial respiration to sustain energy 
metabolism upon nutrient shortage. Importantly, SIRT3 activity, even if it is not 
required for FoxO3a mitochondrial accumulation, is needed for FoxO3A binding 
to mtDNA and the expression of the mitochondrial-encoded core or catalytic 
subunits of the OXPHOS machinery. These findings uncovered an unprecedented 
mechanism and raised the interest in the existence of a mitochondrial tale of the 
“FoxO3A code”, which would imply fine-tuned regulation processes through 
specific post-translational modifications.  
In the last decade, due to their cytostatic and apoptotic abilities, FOXOs 
have been widely investigated as tumour suppressors. Among the FoxOs, the best 
characterised in several human cancers is FoxO3A (Fei et al., 2009; Jiang et al., 
2013; Habashy et al., 2011; Yang et al., 2013; Liu et al., 2015), while FOXO1 
inactivation has been associated with human cervical cancer (Zhang et al., 2015). 
Fascinatingly, recent experimental evidences also showed that overexpression of 
FoxO3A promotes cancer cell growth and tumour progression in different human 
cancer such as hepatocellular carcinoma, breast cancer, blood cancer and 
glioblastoma (Han et al., 2018; Yu et al., 2016, Storz et al., 2009; Scisci et al., 2013; 
Ahn et al., 2018; Liang et al., 2013; Qian et al., 2017; Rehman et al., 2018). Taken 
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together, these studies support the idea of a more complex role of FoxO3A in cancer 
progression, which requires further investigations. Data collected in this project 
contribute to the interpretation of the dichotomic role of FoxO3A in cancer. On one 
hand, data elucidated the contribution of mtFoxO3A in cancer cell survival and 
chemo-resistance. On the other hand, nuclear FoxO3A has been confirmed as a 
master regulator of the expression of fundamental genes required for cell cycle 
arrest and cell death. Specifically, when the mitochondrial rescue mechanism is 
impaired, FoxO3A accumulates into the nucleus and induces the expression of 
genes involved in cell cycle control (p21, p27) and apoptosis (Bim) upon metabolic 
or therapy-dependent stress induction.   
Recent advances in cancer understanding suggest reconsidering the 
“Warburg effect” in its interpretation of the mitochondrial role in tumorigenesis. 
Indeed, several pieces of evidence indicate that, while aberrant tumour cell growth 
is frequently associated with alterations of biochemical metabolism, mitochondrial 
function is not usually impaired (Cairns, Harris, Mak 2011; DeBernardinis and 
Chandel, 2016). Even if there is not any positive selection for mitochondrial 
respiration defects during tumour evolution, aerobic glycolysis is not generally 
caused by impairment of respiratory functions in mitochondria (Ju et al., 2014, 
Stewart et al., 2015). On the contrary, increased energy production, sufficient 
macromolecular biosynthesis and maintenance of redox balance are often observed 
in human cancers (Wallace CD, 2012; Weinberg and Chandel, 2015; Zong, 
Rabinowitz, White, 2016). In addition to respiration, mitochondria are the 
powerhouse for bioenergetics and biosynthetic pathways, being responsible for 
various molecular processes that are critical in the tumorigenesis process, which 
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requires a high level of flexibility to adapt to cellular and environmental alterations. 
Thus, understanding the role of mitochondrial function in cancer might reveal novel 
approaches to targeted cancer therapy. Indeed, recent reports suggested that cancer 
cells are highly susceptible to the inhibition of oxidative phosphorylation, induced 
by biguanides and other complex I-targeting drugs. Of note, this kind of agent can 
act as sensitisers to cancer therapeutics and chemotherapy, as discussed above in 
section 1.1.5 (Kuntz et al., 2017; Tan et al., 2017). 
On light of these considerations, the identification of a novel mitochondrial 
arm of the AMPK-FoxO3A axis aimed to sustain cellular metabolism upon nutrient 
shortage in normal cells (Peserico et al., 2013) represents an attractive incentive to 
investigate the existence of a similar pathway also in cancer cells. Thus, in this 
study, the mitochondrial form of Foxo3A, together with relevant signalling 
cascades, has been explored in tumour cells subjected to metabolic stress, and 
cancer therapeutics. The investigation revealed the involvement of the MEK/ERK 
pathway, as well as the AMPK one, in the mitochondrial signalling of FoxO3A, 
which results in support of the healthy and functionally active state of mitochondria 
in metabolically stressed cancer cells. These results might have important 
implications from a pharmacological point of view. As discussed above (see 
paragraph 1.3), in humans AMPK phosphorylates FoxO3A at least at six known 
residues (Greer et al., 2007a-b, Greer et al., 2009). Data presented here show a novel 
AMPK phosphorylation site, the Serine 30, on the N-terminal domain of FoxO3A, 
evolutionarily conserved from humans to fruit flies (D. melanogaster). The newly 
identified Serine is required in cancer cells for FoxO3A recruitment at the 
mitochondrial surface before undergoing translocation and processing, upon 
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nutrient shortage. The investigation also revealed a novel target site of ERK, the 
Serine 12, which is specific to human FoxO3A. 
Interestingly, in line with previous findings showing that genetic silencing 
of AMPK was sufficient to prevent mtFoxO3A accumulation in normal cells 
subjected to nutrient deprivation (Peserico et al., 2013), here it has been show that 
normal cells and tissues under metabolic stress required only the AMPK signal on 
S30 to direct FoxO3A into the mitochondria. However, ERK involvement in 
FoxO3A mitochondrial localisation is an exclusive requirement of tumour cells. 
This critical difference between normal and cancer cells suggests an attractive 
strategy to be explored for cancer therapy. 
Moreover, in colorectal cancer cells treated with selected chemotherapeutic 
agents, mtFoxO3A is responsible for mitochondrial function preservation, 
chemotherapy resistance and cell survival in a MEK/ERK-dependent manner 
(Figure 5.1). Chemotherapeutic agents do not activate AMPK (see Figure 4.29). 
Keeping in mind that several MEK inhibitors -such as PD0325901, Selumetinib and 
Trametinib- are currently under active development for different kind of cancers 
(Liu et al., 2018), it worth underling that MEK inhibition by Trametinib enhances 
cell death when combined with chemotherapeutics in CRC cells (see Figure 4.31). 
Combination therapy with MEK inhibitors and chemotherapeutic agents is 
predicted to overcome resistance mechanisms and potentiates the antitumour 
activity of each agent, and various phase II/III trials based on such approaches are 
currently ongoing (Zhaoa and Adjei, 2014). Addittionally, ERK1/2 selective 
inhibitors are gaining increasing interest, especially to overcome the acquired drug 
resistance induced by upstream kinases -MEK- inhibitors (Liu et al., 2018). The 
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potential of the combined therapy with MEK or ERK inhibitors with chemotherapy 
in CRC therapy to overcome drug resistance should be further deepened. 
 
Figure 5.1 - FoxO3A as a survival factor in metabolically stressed cancer cells. 
Normal cells and tissues under metabolic stress require only the AMPK 
signal on S30 to direct FoxO3A into the mitochondria. It seems that ERK 
involvement in FoxO3A mitochondrial localization is exclusive to tumour cells, 
which reveals a critical difference between normal and cancer cells that could be 
exploited for cancer therapeutics. In metabolically stressed cancer cells, FoxO3A 
is recruited to the mitochondria through activation of MEK/ERK and AMPK, which 
phosphorylate Serine 12 and 30, respectively, on FoxO3A N-terminal domain. 
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Subsequently, FoxO3A is imported and cleaved to reach mitochondrial DNA, where 
it activates expression of the mitochondrial genome to support mitochondrial 
metabolism. In cancer cells treated with chemotherapeutic agents, accumulation of 
FoxO3A into the mitochondria promoted survival in a MEK/ERK-dependent 
manner, while mitochondrial FoxO3A was required for apoptosis induction by 
Metformin. Image from Celestini et al., 2018. 
As AMPK is a well-established tumour suppressor through LKB1/AMPK 
pathway ability to restrain tumour growth, it may appear not straightforward to 
reconcile this biological activity with its involvement in the promotion of cancer 
cell survival.  However, the evidence collected in this project can reinforce recent 
studies showing AMPK ability to act also as a “tumour promoter”, depending on 
metabolic conditions and surrounding microenvironment of cancer cells (Zadra et 
al., 2015). Moreover, the dual role of AMPK in cancer is supported by the results 
of the use of AMPK modulators in cancer therapy, such as Metformin. The analysis 
of HCT116 FoxO3A+/+ versus HCT116 FoxO3A-/- cells suggests that AMPK-
mtFoxO3A axis may be required for Metformin to extensively induce apoptosis in 
cancer cells. Metformin is a biguanide drug commonly used in the treatment of 
diabetes, which has been proven to have anticancer activity in diabetic patients 
(Evans et al., 2005; Chae et al., 2016; Wheaton et al., 2014).  Clinical studies 
showed that Metformin could reduce the risk of recurrence and cancer-specific 
mortality in patients with CRC and concurrent diabetes (Lee et al., 2012a; Lee et 
al., 2012b). The various direct and indirect mechanisms for the anti-tumour effect 
of Metformin are still under strong debate, as briefly mentioned before (Paragraph 
1.1.5). Specifically, it has been proposed that the anti-proliferative effect of 
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Metformin is due to a specific action of the biguanide on cancer stem cells (Kim et 
al., 2017). Other studies are aimed to ascertain if Metformin anticancer properties 
are linked to its systemic effect on glucose and insulin levels or are mediated by 
mitochondrial electron transport chain (ETC) targeting, as Metformin inhibits the 
activity of Complex I of the mitochondrial machinery responsible for oxidative 
phosphorylation. With a similar mechanism, Metformin induces AMPK activation 
in cultured cells (Wheaton et al., 2014).  Importantly, several phases II/III clinical 
trials are currently evaluating the Metformin efficacy in association with 
chemotherapeutic agents as well as its chemoprevention activity as a single agent 
(Evans et al., 2005; Chae et al., 2016). Experimental evidence collected in this study 
showed that in CRC cells Metformin activity is mediated by AMPK and requires 
mt-FoxO3A to elicit its pro-apoptotic effect in cancer cells. In FoxO3A-/- cell 
model, Metformin treatment combined with Irinotecan lead to an enhanced 
cytotoxic effect (see Figure 4.32). Our data described a kind of “vicious circle” in 
which Metformin activates AMPK, which in turn triggers FoxO3A translocation to 
the mitochondria resulting in increased oxidative phosphorylation (OXPHOS), 
which is blocked by Metformin inhibition of Complex I. Therefore, Metformin 
could be useful to circumvent mtFoxO3A-dependent chemo-resistance and 
sensitise cancer cells to chemotherapy, by enforcing the accumulation of FoxO3A 
into the mitochondria. Consequentially, this event induces an increase in 
mitochondrially encoded protein levels, in mitochondria in which oxidative 
phosphorylation is blocked by complex I inhibition. Thus, OXPHOS inhibitors 
could be adopted as a pharmacological attempt to sensitize cells to chemotherapy.  
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 185 
 
Addittionally, in vivo Metformin-mediated suppression of tumour growth may be 
due on AMPK down-regulation. Cells characterised by defective LKB1/AMPK 
pathway, upon metabolic stress induced by Metformin treatment, show impaired 
ability to restore ATP levels. Consequently, these cells are more susceptible to cell 
death. In cancer therapy, the chemotherapeutic drug Sunitinib inhibits AMPK. The 
combinatorial treatment of Sunitinib and Metformin and, in general, the combined 
use of Metformin with agents that inhibit AMPK could be clinically relevant 
(Laderoute et al., 2010).  
Taken together, data from literature and data collected in this thesis 
encourage to deepen the potential relevance in cancer therapy of the combination 
of chemotherapic agents that can inhibit AMPK with other AMPK-activating drugs 
(Metformin, salicylate etc...), to sensitise cancer cells to chemotherapy and 
overcome the drug-resistance. 
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6 Concluding remarks  
 
The findings presented in this thesis shed light on the role of some major players 
involved in the mitochondrial signalling of FoxO3A in cancer cells. Through data 
collected in this project, we identified new players and mechanism of action, with 
the aim to propose and test new cancer therapy strategy.  
A therapeutic combination involving inhibitors targeting the MAPK pathway   
(MEK and/or ERK), and/or OXPHOS modulators represent an opportunity to 
overcome acquired resistance to current treatments.   
From the perspective of the molecular biology of mtFoxO3A, many aspects may  
be elucidated yet to determine the hierarchy between the identified signalling 
pathways them and/or their possible tissue-specificity. Moreover, there could be 
other potential key proteins actively involved in signalling pathways targeting 
FoxO3A N-terminus and eventually modulating its mitochondrial localisation and 
function. Pharmacologically, these investigations will be instrumental in devising 
personalised therapeutic strategies – employing molecularly targeted drugs – aimed 
at manipulating cellular metabolism to counteract cancer initiation and progression.
 Concluding remarks 
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Appendix Table 1 - List of constructs used in this 
study 
 
Expressed protein Vector Plasmid Figure(s) 
3x-FLAG Mammalian p3xFLAGCMV14 
4.6, 4.7-8, 4.11, 4.24, 
4.26, 4.29-30, 4.32 
3x-FLAG-FoxO3A Mammalian p3xFLAGCMV14 
4.6, 4.7-8, 4.11-13, 
4.17, 4.19, 4.23-24, 
4.26-27, 4.29-30, 
4.32 
3x-HA-FoxO3A-FLAG Mammalian p3xFLAGCMV14 4.6, 4.19 
3x-FLAG-FoxO3A-(Δ1-148) Mammalian p3xFLAGCMV14 4.7 
3x-FLAG-FoxO3A-(Δ80-108) Mammalian p3xFLAGCMV14 4.8 
3x-FLAG-FoxO3A-S12A Mammalian p3xFLAGCMV14 4.11-12, 4.17, 4.29 
3x-FLAG-FoxO3A-S26A Mammalian p3xFLAGCMV14 4.11 
3x-FLAG-FoxO3A-S30A Mammalian p3xFLAGCMV14 
4.11-12, 4.17, 4.29, 
4.32 
3x-FLAG-FoxO3A-S43A Mammalian p3xFLAGCMV14 4.11 
3x-FLAG-FoxO3A-S48A Mammalian p3xFLAGCMV14 4.11 
3x-FLAG-FoxO3A-S55A Mammalian p3xFLAGCMV14 4.11 
3x-FLAG-FoxO3A-S12A/S30A Mammalian p3xFLAGCMV14 
4.12-4.23-24, 4.26, 
4.29, 4.30 
3x-FLAG-FoxO3A-(Δ1-30) Mammalian p3xFLAGCMV14 4.12 
3x-FLAG-FoxO3A-S12D/S30D Mammalian p3xFLAGCMV14 4.23-24 
3xFLAG-FoxO3A-(Δ242-271) Mammalian p3xFLAGCMV14 
4.23-24, 4.26, 4.29, 
4.30, 4.32 
GST-4T-3 Bacterial pGEX-4T-3 4.15 
GST-FoxO3A(1-148) Bacterial pGEX-4T-3 4.15 
GST-FoxO3A(1-148)S12A Bacterial pGEX-4T-3 4.15 
GST-FoxO3A(1-148)S30A Bacterial pGEX-4T-3 4.15 
GST-FoxO3A(1-148)S12A/S30A Bacterial pGEX-4T-3 4.15 
GST-FoxO3A(386-525) Bacterial pGEX-4T-3 4.15 
FoxO3A EGFP – wt Mammalian pEGFP-N3 4.27 
FoxO3A EGFP – S12A/S30A Mammalian pEGFP-N3 4.27 
FoxO3A EGFP – (Δ242-271) Mammalian pEGFP-N3 4.27 
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Appendix Table 2 - List of human cloning and site-
directed mutagenesis primer sequences 
Plasmid(s) Primers sequence (5’-3’) 
FoxO3A-FLAG* 
EGFP-FoxO3A 
Fw GCTCAAGCTTATGGCAGAGGCACCG 
Rv CATGGATCCGCCTGGCACCCAGC 
HA-FoxO3A-FLAG** 
Fw AAGCTTAGCTCTGCTTATATAGACC 
Rv CATGGATCCGCCTGGCACCCAGC 
FoxO3A(Δ1-148)-FLAG*** 
Fw GATATCGGATCCATGAAATGTTCGTCGCGGCGG 
Rv  GATATCCTCGAGTAAGCCTGGCACCCAGCTCTG 
FoxO3A(1-148)-GST^ 
Fw GATATCGGATCCATGGCAGAGGCACCGGCTT 
Rv GATATCCTCGAGTAACCTCGGCTGCCCGGAG 
FoxO3A(386-525)-GST^ 
Fw GGATCCATGCTCATGGACGACCTGCTGGATAAC 
Rv  GATATCCTCGAGTAAGCCTGGCACCCAGCTCTG 
FoxO3A-S12A-FLAG*** 
FoxO3A-(1-148)S12A-GST^^ 
Fw GGCCCCGCTCGCTCCGCTCGA 
Rv GGGGAAGCCGGTGCCTCTG 
FoxO3A-S26A-FLAG*** 
Fw CGAGCCCCAGGCCCGTCCGCGA 
Rv AACTCCGGGTCCAGCTCC 
FoxO3A-S30A-FLAG*** 
FoxO3A-(1-148)S30A-GST^^ 
FoxO3A-S12/S30A-FLAG*** 
EGFP-FoxO3A-S12/S30A 
FoxO3A-(1-148)S12A/S30A-GST^^ 
Fw CCGTCCGCGAGCCTGTACGTG 
Rv CTCTGGGGCTCGAACTCCG 
FoxO3A-S43A-FLAG*** 
Fw GCTCCAAGCGGCCCCTGCCAAGCC 
Rv TCCGGCCTTTGCAGGGGC 
FoxO3A-S48A-FLAG*** 
Fw TGCCAAGCCCGCGGGGGAGAC 
Rv GGGCTCGCTTGGAGCTCC 
FoxO3A-S55A-FLAG*** 
Fw GGCCGCTGACGCCATGATCCC 
Rv GTCTCCCCCGAGGGCTTG 
FoxO3A(Δ1-30)-FLAG*** 
Fw TGTACGTGGCCCCTGCAAAGG 
Rv TGAACCGTCAGAATTAAGCTT 
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* Construct obtained starting from pECE-HA- FoxO3A (kindly provided from Dr. 
M. Greenberg). 
** Construct obtained starting from pECE-HA- FoxO3A (kindly provided from Dr. 
M. Greenberg), followed by HA-FoxO3A fragment insertion into pCMV-14-
3xFLAG backbone. 
*** Construct obtained starting from 3x-FLAG-FoxO3A. 
^ Construct obtained starting from 3x-FLAG-FoxO3A, followed by FoxO3A(1-
148) insertion into and pGEX-4T-3 empty vector. 
^^Construct obtained starting from pGEX-4T-3-FoxO3A(1-148). 
pEGFP-N3 plasmids were obtained through HindIII/BamHI digestion of the 
corresponding p3xFLAG plasmids, followed by fragment insertion into pEGFPN3 
backbone. 
 
  
FoxO3A(Δ80-108)-FLAG*** 
Fw GGGTCTGGGCCAGCCACC 
Rv GATCGCCATGGCCGAGCCG 
FoxO3A-S12-FLAG*** 
Fw GGCCCCGCTCgaTCCGCTCGAAG 
Rv GGGGAAGCCGGTGCCTCT 
FoxO3A-S30D-FLAG*** 
FoxO3A-S12/S30D-FLAG*** 
Fw CCGTCCGCGAgaCTGTACGTGG 
Rv CTCTGGGGCTCGAACTCC 
FoxO3A(Δ242-271) –FLAG*** 
EGFP-FoxO3A(Δ242-271) 
 
Fw GCAGCCCTGCAGACAGCCCC 
Rv CCCCCCATCAGGGTTGATGATCC 
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Appendix Table 3 - List of primary and secondary 
antibodies used 
 
Antibody name Source Identifier 
Monoclonal mouse anti- FoxO3A CST #99199 
Monoclonal rabbit anti- FoxO3A CST #2497 
Monoclonal anti-rabbit COX4 CST #4850 
Monoclonal anti-rabbit BCL2 CST #2870 
Monoclonal anti-rabbit PDH CST #3205 
Mouse monoclonal FLAG M2 SIGMA #F1804 
Rabbit anti-HA-TAG  CST #3724 
Mouse monoclonal anti-bACTIN CST #3700 
Rabbit polyclonal anti-pAMPK-α Thr 172 CST #2531 
Rabbit polyclonal anti-pAMPK1-α CST #2532 
Mouse monoclonal anti- p44/42 MAP2K1- ERK1/2 
Thr202/Tyr204 
CST #9106 
Rabbit polyclonal anti- 44/42 MA2PK1- ERK1/2 CST #9102 
Rabbit polyclonal anti-p-Acetyl-CoA Ser 79 CST #3661 
Rabbit monoclonal anti-TFAM CST #8076 
Polyclonal rabbit anti-HSP60 D307 CST #4870 
Rabbit anti- IgG CST #2729S 
Rabbit polyclonal anti-mtRNAPOL H300 Santa Cruz #67350 
Rabbit monoclonal anti- SIRT3  CST #5490 
Rabbit monoclonal anti-LAMIN B1 CST #12586S 
Rabbit polyclonal anti- PARP1 p85 fragment PROMEGA #G7341 
Amersham ECL Rabbit IgG, HRP-linked whole Ab (from 
donkey) 
GE  NA934 
Amersham ECL Mouse IgG, HRP-linked whole Ab (from 
sheep) 
GE  NA931 
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Appendix Table 4 -List of human mRNA primer 
sequences 
 
Primer Sequence (5’-3’) 
Atp6 
Fw GCCGCAGTACTGATCATTCTATTTC 
Rv TCGGTTGTTGATGAGATATTTGGA 
Atp8 
Fw CCCTCACCAAAGCCCATAAA 
Rv GAATGAAGCGAACAGATTTTCGT 
Cox1 
Fw CCCCGCATAAACAACATAAGC 
Rv CAGATGCGAGCAGGAGTAGGA 
Cox2 
Fw ATGGCACATGCAGCGCAAGTAGG 
Rv GGCATACAGGACTAGGAAGCAG 
Cox3 
Fw TTCCACGGACTTCACGTCATT 
Rv TGGCGGATGAAGCAGATAGTG 
Cyt B 
Fw TCGGCATTATCCTCCTGCTT 
Rv CTCACGGGAGGACATAGCCTCT 
ND1 
Fw CCCGCCACATCTACCATCA 
Rv GAGCGATGGTGAGAGCTAAGGT 
ND2 
Fw AAACCCTCGTTCCACAGAAGC 
Rv GGATTATGGATGCGGTTGCT 
ND3 
Fw CCTACCATGAGCCCTACAAACAAC 
Rv GGATGATGATTAATAAGAGGGATGACA 
ND4 
Fw ACAAGCTCCATCTGCCTACGA 
Rv GGCTGATTGAAGAGTATGCAATGA 
ND4L 
Fw TCAACACCCACTCCCTCTTAGC 
Rv CGCAGGCGGCAAAGACT 
ND5 
Fw GCAGCCATTCAAGCAATCCTA 
Rv AGGCGAGGATGAAACCGATA 
ND6 
Fw ACCCCCATGCCTCAGGAT 
Rv GGAATGATGGTTGTCTTTGGATATACT 
D-Loop 
Fw GCGTCTCGCAATGCTATCG 
Rv GAGCTCTCCATGCATTTGGTATT 
Bim 
Fw CACAAACCCCAAGTCCTCCTT 
Rv TGGAAGCCATTGCACTGAGA 
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Appendix Table 5 - List of human DNA primer 
sequences 
 
Primer name Sequence (5’-3’) 
FHRE#1 
Fw CCGGAGCACCCTATGTCG 
Rv GCCTGTAATATTGAACGTAGGTGCC 
FHRE#2 
Fw CATTACTGCCAGCCACCATGA 
Rv GGAGGGGGTTTTGATGTGGAT 
p21 
Fw ATGTCCGTCAGAACCCATGC 
RvAGTGGTGTCTCGGTGACAAAGTC 
p27 
Fw ACCTTCGCGGTCCTCTGG 
RvAACTAGCCAAACGGCCGG 
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